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Abstract 
Prostate cancer has emerged as the most frequently diagnosed cancer, except for 
non-melanoma skin cancer, among men in many Western countries in the last decade. 
In the United Kingdom (UK), prostate cancer accounts for nearly a quarter of all new 
male cancer diagnoses. Increasing age and some genetic and ethnic risk factors have 
been identified but few modifiable risk factors are known. The introduction of 
Prostate Specific Antigen (PSA) testing has increased the detection of previously 
undiagnosed disease but its contribution to the observed increases in prostate cancer 
incidence is not clear. Considerable variations in the incidence of prostate cancer 
have been observed in different geographic regions and socio-economic groups across 
the UK but it is not known whether, or to what extent, these may be attributed to 
differential uptakes of PSA testing. Prostate cancer is the third most common cause of 
cancer death in men but many cases do not progress. There is therefore an important 
clinical need for better prognostic markers so that the increasing numbers of men 
with prostate cancer can be appropriately managed.  
This thesis begins with a descriptive epidemiological study using cancer registry 
incidence data from the West of Scotland from 1991 to 2007. The aim was to 
determine whether the incidence of prostate cancer was continuing to rise and to 
describe any demographic or socio-economic patterns that might suggest particular 
at-risk groups. To understand whether any socio-economic differentials in incidence 
might be due to PSA testing, I examined Gleason grade-specific prostate cancer 
incidence by socio-economic groups over time. Socio-economic circumstances were 
measured using census-derived Carstairs scores. Overall (age adjusted) prostate 
cancer incidence increased by 70% from 44 per 100,000 in 1991 to 75 per 100,000 in 
2007, an average annual growth of 3.59%. This pattern was driven by significant 
increases in both low and high grade cancers with no convincing change in their 
proportions over time. Incidence was inversely associated with deprivation with the 
highest rates among the most affluent groups.  
To explore the role of potentially modifiable risk factors on prostate cancer 
incidence, the Midspan and Collaborative prospective cohort studies were analysed. 
An analysis of the relationship between cholesterol and prostate cancer incidence was 
conducted on the Midspan cohort, which comprises 12,926 men who were enrolled 
between 1970 and 1976 and followed up to 31st December 2007. Cox Proportional 
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Hazards Models were used to evaluate the association between baseline plasma 
cholesterol and Gleason grade-specific prostate cancer incidence. Following up to 37 
years’ follow-up, 650 men developed prostate cancer. Their baseline plasma 
cholesterol level was positively associated with hazard of high grade (Gleason score 
≥8) prostate cancer incidence (n=119). The association was greatest among men in 
the 4th highest quintile for cholesterol, 6.1 to <6.69 mmol/l, Hazard Ratio 2.28, 95% 
CI 1.27 to 4.10, compared with the baseline of <5.05 mmol/l. This association 
remained significant after adjustment for age, body mass index, smoking and socio-
economic status.  
Evidence on the possible role of tea and coffee consumption in the development of 
prostate cancer remains limited to a small number of studies with short follow-up and 
small numbers of cases. Therefore to understand the relationship of tea and coffee 
consumption with overall as well as grade-specific prostate cancer, a prospective 
cohort study of 6016 men was carried out, who were enrolled in the Collaborative 
cohort study between 1970 and 1973 and followed up to 31st December 2007. Three 
hundred and eighteen men developed prostate cancer in up to 37 years’ follow-up. I 
found a positive association between consumption of tea and overall risk of prostate 
cancer incidence (p=0.02). The association was greatest among men who drank ≥7 
cups of tea per day (HR 1.50, 95% CI 1.06 to 2.12) compared with the baseline of 0-3 
cups per day. However, I did not find any significant association between tea intake 
and low (Gleason < 7) or high grade (Gleason 8-10) prostate cancer incidence. Higher 
coffee consumption was inversely associated with risk of high grade disease (HR 0.46, 
95% CI 0.21-0.99) but not with overall risk of prostate cancer. These associations 
remained significant after adjustment for age, Body Mass Index, smoking, social class, 
cholesterol level, systolic blood pressure and alcohol consumption.  
Although survival of prostate cancer patients has improved over time, little is known 
about the major prognostic factors. To understand the socio-economic differences 
and major determinants of survival, an investigation was carried out using cancer 
registry incidence data from the West of Scotland from 1991 to 2007, linked with 
General Registrar Office (Scotland) death records up to 31st December 2008. Socio-
economic circumstances were measured using the Scottish Index for Multiple 
Deprivation (SIMD). Age, sex and deprivation specific mortality rates were obtained 
from General Registrar Office for Scotland (GRO(S)). One, three and five year relative 
survival was estimated using the complete approach. Survival gradients across 
4 
 
deprivation quintiles were estimated using linear regression, weighted by the variance 
of the relative survival estimate, using STATA software (StataCorp, version 11). Five 
year relative survival increased from 58.2% to 78.6% in men over the same period (an 
average deprivation adjusted increase of 10.2% between six years periods). Despite 
substantial improvements in survival of prostate cancer patients, there was a 
deprivation gap (that is, better survival for the least deprived compared with the 
most deprived) between the three time periods. The deprivation gap in five year 
relative survival widened from -4.76 in 1991-1996 to -10.08 in 2003-2007. Age, 
Gleason grade and socio-economic status appeared as significant determinants of 
survival. 
There is some evidence that systemic inflammation may be associated with survival in 
patients with prostate cancer although its relationship to tumour grade and socio-
economic circumstances has not been previously studied. I therefore investigated the 
association between inflammation-based prognostic scores and survival, using the 
modified Glasgow Prognostic Score (mGPS) and Neutrophil Lymphocyte Ratio (NLR) as 
well as Gleason grade. The patient cohort within the Glasgow Inflammation Outcome 
Study who had a diagnosis of prostate cancer was included in this study. The mGPS is 
a categorical score constructed by combining serum C-reactive protein and albumin 
levels, while the NLR is obtained by calculating the ratio of neutrophils to 
lymphocytes. The relationship between mGPS and NLR and five-year relative survival 
was explored after adjusting for age, socio-economic circumstances and Gleason 
grade. Of the 897 prostate cancer patients in the Glasgow Inflammation Outcome 
Study, 422 (47%) died during a maximum follow-up of 6.2 years. Systemic 
inflammation had a significant prognostic value. The mGPS predicted poorer 5-year 
overall and relative survival independent of age, socio-economic circumstances, 
disease grade and NLR. Raised mGPS also had a significant association with excess risk 
of death (mGPS 2: Relative Excess Risk = 2.08, 95% CI 1.13-3.81) among aggressive, 
clinically significant prostate cancer (Gleason score 8-10). Prostate cancer patients 
with a raised mGPS had significantly higher risks of death overall as well as for high 
grade disease. Inflammation-based prognostic scores can potentially predict patient 
outcome and a further prospective study is warranted to assess their clinical value. 
Although the study of the epidemiology of prostate cancer is complicated by changing 
diagnostic sensitivity and disease grade definitions, the increasing number of men 
diagnosed with the disease demands continuing research into understanding risk 
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factors, prognostic factors and more effective treatment. However, it seems unlikely 
that a simple, modifiable risk factor exists for prostate cancer and that PSA testing 
and an aging population will continue to drive increasing incidence. 
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1.1 Chapter outline 
This chapter will briefly describe prostate cancer (PC), its diagnosis and 
management. Furthermore, risk and prognostic factors for PC, and finally the 
aims and objectives of this thesis will be described. 
Section 1.1: briefly describes the prostate gland anatomy and pathology, 
particularly PC. Furthermore, this section deals with the clinical presentation, 
diagnosis and treatment of PC.   
Section 1.2: describes the cancer registration process and its benefits, 
establishment of the Scottish Cancer Registry and measures of cancer burden, 
particularly incidence.  
Section 1.3: describes the literature on burden of PC and international variations 
in incidence of PC.  
Section 1.4: summarises the literature on what is known about the risk factors 
associated with the development and progression of PC.  
Section 1.5: discusses factors associated with survival of PC patients. 
Section 1.6: summarises the findings of existing literature and their limitations.  
Section 1.7: states the aims and objectives of this thesis. 
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In this section, a short overview of the anatomy and physiology of the prostate 
gland is presented along with a discussion on the diagnosis and management of 
PC. 
1.1.1 Prostate gland 
The prostate gland is a small, walnut sized and shaped gland located just below 
the urinary bladder in males. It surrounds the urethra which is a tube connecting 
the urinary bladder to the genitals for the removal of fluids out of the body 
(McNeal, 1980; McNeal and Bostwick, 1984). The prostate gland has a 
fibromuscular function to restrict the urine but the principal function of gland is 
secretory in nature. It produces a number of essential proteins for the function 
of sperm such as acid phosphatase, citric acid and bioavailable zinc (Devens et 
al., 2000). The prostate gland makes some of the highest amounts of polyamine, 
which contribute to the regulation of sperm pH, preserving a mildly alkaline 
environment for the sperm within the acidic female cervix (Devens et al., 2000). 
The prostate gland comprises three zones, which are composed of relatively 
simple secretory structures – the central, peripheral and transitional zones. 
Significant distinctive gene expressions have been observed between these three 
zones (McNeal, 1981). Transitional zone is the most common site for 
proliferative disorders i.e. benign prostatic hyperplasia (BPH), while majority of 
PCs originate in the peripheral zone of the prostate gland (McNeal, 1980). 
1.1.2 Prostate cancer 
The vast majority (approximately 95%) of prostatic tumours are 
adenocarcinomas. ‘Adeno’ signifies the tumour “pertaining to the glandular 
structure” while carcinoma relates to the origin of a cancer from the prostatic 
epithelium (McNeal and Gleason, 1991).  
1.1.3 Diagnosis of prostate cancer 
Investigation for PC can be prompted by clinical symptoms or by screening of at 
risk individuals by clinical examination and/or serum Prostate Specific Antigen 
(PSA) tests. However, the definitive diagnosis can only be made by the 
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histological examination of prostatic tissue obtained by biopsy. In the following 
subheadings, I will briefly describe the clinical presentation and role of 
diagnostic tests with particular emphasis on PSA testing in diagnosis of PC.  
1.1.3.1 Clinical presentation  
Early PCs are unlikely to produce any symptoms, however progressed disease 
may present with specific lower urinary tract symptoms including frequent 
urination, nocturia (increased frequency of urination at night), haematuria 
(blood in urine) or dysuria (pain during urination)(Frankel et al., 2003). The 
pattern of clinical presentation of PC has dramatically changed over time and 
now the majority of PC cases remain asymptomatic and malignancy associated 
signs and symptoms are less common at the time of diagnosis. The clinical 
presentation of PC changed significantly since 1990s due to increased utilisation 
of PSA and prostatic biopsies, aimed to detect early stage disease and in most 
cases small tumours in asymptomatic cases (Frankel et al., 2003).  
1.1.3.2 Diagnostic testing and Prostate Specific Antigen 
Diagnostic methods to detect an early stage PC included the digital rectal 
examination (DRE), PSA testing and transrectal ultrasound guided prostatic 
biopsies. The main limitations of digital rectal examination were the significant 
inter- (and even intra-) examiner variability, and most PCs detectable by DRE 
tended to be locally advanced, namely ≥T3 disease (Hoffman, 2011). Since the 
introduction of PSA testing in late 1980s, digital rectal examination is replaced 
by PSA testing as the main diagnostic tool (Croswell et al., 2011). 
PSA is a glycoprotein which is present in small quantities in the serum of men 
with healthy prostates. Its level is often raised in prostate disorders including 
PC. PSA testing was not initially envisioned as a screening strategy rather its first 
use was for the evaluation of treatment responses in men with PC (Croswell et 
al., 2011). Since the advent of PSA testing, the spectrum of PC cases has 
changed in many Western countries including the USA and the UK: At the 
population level, significantly more men are now diagnosed with localised and 
low grade disease than previously. Furthermore, a significant reduction in 
mortality has also been attributed to PSA screening in the US, where PSA 
screening was employed at the population level (Hoffman, 2011). Results 
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reported by randomised controlled trials in recent years have produced 
debatable benefit for large scale routine population-wide PSA screening. The 
European Randomised Study of Screening for PC showed a moderate reduction in 
mortality (20%) during 9 years of study period (Schroder et al., 2009). However, 
the absolute benefit of screening was only 0.7 deaths per 1000 men, suggesting 
that 1410 men would need to be screened approximately twice over a period of 
9 years to prevent 1 death from PC (Schroder et al., 2009). In contrast, the 
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, another 
large study, did not show any significant benefit of screening by PSA (Andriole et 
al., 2009). It is worth noting that data from the PLCO study was compromised by 
significant contamination of the control arm with unscheduled PSA testing.  
Although, there was some evidence of potential benefit from PSA screening, 
significant harms may also result from associated with over-diagnosis. Initially, a 
PSA value of >4.0 ng/ml was considered abnormal, though lower levels have also 
been proposed subsequently but no clinical benefits have been observed in 
diagnosis with modified cut offs. There are several major limitations of the PSA 
test as a screening tool. First, there is a high risk of false positives associated 
with abnormal PSA levels. Besides PC, other causes of elevated PSA levels 
include BPH, prostatitis, urinary tract infection, perineal trauma or recent use of 
instrumentation of the urinary tract, including digital rectal examination 
(Hoffman, 2011). Moreover, a normal PSA test does not rule out PC nor any clear 
cut-off value at which men can be assured that they do not harbour PC (Croswell 
et al., 2011). Patients with abnormal PSA test results are typically investigated 
further by transrectal ultrasound guided prostatic biopsies in order to 
definitively diagnose PC in around 15% of patients. Biopsies may result in 
significant adverse effects including bleeding (haematuria, haematospermia), 
pain and infection.  
The biggest challenge which is considered as the most significant limitation of 
PSA testing is that 23 to 42% of the PSA-detected cases may be over-diagnosed 
because on the basis of life expectancy at the time of diagnosis and natural 
history of the cancer in the absence of screening, it would be expected that 
these men may never present with a symptomatic disease during their lifetime 
(Croswell et al., 2011;Hoffman, 2011). 
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So given these benefits and harms, there is no national programme of PSA-based 
testing in the UK. However, it is recommended that patients should be involved 
in the decision making process of testing after informing the possible benefits 
and harms of testing. 
1.1.3.3 Prostate cancer stage and grade 
Disease stage is a measure of extent of the cancer locally within the gland and 
its invasion around the prostate itself and more distally as metastatic lesions. 
The TNM classification is used to stage PC, where T represents tumour and its 
invasion into adjacent structures, N represents if the regional lymph nodes are 
involved or not, and M describes the presence or absence of distant metastasis. 
Gleason sum score is the score based on histological pattern of tumour which is 
widely used as a measure of aggressiveness of cancer (McNeal and Gleason, 
1991). This score is sum of the assigned grades ranging from 1-5 to the most 
common and the second most common morphologic tumour patterns 
respectively. Gleason score (range 2-10) is a highly useful prognostic factor for 
PC patients (Sogani et al., 1985). Risk stratification of men with localised PC is 
done by combining the PSA, Gleason grade and clinical stage which include low 
risk men (PSA < 10ng/ml and Gleason grade ≤ 6 and clinical stage T1-T2a), 
intermediate risk men (PSA 10-20ng/ml or Gleason grade = 7 or clinical stage 
T2b-T2c) and high risk men (PSA > 20ng/ml or Gleason grade 8-10 or clinical 
stage T3-T4). These risk stratifications then guide the treatment decisions. 
1.1.4 Treatment of prostate cancer 
There are a variety of treatment modalities for PC, with some options more 
suitable for individual patients. The treatment choice strongly is often 
influenced by the risk of patients to progress or die of the disease as judged by 
patient’s age, Gleason score, tumour stage and serum PSA levels. For early PC, 
the main treatment modalities include surgery, radiotherapy and active 
surveillance. For patients with less favourable general health status, androgen 
ablation hormone therapy or PSA monitoring (watchful waiting) can be 
considered. 
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1.1.4.1 Radical prostatectomy  
Surgical treatment has significant benefits and intention of treatment is usually 
curative. Radical prostatectomy (removal of prostate gland) allows a complete 
pathological assessment of tumour. Furthermore, extension to surrounding 
structures and presence of surgical margins can also be assessed by this 
procedure (Heidenreich et al., 2011). Following a radical prostatectomy, PSA 
should not be detectable as any rise in PSA indicates the recurrence of disease. 
Given the benefits of surgical treatment, side effects can also occur as urinary 
leakage, impotence and urinary incontinence. Sexual dysfunction can occur in 
32% to 53% of cases receiving surgical treatment (Knight and Latini, 2009). To 
minimise the adverse effects of radical prostatectomy, laparoscopic 
prostatectomy has been introduced as a less invasive surgical approach and 
showed some benefits compared to open radical prostatectomy. Guidelines now 
suggest that patients must be engaged in decision making process of most 
appropriate therapy after sharing the possible harms and benefits associated 
with treatment. 
1.1.4.2 Radiotherapy 
External beam therapy or brachytherapy are commonly used radiological 
approaches. Radiotherapy is also used with a curative intent as radical 
prostatectomy. Advantages of using external beam therapy include reduction of 
risks associated with surgical therapy i.e. no risk of anaesthesia, no inpatient 
hospital stay and may even be used in men with co-morbidities (Heidenreich et 
al., 2011). Urinary incontinence rate is lower in external beam therapy 
compared with prostatectomy. Sexual dysfunction can also result following 
radiation therapy. A main problem associated with external beam therapy is the 
risk of radiation induced damage to the rectum, which is behind the prostate, 
and the bladder. These radiations can have serious early and late rectal 
complications, which can be avoided by brachytherapy (the placement of 
radioactive pellets within the prostate).  
1.1.4.3 Active surveillance 
Currently, active surveillance is considered usually for men with low PSA-level, 
localised disease and Gleason score ≤ 6 (Albertsen, 2010). These patients are 
27 
Chapter 1 
 
monitored with an intention that if there are any signs of disease progression, 
active treatment or intervention will be started. Follow-up of these men on 
active surveillance includes PSA-testing, digital rectal examination and 
sometimes prostatic biopsy (Albertsen, 2010;Heidenreich et al., 2011). This 
approach prevents the serious side effects associated with different treatment 
modalities. Given that in PSA-era most patients are diagnosed with small and 
asymptomatic tumours which may not progress, this approach seems reasonable. 
However, the most significant disadvantage of this approach is men are not 
“cured” from the cancer and they have to live with the disease which can have 
psychological effects. Some evidence suggests that men on active surveillance 
had highest quality of life compared with other treatment modalities for 
localised PC (Albertsen, 2010;Hayes et al., 2010). Although, active surveillance 
has emerged as a good treatment option, it remains difficult to predict the 
tumour progression of individual patients, which might compromise the 
confidence of a cure subsequently. 
1.1.4.4 Hormonal therapy 
Hormonal therapy was previously used to treat the metastatic PC cases but in 
more recent days androgen deprivation therapy had become the second most 
commonly used treatment modality after the surgery (Krahn et al., 2011). Some 
evidence suggested that hormonal therapy prolongs the survival of PC patients 
but significant side effects are also reported in recent years (Isbarn et al., 
2009). Because androgens are essential for the physiological activity of many 
body functions so the androgen deprivation therapy has side effects including 
loss of libido, erectile dysfunction, fatigue, depression, osteoporosis, new onset 
diabetes and hypertension and even increase the risk of cardiovascular mortality 
(Isbarn et al., 2009). Beyond the survival improvements, these side effects 
significantly affect the quality of life of men receiving androgen deprivation 
therapy and some suggested that the possible benefits and harms should be 
discussed with the patients before initiation of treatment. 
1.1.4.5 Concluding remarks on treatment 
Comparison of different treatment modalities is a critical objective and has 
significant implications for clinician as well as the patients. Treatment goals are 
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to prevent death and disability from prostate cancer while minimizing 
intervention-related complications (Wilt et al., 2008). Most of the evidence on 
comparative effectiveness of radical treatment and active surveillance or 
watchful waiting has emerged from observational studies. These studies are 
subject to bias that are caused by selection of patients into treatment for 
reasons related to expected survival (i.e. patients with a better prognosis may 
be more likely to receive radical treatment). Furthermore, most observational 
studies failed to adequately control for important confounding factors (Hadley et 
al., 2010;Wilt et al., 2008). The randomised control trial is considered the most 
valid methodology for assessing treatments’ efficacy; however, little evidence is 
available from these trials on the comparative effectiveness and harms of 
treatment for clinically localised PC, particularly in men with PSA-detected 
disease.  
Recent report from Prostate Cancer Intervention versus Observation Trial 
(PIVOT), suggests that among men with localised PC detected during the early 
era of PSA testing, radical prostatectomy did not significantly reduce overall and 
PC mortality, as compared with observation, through at least 12 years follow-up 
(Wilt et al., 2012). These findings were in contrast with the Scandinavian 
Prostate Cancer Group 4 (SPCG-4) trial of radical prostatectomy versus watchful 
waiting in men with PC. In SPCG-4 trial, men treated with radical prostatectomy 
showed lower all-cause mortality (a difference of 6.6%, 95% CI -1.3 to 14.5), 
lower PC-specific mortality (a difference of 6.1%, 95% CI 0.2-12.0) and lower 
incidence of distant metastasis (a difference of 11.7%, 95% CI 4.8-18.6), 
compared with watchful-waiting group (Bill-Axelson et al., 2011b). Higher 
proportion of men detected before widespread PSA-testing, lower percentage of 
nonpalpable tumours (stage T1c, 10%) and higher percentage of men with PSA > 
10ng/ml in SPCG-4 trial, may explain the differential results of PIVOT and SPCG-
4 trials. Despite the findings of these trials, treatment of early-stage PC remains 
controversial, especially for tumours detected by means of PSA-testing.  
In recent years, significant advances have taken place in management of PC 
patients. However no definitive treatment is available which suits every case of 
PC. These treatment modalities are used as a single treatment modality or in 
combination in range of clinical scenarios. Recent guidelines suggest that every 
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treatment option has its own benefits and risks, so individual patients should be 
included in the decision making process for selection of treatment. 
1.2 Cancer registration 
International Agency for Research on Cancer described cancer registration as the 
“systematic collection, storage, analysis, interpretation and reporting of data on 
subjects – performed by cancer registry organisation” (Jensen and Storm, 1991). 
Cancer registries can be broadly classified into hospital-based and population-
based registries. 
The basic aim of both of these registries is to collect information on cancer 
patients. The purpose of hospital-based registry is narrow and includes planning, 
administration and monitoring of hospital services and resources. The data 
collected in hospital-based registries is less beneficial for epidemiological 
studies as it is generally not possible to clearly define the catchment area of the 
hospital and the cases in one particular hospital might not truly represent the 
whole population in that region (Jensen and Whelan, 1991). Population-based 
registries collect information on all new cancer cases in a defined geographical 
region. As the data in this registry originate from a defined geographical region, 
the denominator population from which cancer patients came can be defined 
more clearly. Thus, these data can be used for descriptive epidemiological 
studies and inform public health purposes including health need assessment, 
allocation of resources, research on aetiological factors and evaluation of 
preventive services (Jensen and Whelan, 1991). 
Cancer registries routinely collect the information on demographic profile of 
cancer cases, including their age, sex, post-code of residence and date of birth. 
Furthermore, disease related characteristics are also collected including date of 
diagnosis, tumour type, site, primary or secondary tumour and cancer grade and 
stage (however their accuracy and completeness significantly vary between 
registries). In this thesis, only population-based cancer registry will be 
considered for further discussion. 
There are several benefits of using the routinely collected data by the cancer 
registries. Cancer registries collect the information of newly diagnosed cancer 
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cases. Population level coverage of cancer registry is a particular advantage, 
which estimates the incidence rates and prevalence from whole population and 
not from a sample (Bain et al., 1997). So the estimates made by the cancer 
registry data are more likely to be exact, depending on the quality of data. 
Another advantage is the availability of routine data for a long period of time 
and this is particularly advantageous when investigating the trends of disease 
burden over time (Bain et al., 1997) Furthermore, large number of records in 
population-based cancer registries reduce the statistical problems of sampling 
error and selection bias (Bain et al., 1997). However the usefulness of these 
data is based on their quality so it is essential to understand the various factors 
determining the quality of data, particularly the completeness and accuracy of 
the collected data. As all the analysis in this thesis will be based on the cancer 
data of Scottish Cancer Registry, therefore its development and data quality 
issues will be discussed first. 
1.2.1 Scottish cancer registry 
The Scottish Cancer Registry was established in 1958 and has been collecting 
information for more than 50 years now. Cancer registration database currently 
holds the records of 1,200,000 cancer patients and on an average, 40,000 
registrations are made per annum in Scotland (Information Services Division, 
2011). This registry is responsible for the registration of all newly diagnosed 
malignant neoplasms in residents of Scotland (Information Services Division, 
2011). Historically there were five semi-independent cancer registries in 
Scotland before 1997, since then data are pooled together as the Scottish Cancer 
Registry. Reorganization took place and a single cancer registry was established 
which is independently collecting data since January 1st, 1997. Part of this re-
organization, registry also started collecting additional information about the 
disease stage (only for breast, cervical and colorectal cancers), treatment 
including radio and chemotherapy for all the patients (Information Services 
Division, 2011). Several in-house studies by authors of Scottish Cancer Registry 
have assessed the completeness and reliability of the Scottish Cancer Registry 
data. A study in 1990 accessed the data of a computer generated random sample 
of 2,021 cancer patients and compared the cancer registry records with relevant 
medical records (Brewster et al., 1994). Discrepancy rate was different between 
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different variables - 7.7% in histological verification status, 5.4% in ICD-9 site 
codes and 14.5% in ICD-0 morphology codes were recorded (Brewster et al., 
1994). However, the Scottish Cancer Registry data showed a high level of 
accuracy on the whole - 97.2% of the records were accurate and overall 
discrepancy rate remained 2.8% (Brewster et al., 1994). Another study looking at 
the accuracy of colorectal cancer patients in Scotland reported similar findings: 
95% of the data was found to be accurate (Brewster et al., 1995). 
Three studies, independent of Scottish Cancer Registry, of cancer ascertainment 
of malignant tumours have also been published. One of these studies compared 
the data of cutaneous malignant melanoma cases following screening as part of 
a health education programme. This study included cases of seven different 
health boards from England and one health board of Scotland. Case 
ascertainment was found 96% for invasive malignant melanoma and 100% for in 
situ melanoma in Scottish Cancer Registry (Melia et al., 1995). However, case 
ascertainment remained 74% in English cancer registries (Melia et al., 1995). In 
contrast to these, two independent studies reported that registered cases of 
malignant melanoma and primary intracranial tumours in Scottish Cancer 
Registry were significantly underestimated (Counsell et al., 1997;Lucke et al., 
1997). 
In general, the quality of data in Scottish Cancer Registry has been assessed for 
many different tumours, suggesting high level of completeness and accuracy. 
Very few cancer registries conduct studies to assess the data quality and publish 
their results. However where literature is available, data quality of Scottish 
Cancer Registry seems fairly comparable with other cancer registries. 
1.2.2 Measures of cancer burden 
The burden of cancer on society is used to describe the epidemiological 
quantification of occurrence of disease in a given population. Different measures 
are used for the estimation of cancer burden.  
Incidence: 
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Incidence describes newly diagnosed cases of cancer in a defined population 
over a specified period. Incidence rates of a cancer mainly reflect the 
distribution of risk factors in population and diagnostic abilities of health 
services. So the incidence rates are useful measure of burden, where the prime 
objective is to reduce the risk of cancer through successful primary prevention. 
Similarly, efforts for successful early detection of cancer can also be examined 
by estimating incidence rates. 
Prevalence: 
The prevalence of cancer is the number of individuals living in a population, who 
have had a diagnosis of cancer. A time cut-off is usually applied to estimate 
number of cancer cases in a defined population diagnosed during 5, 10 or 15 
years and referred as “limited-duration prevalence”. Prevalence is a useful 
measure for administrative and planning purposes. For example, successful 
primary prevention efforts reduce the prevalence by reducing the incidence of 
cancer, while improvements in services - early diagnosis and advances in 
treatment, increase the prevalence. 
Survival: 
Cancer survival relates to the time course of disease following the diagnosis, 
extending to death due to cancer itself or other causes. Cancer survival is 
usually expressed as the proportion of patients alive at five years or ten years 
after diagnosis. Using population-based data, cancer-specific survival is usually 
expressed as relative survival, which is a ratio of the observed survival for a 
group of cancer patients to the survival expected for people of the same age, 
sex and socioeconomic status in the general population. Cancer survival is 
perhaps the most widely used measure of the effects of different factors i.e. 
timely diagnosis, effectiveness of treatment, socioeconomic circumstances and 
other factors related to health services.  
 In practice, incidence data provide better overall measure of burden of disease 
in a population, so in this thesis we will focus on incidence. Also, a main 
component of this thesis is concerned with the aetiological factors associated 
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with PC - therefore incidence would be a more appropriate measure to reflect 
the risk of developing disease.  
1.2.2.1 Incidence 
Incidence of a cancer represents the occurrence of new cases arising in a given 
period in a specified population. Incidence basically represents the risk of 
developing a cancer due to various underlying factors (Last, 2001). The 
particular advantage of incidence rate is that it allows comparison of risk and 
burden between populations, countries and time periods. Many factors can 
influence the incidence rate including diagnostic intensity, coding and reporting. 
These factors can cause an underestimation or over-estimation of incidence and 
may affect the comparison between population groups and time periods 
(Rothman et al. 2008).  
To calculate the incidence rate of a cancer, for example PC, following 
information is required, i.e. number of individuals diagnosed with a cancer, 
population from which individuals come from and the time period over which the 
data were collected (Rothman et al. 2008). All these parameters can directly 
affect the incidence rates of a population. Different types of incidence rates can 
be calculated using this information i.e. crude incidence rate and age 
standardised incidence rates.  
Crude incidence rate is the number of new cases occurring in a year and usually 
per 100,000 persons in a population. Population at risk is an important factor in 
calculating incidence rates (Bonita et al., 2006). Ideally, these should only 
include people who are potentially at risk of developing a cancer. For instance, 
females should not be included when calculating the crude incidence rates for 
PC. The crude incidence rate is a reliable measure of frequency of disease in a 
population. However, in the example of PC which typically affects men over 50 
years of age, crude incidence rate can heavily be influenced by the age 
structure of a population. In a population where the majority of men are young, 
crude incidence rate is likely to be low and opposite would be true if higher 
proportion of men in a population is old. Similarly, if age-structure of a 
population is varying over time, difference in crude incidence rates could be 
because of a change in age structure rather than the risk of cancer.  
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Therefore, crude incidence has a limited use as it cannot effectively compare 
the burden of disease between populations, cancer registries and over time, as 
it does not take into account the aging structure of a population (Rothman et 
al., 2008). Comparing the rates of incidence between populations, or between 
time periods or sub groups of population, the crude estimates can be misleading. 
We need a ‘Standard Population’ with which we can calculate age-standardised 
rates. For such comparisons, age-standardised rates are used.  
Age-standardisation controls for the changing age structure of population and 
this is the only viable method to compare the rates over time, between 
populations and within population groups. There are two different methods of 
age-standardisation: the direct and the indirect method of standardisation. The 
indirect method is most commonly used to calculate the expected mortality 
rates for an index population, i.e. age specific mortality from a reference 
population. The direct method adjusts for the differences in age-structure of the 
populations, and it is therefore widely used to compare the incidence rates 
between populations and within population over time. The direct standardisation 
is calculated by estimating the crude incidence rates for each age-group (usually 
5-years groups), followed by normalising/correcting these rates to the numbers 
for the respective age specific groups within a fixed reference ‘standard 
population’ of 100,000 people, thus giving an incidence for each of the age-
groups in the standard population (Waterhouse et al., 1976). The age-group 
specific incidence rates are then added together to calculate the overall 
incidence rates for standard population (100,000). Thus age-standardised rates 
can be considered as a weighted average of age-specific rates, the weights being 
taken from the standard population (Waterhouse et al., 1976). Standard 
population can be chosen arbitrarily; the European Standard Population (which 
gives European Age-Standardised Rates) and the World Standard Population are 
two common options (Waterhouse et al., 1976). The European-standard 
population represents the age structure of most of the European countries and 
have been assessed in relation to the Scottish population and found broadly 
comparable (Harris et al., 1998). 
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1.3 International variations in incidence of PC 
Worldwide, 913,000 new cases of PC occurred in 2008, ranking it among the top 
five commonest cancers globally (Ferlay et al., 2010). Lung cancer is the most 
common cancer among men worldwide but in developed world, PC is now the 
commonest cancer among men with 658,000 cases in 2008 (Ferlay et al., 2010). 
The incidence of PC varies significantly in different countries. Generally, more 
developed countries have a higher incidence compared to less developed 
countries. In the year 2008, the age standardised rate (world population) was 
more than five times higher in the developed world (63 per 100,000) when 
compared with less developed world (12 per 100,000) (Ferlay et al., 2010).  
Worldwide incidence varied by 25-fold in 2008 with the highest rates observed in 
Australia and New Zealand and lowest in Micronesia and Polynesia. These large 
variations in incidence could be due to a combination of underlying factors, 
including genetic susceptibility, exposure to unknown risk factors and 
artefactual increases by testing for PC in different countries (Gronberg, 2003). 
Access to and quality of the healthcare services can at least partially explain the 
large differences in incidence rates between the developed and less developed 
countries.  
PC is a condition which is strongly associated with increasing age - approximately 
75% of the total cases occur among individuals of more than 65 years of age. It is 
therefore significantly more common in those countries where the proportion of 
elderly population is higher (Ferlay et al., 2010). However the lower incidence 
rates in developing countries is not only because of the lower proportion of 
elderly population and lower detection but also because of poor recording of 
cancer cases. In year 2006 only 21% of the worlds’ population was covered by 
population-based cancer registries, with very low level of coverage in Asian and 
African countries, 8% and 11% of the total populations respectively (Ferlay et al., 
2010). Although the general idea of disease burden seems reasonably 
straightforward, the burden can be measured or presented using multiple 
dimensions.  
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In addition, the quality of cancer registration and accuracy and completeness of 
cancer data could explain the difference in incidence rates between countries. 
For example, a few decades earlier, when reliable cancer registration data did 
not exist in the African countries, rates of PC in Africa were taken as 
approximately similar to that in the Asian countries (Gronberg, 2003). However, 
one decade ago, PC was reported as very common in Uganda (Wabinga et al., 
2000), and the most common cancer among men in Nigeria (Ogunbiyi and Shittu, 
1999). Migration studies have suggested that men who moved from Japan (a 
country with low incidence of PC) to the US (a country with higher incidence of 
PC), experienced an increase in incidence (Gronberg, 2003). These findings 
suggest that differences observed between countries and racial groups may be 
due to the differences in lifestyle and dietary factors. 
Most up to date cancer statistics have shown variations in incidence rates of PC 
between countries of the developed world. Highest rates were observed in 
Australia, New Zealand, Western and Northern Europe and North America (Ferlay 
et al., 2010). Southern and Eastern European countries experienced lower 
incidence rates compared with other developed world countries (Ferlay et al., 
2010).  
Age standardised incidence rates of PC have dramatically increased in last two 
decades in the UK and Europe (Bray et al., 2010). These increases have largely 
been attributed to the opportunistic testing of asymptomatic PC by PSA (Bray et 
al., 2010;Brewster et al., 2000;Carsin et al., 2010). A decline in mortality rate 
has also been observed which is also attributed to the PSA based testing, which 
led to earlier diagnosis and prompt treatment of localised disease (Collin et al., 
2008;Hussain et al., 2008).  
In the UK, PC is the most commonly diagnosed cancer, excluding non-melanoma 
skin cancer, in men and accounts for nearly a quarter (24%) of all new male 
cancer diagnoses (Cancer Research UK, 2008). As variations in incidence rates 
are noted within the developed countries, similar variations have been observed 
within the four nations within the UK. Wales observed highest incidence rate in 
2008 (age-standardised rates, 119.9 per 100,000) while lowest were observed in 
Scotland (age standardised rates, 85.7 per 100,000) during the same year 
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(Cancer Research UK, 2008). As there are no policy guidelines for the mass 
screening on population level, so the observed differences in the UK are 
attributed to differential uptake of PSA-testing (Westlake and Cooper, 2008). 
It is worth noting that, as these rates are age-standardised, these estimates have 
accounted for the changing age-structure of the population. Therefore, any 
differences observed between countries are unlikely due to the aging 
population. The apparent increase then can be attributed to a real increase in 
risk of the disease and/or an artefact of increased detection of cases by testing. 
The observed increase in incidence of PC in 1970s and 1980s has partially been 
attributed to the transurethral resection of prostate (TURP) for the treatment of 
BPH, which led to incidental finding of PC in approximately 10% of the cases 
(Brewster et al., 2000;Quinn and Babb, 2002). In late 1990s and more recently, 
differences in incidence rates within the UK countries are mainly attributed to 
varying intensity and utilisation of PSA testing in different countries. However, 
the PSA issue still remained unresolved whether the observed increasing rates 
are merely because of increased detection or due to a true increase in the risk 
of this disease.  
1.4 Aetiological factors 
No single factor is considered to be solely responsible for development of PC. 
Many risk factors have been identified which are associated with the 
pathogenesis and cancer development. Evidence on these risk factors and their 
association with PC mainly comes from observational studies. The effects of 
dietary components and role of some chemopreventive agents have also been 
investigated by randomised controlled trials. The review of evidence in this 
section of the chapter will be confined to the evidence of different factors and 
their association with the PC risk. For the purpose of simplicity, the risk factors 
are classified and presented as (1) Non-modifiable risk factors and (2) Modifiable 
risk factors.  
1.4.1 Non-modifiable risk factors 
The risk factors which are beyond the human control like age, family history of 
PC, race, socio-economic circumstances and hormonal levels are considered as 
38 
Chapter 1 
 
non-modifiable risk factors and they have a strong association with the risk of 
PC. A brief review of the evidence on these factors and their association with PC 
is attempted in this section.  
1.4.1.1 Age 
Age is one of the strongest risk factors of PC. PC is uncommon among individuals 
younger than 50 years (<0.1% of all patients) and more than three quarters of 
cases are diagnosed in men over 65 years. The largest number of cases are 
diagnosed in 70-74 age group (Cancer Research UK, 2008) and the cumulative 
risk of PC at the age of 74 years has been calculated from 0.5% to 12.8% 
worldwide (Ferlay et al., 2010). However, post-mortem data have found 
different results which showed that microscopic lesions were found in half of all 
men in their fifties and more than 80% of men older than 80 years (Cancer 
Research UK, 2008). These are the men who never manifest the disease during 
their lifetime, suggesting that a significant proportion of men remain 
asymptomatic despite having the disease. 
An age migration has been brought about due to earlier diagnosis of PC by PSA 
(Mettlin and Murphy, 1994). Due to PSA testing and screening in different 
countries, the whole spectrum of PC has changed in the last few decades. A 
relatively larger proportion of men is now diagnosed before the age of sixty 
years compared to few decades earlier (Mettlin and Murphy, 1994). Also, a 
higher proportion of men are now diagnosed at an earlier stage and grade with 
smaller tumour volume (Mettlin and Murphy, 1994). Whether the age and stage 
shift of PC patients has a beneficial effect on health and quality of life for 
individuals as well as at the population level remains unclear and debatable. 
Further research into survivorship experience of clinically presented and screen 
detected patients may provide valuable information on harms and benefits of 
early diagnosis.  
1.4.1.2 Family history 
Family history has now been firmly established as a risk factor for PC. PC can be 
grouped as one of the three groups - sporadic, familial or hereditary (Bratt, 
2002). Disease is marked as familial cancer if one or more than one first-degree 
relative are affected by the PC. Hereditary PC refers to a subset of familial PC 
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that shows a pattern of cancer distribution consistent with Mendelian 
inheritance of a susceptibility gene (Bratt, 2002). 
Several epidemiological studies have shown an augmented risk of PC for sons and 
brothers of men with the disease. Relative risk of an individual to develop PC 
increases significantly in accordance to the number of individuals affected in 
family, their relationship with the index case(s) and the age at which they 
developed the disease (Carter et al., 1992). If a brother or father of an 
individual had PC, the relative risk in such an individual is doubled with an 
absolute risk of 15%. If a brother or father had the disease before the age of 60 
years, then the relative risk increases three fold and absolute risk becomes 20%. 
The relative risk amplifies to four times and absolute risk is 30% if both father 
and a brother have PC (Bratt, 2002). Regarding the clinical features of patients 
with hereditary and sporadic PC, there are generally no differences in tumour 
grade and pathological stage at diagnosis.  
The most prominent clinical characteristic of hereditary PC is the relatively 
earlier age at diagnosis. Patients from families with hereditary PC are generally 
diagnosed six to seven years earlier than those with sporadic cancer (Bratt, 
2002). This could be attributed to the increased awareness of symptoms and 
more enthusiastic participation in testing, both of which result in earlier 
diagnosis of hereditary cases not only at a lower age but also at a lower grade 
and in localised form. In terms of comparing the survival of these patients, no 
significant difference was observed in earlier studies between men who had 
familial or sporadic PC (Gronberg et al., 1998;Hanlon and Hanks, 1998). 
However, survival comparison between these two groups is difficult because 
earlier age at diagnosis with better differentiated and localised disease among 
hereditary cancers could lead to a longer survival, i.e. lead time bias.  
Similar to other malignancies, particularly solid tumours, PC is a complex disease 
with its initiation arising from interaction between genetic and non-genetic 
factors. There have been many efforts to identify the causative gene(s) for PC, 
despite that most of the existing evidence is elusive (National Cancer Institute, 
2011). Several candidate loci have been identified by genome-wide linkage 
analysis studies in high risk families, but occasionally subsequent studies failed 
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to confirm these candidate susceptibility loci among PC patients (National 
Cancer Institute, 2011).  
Not only the history of PC but also, the history of colorectal or bladder cancer in 
parents has a higher than multiplicative interaction on an individual’s risk of 
developing PC (Zhang et al., 2009). Diagnosis of a cancer among a family 
member usually leads to more intense testing among other family members. 
Therefore, the observed higher risk of cancers among family members could be 
due to higher consciousness and testing for cancer, and not necessarily due to 
genetic composition of the individuals.  
1.4.1.3 Race 
Racial differences exist in the incidence of PC. Black men have a higher risk of 
PC development (1.5 to 2 times) compared with White men, while Caucasians 
are observed to have a higher risk than Asians (Brawley et al., 2007;Krieger et 
al., 1999). These differences in incidence of PC have raised a question, whether 
the difference in incidence of PC among various races is just a result of genetic 
predisposition of certain races to develop the disease or a product of differential 
distribution of other factors like socio-economic status of individuals, their 
dietary and lifestyle habits and access to health care services.  
Asian men have a lower incidence of PC, while the Japanese and Chinese 
immigrants in Western countries experienced a higher incidence compared to 
their counterparts (Brawley et al., 2007). If genetic pre-disposition is the major 
contributing factor, then the substantial difference in incidence among men of 
same origin, living in different countries cannot be explained. These findings 
have suggested the possible role of lifestyle and dietary patterns as contributing 
factors in disease development. Although genetics play a vital role in PC 
development, considerable evidence suggests that environmental factors 
(possibly diet and lifestyle) are important and it is the gene-environment 
interactions that play a central role in the development of PC (Giovannucci et 
al., 2007; Whittemore et al., 1995).  
Another important consideration arises from the findings of autopsy studies 
which suggest that the prevalence of small PCs is relatively higher among 
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numerous populations, and there are little or no racial/ethnic variations in the 
incidence (Sanchez-Chapado et al., 2003;Soos et al., 2005). These findings lead 
to further questions about the factors which promote these small slow growing 
tumours and how they differ from the factors responsible for the development of 
larger and clinically significant disease. Again, multiple factors including 
androgen level in the body, lifestyle factors and diet are considered to be 
associated with differential tumour biology among different races but the 
evidence on these remains mostly equivocal (Brawley et al., 2007).  
1.4.1.4 Socio-economic circumstances 
Socio-economic circumstances have been related to the incidence of many 
cancers including PC. It is unclear whether the increased incidence in specific 
socio-economic groups reflects real risk factors being more prevalent in some 
groups (discussed later) or simply results from the readiness to diagnose the 
condition.  
Prostatic carcinogenesis is believed to be a multistep process. Along with race, 
evidence suggests that lifestyle and environmental factors do contribute in this 
carcinogenic process. Studies have also indicated that the differences in risk of 
PC between different racial origins are mainly driven by the socio-economic 
circumstances of the individuals (Dale et al., 1996). Many other factors are 
thought to be associated with the socio-economic differences in cancer 
development. For prostate particularly where the aetiology is poorly understood, 
the involvement of socio-economic status in the risk of disease can be due to the 
differential distribution of currently unknown risk factors - environmental 
exposures such as diet and sexual activity being the examples of such risk 
factors.  
Another important aspect in context of socio-economic circumstances is the 
capacity to access the health care services and quality of testing services 
available to different socio-economic groups. These obviously vary in different 
countries. For instance, in the US, where access to services mainly depends on 
the ability to pay for a medical insurance, individuals of low socio-economic 
circumstances are less likely to have good access to health services and 
ultimately are less likely to be diagnosed earlier (Dale et al., 1996).  
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Surprisingly, in the UK, where National Health Services is being financed by 
central Government and services are free at the point of use for everyone, 
similar socio-economic disparities in incidence of different cancers and other 
chronic disease have been observed. It has been reported from England that 
most affluent people are more likely to have higher incidence of the PC 
compared with the most deprived group (Dutta et al., 2005). Differential use of 
PSA testing may explain these differences between socio-economic groups. 
However, other factors which could be the higher level of education, health 
consciousness and heightened awareness about the disease among most affluent 
people are hardly examined in most of the PC research in this country. There has 
been no published data from Scotland on the incidence trend of PC in relation to 
the socio-economic circumstances. However, evidence suggests that the health 
of Scottish population is poorer than the rest of the UK (Hanlon et al., 2005).  
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Area bases measures of socio-economic circumstances: 
In most of epidemiological research socio-economic circumstances of individuals 
are measured by using variety of different indexes such as education, income, 
car and house ownership. Area-based indices are also widely used as a measure 
of socio-economic circumstances. Many deprivation indices have been derived 
since the 1980s and there has been a wide debate on the use of these indices. 
Area-based measures of socio-economic circumstances are usually derived using 
the census and administrative data. Carstairs and Morris devised an area-based 
measure of socio-economic status which was based on the data of 1981 and 1991 
Censuses respectively. Carstairs scores are basically un-weighted combinations 
of four Census variables namely unemployment, overcrowding, car ownership 
and low social class (Carstairs and Morris, 1989;Morgan and Baker, 2006). Each of 
the four variables are transformed or standardised to a common scale (i.e. with 
a mean of zero and standard deviation of one) so that the value of no one 
variable dominates the overall score of individuals (Morgan and Baker, 2006). In 
Carstairs score, deprivation group 1 represents the most affluent while the 7 
represents the most deprived.  
In Scotland, another area-based measure – Scottish Index of Multiple Deprivation 
(SIMD) is widely used. This is a postcode based measure of socio-economic 
circumstances derived by post code of residence. The SIMD score is based on 
detailed information on seven key domains including income and benefits, 
employment in working age population, health and healthcare utilisation, 
education attainment, access to services and transport, recorded crime rates 
and housing quality and overcrowding (Scottish Government, 2006). SIMD 
quintiles are commonly used, 1 representing the least deprived quintile and 5 
representing the most deprived quintile. 
All area-based measures assume that the individuals with a living area 
experience similar socio-economic circumstances, and that the ‘background’ risk 
factors of the population are evenly distributed within the area. However, there 
is an on going debate that the choice of area-based measure can influence the 
magnitude of deprivation gradient in health between different socio-economic 
groups. The choice of measurement index can impact on the observed 
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deprivation gradient in incidence and survival between groups of cancer 
sufferers (Donnelly and Gavin, 2011). These measures may not be truly 
representing the socio-economic circumstances of individuals even though they 
can provide valuable information about factors at the population level, which is 
of particular importance when considering access to the health care services, 
and utilisation of services.  
1.4.1.5 Hormones as risk factors 
Although there is sufficient biological evidence that hormones, particularly the 
androgens play a vital role in the development of PC but most of the 
epidemiological evidence remained inconclusive in a hormone dose to cancer 
risk context (Hsing, 2001). Testosterone and dihydrotestosterone are the two 
most important androgens of adult males. Testosterone is the major circulating 
male hormone, while dihydrotestosterone is synthesised in tissues. The latter is 
derived from testosterone mainly in the prostate gland and skin by the 5 alpha 
reductase isoenzymes type 1 and type 2 (Hsing, 2001). Physicians’ Health Study 
observed a strong trend of increased PC risk with increasing levels of plasma 
testosterone (ORs by quartile = 1.00, 1.41, 1.98, and 2.60 (95% CI = 1.34-5.02); P 
for trend = 0.004) and an inverse trend in risk was seen with increasing levels of 
sex hormone binding globulin (ORs by quartile = 1.00, 0.93, 0.61, and 0.46 (95% 
CI = 0.24-0.89); P for trend = 0.01) (Wolk et al., 1997). Epidemiological evidence 
on hormones and PC risk initially emerged from case-control studies but later on 
most of the studies reported inconsistent evidence (Hsing, 2001). A main 
limitation inherent in the case-control design of such studies was the inability to 
obtain the hormonal status of participants either before diagnosis or (even 
harder) before the onset of prostate carcinogenesis, as the disease process or 
disease itself might have altered the hormonal profile among patients in such a 
study design.  
A meta analysis of 9 prospective studies reported that there was no significant 
evidence that the serum testosterone concentrations were different between PC 
cases and controls, with a pooled risk ratio 0.99 (95% CI 0.95-1.02) (Eaton et al., 
1999). Methodological limitations could partially explain the mixed results in 
different studies. For instance, intra-person and laboratory variations can affect 
the measurement of hormonal levels between different studies. Similarly, the 
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timing of measurement of hormone level could also explain the difference 
between studies. For example, if testosterone is a major risk factor for the 
development of disease, then the most appropriate timing of sampling might be 
the age between 15 to 23 years (Gronberg, 2003).  
1.4.2 Modifiable factors 
Modifiable risk factors have been substantially examined for their relationship 
with the development and progression of PC. Generally, to date, there is no 
known means of preventing PC, and no well established modifiable risk factor is 
known to alter the risk of this cancer. Factors studied in details fall broadly in 
the following classes: dietary factors (tea coffee, fat, meat intake, lycopene, 
soy and vitamins), lifestyle and co-morbidities (smoking, alcohol, physical 
activity, obesity and diabetes), and medications and supplements (statins, 
finasteride, non-steroidal anti-inflammatory drugs and vitamin). 
1.4.2.1 Tea and coffee as risk factors 
Tea and coffee are among the most popular beverages worldwide and have been 
investigated for their role in PC development. These beverages are also among 
the few potentially modifiable risk factors for PC but the epidemiological 
evidence is inconclusive and therefore no recommended guidelines are available 
for their consumption. Preparation of these beverages also differs between 
various regions of the world. Both tea and coffee are thought to be protective 
factors against the PC but the evidence has not achieved that level to 
recommend their use for the prevention of PC (Lee et al., 2009).  
Tea (Camellia Sinesis) is one of the most popular and commonly consumed 
beverages in the world (Bokuchava and Skobeleva, 1980). Green tea is more 
commonly consumed in Asian countries while black tea is predominantly used in 
Western countries. Green tea is prepared from the dried leaves of the plant, 
whereas the preparation of black tea includes crushing of leaves and a 
fermentation process (Bokuchava and Skobeleva, 1980). These differences in the 
preparation process are responsible for variations in the taste and chemical 
composition of teas and may also influence their carcinogenicity. Tea 
consumption has been investigated for its possible effects on health outcomes in 
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the last three decades (Mckay and Blumberg, 2002). Most of the in vitro cell 
culture, in vivo animal and clinical interventional studies investigated the effect 
of green tea or purified extracts on PC carcinogenesis and reported its 
chemopreventive effect but results from epidemiological studies on green tea 
consumption and carcinogenesis are mixed (Henning et al., 2011;Mckay and 
Blumberg, 2002). Population-based studies on the role of tea and PC risk have 
shown mixed results, some showing a positive association (Sharpe and 
Siemiatycki, 2002), some negative (Jain et al., 1998;Severson et al., 1989) while 
others found none (Ellison, 2000;Heilbrun et al., 1986;La et al., 1992;Villeneuve 
et al., 1999). 
Recent review on tea and PC suggested that tea is a healthier alternative to 
coffee as evidence on a preventive effect of tea has been more pronounced in 
epidemiological evidence (Lee et al., 2009). Most of the laboratory and 
epidemiological studies which provided stronger evidence on protective effects 
of tea were carried out on green tea which is more common in some Asian 
countries including China and Japan. Extracts of tea have been widely used in 
both in vivo and in vitro studies have and found significant effect on cancer cell 
death. On the other hand, black tea, which is much more common in most of the 
Western countries has not been widely studied and evidence on black tea and PC 
is limited to few studies with smaller number of cases and short follow-ups 
(Chhabra and Yang, 2001).  
Evidence for an association between black tea and PC incidence is much weaker 
than that for green tea (Henning et al., 2011). Research is either limited to case 
control studies (Ellison, 2000;Jain et al., 1998;Villeneuve et al., 1999), which 
are prone to biases, or cohort studies (Heilbrun et al., 1986;Kinlen et al., 1988) 
with small number of PC cases, short follow-up periods and inadequate 
adjustments for potential confounding effects.  
A meta-analysis of twelve epidemiological studies (eight case-control and four 
prospective cohorts) (Park et al., 2010) and reviews on role of coffee in PC risk 
(Lee et al., 2009;Dagnelie et al., 2004) remained inconclusive. However, a 
recent study on coffee consumption and PC risk, from a large, prospective 
cohort (Wilson et al., 2011), reported a weak inverse association with overall 
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risk and strong inverse association between higher coffee intake and aggressive 
as well as lethal PC (Wilson et al., 2011). Although the authors did not 
recommend that coffee consumption should be increased to reduce the risk of 
PC. However, study provides the evidence that future research should 
investigate the role of these factors in relation to grade-specific incidence of PC.  
Coffee contains several hundreds of volatile and non-volatile compounds which 
have the tendency to modify the effect of many other substances in human body 
(including dietary components), but we often know little or nothing at all which 
substance or groups of substances will be affected in which direction and that is 
mainly due to extremely complex biological processes (Porta et al., 2003;Spiller, 
1984). Given that coffee compounds have very strong metabolic, physiological, 
cellular and molecular effects, clinical and epidemiological data from large 
human groups should be carefully analysed for interactions (Porta et al., 2003).  
Common limitations of the studies on tea/coffee and PC risk are short follow-up 
of studies and lack of Gleason grade information. Considerable interest has 
developed in recent years to explore how some of the dietary and lifestyle 
factors are associated with the biology of prostate tumours and certain 
behaviours are linked with more aggressive or fatal disease.  
1.4.2.2 Fat intake 
Dietary components are considered important in the aetiology of PC. Increased 
rates of PC among Japanese and Chinese immigrants in the US suggested a 
significant role for dietary and lifestyle habits in the development of PC 
(Gronberg, 2003).  
Many observational studies examined the role of fat intake in aetiology of PC. 
Earlier studies showed some positive associations while the data presented from 
larger prospective cohorts in more recent years suggested no relationship 
between fat intake and PC. The Health Professional Follow-up Study, a 
prospective study of 51529 men in the US reported that total fat intake was 
directly related with advanced stage PC (RR = 1.79, 95% CI = 1.04 -3.07) 
(Giovannucci et al., 1993). Mono-unsaturated fat and saturated fat were also 
positively associated with the advanced stage PC (Giovannucci et al., 1993). 
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These results remained consistent even after adjustments for age, energy 
intake, BMI, marital status and history of vasectomy. The interesting fact is that 
fat intake might be different between different racial or socio-economic groups; 
however this study did not account for potential effect socio-economic status 
and race.  
The Malmo Diet and Cancer study in Sweden, a large prospective cohort study, 
reported no significant association between fat intake and overall PC risk 
(Wallstrom et al., 2007). Some biological research has provided evidence of a 
protective role of fish fat in PC, but the Malmo Diet and Cancer study showed 
that Eicosapentaenoic acid and Docosahexaenoic acid (DHA), predominantly 
found in fatty fish, were associated with increased risk of PC (HR for highest vs 
lowest quintiles of DHA = 1.35, 95% CI 1.07-1.69) (Wallstrom et al., 2007). The 
main limitation of this study was that majority of the participants were younger 
than 50 years and median follow-up time was only 11 years. The role of fat 
consumption in carcinogenesis might even start long before the actual 
manifestation of the cancer. Therefore, studies with shorter follow-up are 
unlikely to capture any real associations.  
The European Prospective Investigation into Cancer and Nutrition (EPIC), another 
large multicenter prospective study of 142,520 men, also did not find any 
significant relationship between dietary fat intake and the risk of PC (Crowe et 
al., 2008). The EPIC study also had a relatively short follow-up period (median 
follow-up at 8.8 years) and the risk estimate significantly differed when 
stratified analysis was performed based on the data from different countries. 
However, the question still remained unanswered whether this heterogeneity 
was attributable to the true biological differences of individuals between 
different countries or just random variation (Crowe et al., 2008). 
In summary, most studies have provided mixed results on the relationship 
between fat intake (total, monounsaturated, polyunsaturated) and PC risk.  
1.4.2.3 Plasma cholesterol as a risk factor 
It has been observed for about a century that the levels of cholesterol, fatty 
deposits, lecithin and some other lipids in the diseased prostate are elevated 
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(White RM, 1909). Several studies have explored the relationship between 
plasma cholesterol levels and the incidence of PC and its associated mortality 
with inconsistent conclusions (Bravi et al., 2006;Hiatt and Fireman, 1986;Kark et 
al., 1982;Knekt et al., 1988;Davey Smith et al., 1992;Thompson et al., 1989). 
Some found a positive association between cholesterol and PC mortality (Batty 
et al., 2011;Bravi et al., 2006) while others revealed either an inverse 
relationship (Kark et al., 1982;Thompson et al., 1989) or no overall association 
with incidence (Hiatt and Fireman, 1986;Knekt et al., 1988). The imprecision of 
death record data may make it difficult to differentiate between risk factors for 
a variety of causes of mortality among PC patients and mortality from PC itself. 
The well-established relationship between serum lipids and cardiovascular risk 
(Preiss, 2009), for example, may confound the apparent positive association 
between cholesterol and mortality in PC patients. 
A few decades ago, there was concern that a low circulatory cholesterol 
concentration as a result of statins use, which is cardio-protective, might 
increase the risk of some non-cardiac events particularly cancers. Some of these 
studies reported an inverse association between cholesterol and PC (Kark et al., 
1982;Thompson et al., 1989). These studies might have been influenced by the 
“reverse causality” – i.e. cholesterol was modified by undiagnosed disease and 
not a causal factor for it, may have partly explained their observations. 
In general, the evidence on the role of cholesterol in prostate carcinogenesis 
remains equivocal and limited. A few studies have investigated the role of risk 
cholesterol in relation to grade-specific PC risk. There is no study published on 
the role of cholesterol on grade-specific PC risk from the UK population to date. 
Further evidence is required before making any recommendations about statins 
or cholesterol level management in relation to PC.  
1.4.2.4 Smoking 
The role of lifestyle has been widely studied in relation to different cancers and 
considered very important in disease development. Evidence of these factors 
with regard to PC is equivocal. One important fact which needs to be considered 
is the competing risks. Individuals with health risk behaviours like smoking, 
sedentary lifestyle and higher alcohol intake may be at a higher risk of death 
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due to other chronic diseases. If this is the case then evidence should suggest 
lower risk of PC among those who had high alcohol intake, smoking habits and 
physical inactivity. Therefore, some of the evidence on these factors will be 
briefly reviewed in the following section 
Carcinogens in tobacco directly affect the sex hormone and growth factor 
profiles which can ultimately lead to altered risk of PC. Evidence on smoking and 
its association with overall risk of PC is inconsistent. However, smoking has a 
stronger relationship with advanced and fatal PC (Watters et al., 2009;Zu and 
Giovannucci, 2009;Huncharek et al., 2010). In a large prospective study, current 
and former smokers had a significantly lower risk of developing non-advanced PC 
(18% and 11% respectively) (Watters et al., 2009), while ‘current’ smoking status 
had a significantly higher risk (Huncharek et al., 2008) of fatal PC (Watters et 
al., 2009). Consistent with this, a meta-analysis of 24 prospective studies which 
enrolled 21,579 PC patients reported that the current smokers had 14% higher 
risk of fatal PC than the non-smokers (Huncharek et al., 2010), Additionally they 
reported the dose-response effect of smoking and concluded that the heavy 
smokers had 24% to 30% higher risk of death from PC (Huncharek et al., 2010).  
1.4.2.5 Alcohol 
Alcohol consumption and its association with cancer risk has been extensively 
studied in epidemiological research, however there is little evidence on its role 
in PC risk. Alcohol use might have adverse and protective effects on prostate 
carcinogenesis because experimental evidence suggests that ethanol alters the 
sex hormones profile in such a way that the growth of prostate cells is reduced, 
while it can enhance the early stage carcinogenesis due to the oxidative stress it 
causes (Baglietto et al., 2006).  
Multiple studies have suggested that alcohol consumption has no association with 
the overall risk of PC (Gong et al., 2009;Baglietto et al., 2006), while results 
from the Prostate Cancer Prevention Trial (PCPT) suggested that heavy drinking 
(>4 or 5 drinks per day) doubles the risk of advanced PC (Gong et al., 2009). 
Results of a meta analysis published on alcohol use and PC risk were also 
inconsistent, i.e. suggestive of no association of alcohol consumption and the 
risk of PC and mortality (Middleton et al., 2009). 
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1.4.2.6 Physical activity 
The exact mechanism by which physical activity may influence the risk of PC is 
unknown. However, there are some speculations that physical activity affects 
certain hormones which are associated with prostate carcinogenesis. However, 
epidemiological studies on the strength of effect are inconclusive.  
Recent evidence from a large prospective study reported that exercise at the 
baseline or during adolescence was not significantly associated with total, 
advanced or fatal PC risk (Moore et al., 2008). Results from Health Professionals 
Follow-up Study suggested that there were no association between the vigorous 
physical activity and PC risk, although there was some risk reduction in fatal PC 
but not statistically significant (RR 0.59, 95% CI 0.35-1.01)(Giovannucci et al., 
2007). A recently published prospective study measured the lifetime physical 
activity and observed its association with PC risk (Orsini et al., 2009). They 
reported that lifetime vigorous physical activity was associated with increased 
risk of low grade and non advanced cancer while it reduces the risk of advance 
and fatal PC (Orsini et al., 2009).  
1.4.2.7 Diabetes mellitus 
Diabetes has been found to reduce the risk of PC, both low and high grade 
disease. The PCPT, a large randomised control trial, reported a 47% risk 
reduction of low grade disease and 27% reduction in risk of high grade PC among 
those who had a history of diabetes mellitus (Gong et al., 2006). The main 
concerns on these findings from PCPT were the short follow-up of the individuals 
and extensive screening of study participants as everyone had to have a prostate 
biopsy at the end of study. Individuals, with a history of diabetes mellitus may 
have introduced a survival bias as these would have been those who were 
otherwise healthy and escaped from death due to other diabetes related causes, 
for example cardiovascular mortality. 
A multiethnic cohort study carried out on 5941 PC patients reported that 
diabetics had a significantly lower risk of PC than non-diabetics (RR = 0.81, 95% 
CI: 0.74, 0.87; P < 0.001) (Waters et al., 2009). Similar findings of protective 
effect of diabetes mellitus on PC have also been reported from Health 
Professional Follow-up Study (Kasper et al., 2009) and Prostate, Lung, Colorectal 
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and Ovarian (PLCO) cancer screening trial (Leitzmann et al., 2008). 
Interestingly, most of these studies relied on self reported diabetes mellitus. 
Individuals who had a diagnosis of diabetes mellitus are likely to also take 
medication (including aspirin and statins to reduce the risk of cardiovascular 
events) and may also make lifestyle and dietary modifications to manage their 
disease. These studies did not account for the effect of drugs in use by the 
participants. In addition, the apparent association between diabetes mellitus 
and PC may have been confounded by some unknown factors as well. 
More recently, these findings have also been challenged by studies published 
from national insurance data of Taiwanese men and also from a prospective 
study, which reported a significantly higher risk of PC in patients who had a 
history of diabetes (Lee et al., 2011;Tseng, 2011). Ohsaki cohort study of 
Japanese men also reported similar findings of increased of advanced stage 
disease among diabetic patients (Li et al., 2010).  
The biological mechanism which is thought to underlie the relationship between 
diabetes and PC is the reduction in concentration of insulin like growth factor-1 
and testosterone. As the evidence from different populations showed contrasting 
findings, the question still remains unanswered that whether the observed 
associations are real or affected by some residual confounding or biases.  
1.4.2.8 Body size and prostate cancer risk 
Body size has been extensively studied in relation to the risk of PC. Different 
measures of body size are used. Height, BMI (general obesity) and WHR (central 
obesity) are the common methods to quantify the body size. 
A meta-analysis on 56 observational studies reported that BMI was positively 
associated with the risk of advanced disease (random effects RR 1.12 per 5 
kg/m2 increment, 95% CI 1.01–1.23) but not with localized disease (random 
effects RR 0.96 per 5 kg/m2 increment, 95% CI 0.89–1.03) (MacInnis and English, 
2006). This meta-analysis also suggested that height was marginally significant 
and increasing height was related to increased risk of PC (MacInnis and English, 
2006).  
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Possible mechanism linking obesity and PC is the complex interaction of obesity 
with the testosterone and androgens (Mistry et al., 2007). Another meta-analysis 
of 58 observational studies also suggested an increasing risk of PC with height 
(Zuccolo et al., 2008).  
Recent findings from US national surveys indicate the fact that the observational 
investigations of obesity and PC may have under-estimated the observed 
associations between obesity and PC incidence. PC diagnosis is now made by 
prostatic biopsy, while in the first place, an indication for biopsy is increased 
level of PSA. Data from three national surveys suggested that obese men were 
17% more likely to have lower PSA (lower than the threshold for biopsy 
indication < 4ng/mL) compared with lean men with a desirable BMI (Parekh et 
al., 2010). Possible mechanism involved in this association is that obese 
individuals tend to have low testosterone and that could lead to lower PSA. 
Another explanation is the blood dilution among obese individuals that may lead 
to a lower PSA level and ultimately lower reported incidence. Prostate testing 
for cancer and treatment study (ProtecT) from the UK reported that obese men 
were less likely to have low grade PC, however no association was observed 
between high grade or advanced PC (Dimitropoulou et al., 2011).  
Taken together, the findings of recent US survey and earlier observational 
studies, obesity’s relationship with high grade disease seems plausible as obese 
individuals are more likely to have lower PSA. As a result, chances of earlier 
detection reduce and obese men may present at a later stage with more 
aggressive disease, which has been reported from large cohorts (Gong et al. 
2006).  
Obesity, dietary habits and lifestyle are strongly related with hormones including 
leptin, insulin and insulin like growth factors. Insulin and leptin have also been 
examined for their association with the risk of developing PC. Insulin is mainly 
known to increase the risk of different cancers through its effect on cell 
proliferation, differentiation and apoptosis. The existing epidemiological 
evidence has not as yet established a clear causal association of these hormones 
with PC (Albanes et al., 2009;Hsing et al., 2001;Nandeesha, 2009).  
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In the recent years, insulin like growth factor (Gennigens et al., 2006) family has 
been identified as a factor which is not only associated with the overall risk of 
PC but also suggested to be a key factor in metastatic disease. Substantial 
biological evidence has suggested that increased level of IGF-I and II increase the 
risk of PC development whereas a recent meta analysis of 12 large prospective 
studies showed only a moderate increase in the risk of PC (Gennigens et al., 
2006). Biological evidence suggests that IGFs may possess a tendency to induce 
prostatic epithelial proliferation. However, IGF-1 has shown a significant 
relationship with PSA (Oliver et al., 2004) even among healthy individuals with 
no evidence of PC. The IGF system therefore might be a link between the 
lifestyle and dietary factors and PC. Consumption of high amount of fat, proteins 
and dairy products has been related to the IGF-1 (Key, 2011). Heavy 
consumption of these aforementioned products along with a sedentary lifestyle 
could lead to increased production of insulin that in turn can raise the level of 
IGF, thus explaining how IGF could be a risk factor of PC (Key, 2011).  
1.4.2.9 Meat intake 
Evidence on the role of meat intake in the aetiology of PC is “limited-
suggestive” of increased risk with increased consumption, while the evidence on 
red meat is even at a lower level of “limited-no conclusion” (Sinha et al., 2009). 
The increased risk due to higher consumption of meat is due to the high fat 
content of red and processed meat. Several mechanisms have been proposed 
which can increase the risk of PC with higher consumption of fat. One 
explanation is that higher fat intake can increase the level of sex hormones, 
which is possibly linked with the PC risk (Giovannucci et al., 1993). 
A population-based case control study conducted in the US showed a higher risk 
of PC among Black Americans due to higher consumption of meat (Hayes et al., 
1999). The increased intake (grams/day) of meat was shown to double the risk of 
PC among Black Americans, (P trend = 0.007) but not in Whites (Hsing et al., 
2001). However, these findings were not replicated from a nationally 
representative sample, which reported no association between meat and animal 
fat intake with PC (Tseng et al., 2004). More recently, the evidence from 
prospective studies also provided mixed results of no association or positive 
association (Rohrmann et al., 2007).  
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Several limitations are inherent in these studies, which could be attributed to 
mixed results. First, although most studies used validated questionnaire based 
methods to collect the information of meat consumption, the possibility of 
measurement error in assessing the dietary intake could not be completely ruled 
out. Also, cooking practices are very different between different populations, 
and these cooking practices along with the addition of other ingredients in food 
could also alter any potential link between meat intake and PC (John et al., 
2011).  
Interestingly, recently published data from multiethnic cohort suggested no 
evidence of relationship between intake of meat, or well cooked meat with the 
risk of PC. Furthermore, they could not find any significant relationship between 
exposure to heterocyclic amines and PC risk (John et al., 2011;Sharma et al., 
2010). 
1.4.2.10 Lycopene 
Lycopene is an acyclic isomer of beta-carotene for which the main source is 
tomato and its products. Other sources of lycopene include pink grapefruit, 
watermelon, rosehip, apricot, and guava but the amount of lycopene content 
among these is little compared to tomato. Besides blood plasma, lycopene is 
concentrated in adrenal gland, testes, liver and in the prostate gland. It is the 
most predominant carotenoid, where it functions as a potent antioxidant and 
protects the cells, lipid layers and proteins from oxidative damage. Earlier, 
epidemiological studies showed a significant risk reduction of PC from 15% 
(Giovannucci et al., 2002) to 25% (Gann et al., 1999) among those consuming a 
diet rich in lycopene but later many prospective studies observed no association 
between lycopene and overall PC risk (Haseen et al., 2009;Schuurman et al., 
2002). Null findings from many prospective studies could be explained by many 
factors including small number of cases particularly advanced stage disease, 
where lycopene has shown higher preventive value. In some studies, lycopene 
intake was too low to observe a possible threshold effect, and finally the 
widespread use of PSA testing has made it difficult to understand the true causes 
of PC, as many more cases are now diagnosed on a low grade and stage with very 
small tumour size which otherwise might remain asymptomatic during lifetime of 
the individual. Furthermore, self reporting of tomato intake and its products 
56 
Chapter 1 
 
(which are rich in lycopene) can bias the results as the exposure assessment may 
have varied due to the participants’ and the interviewer’s related factors.  
However, some recent studies analysing serum lycopene levels rather than self 
reported intake of lycopene rich foods also found no association between 
lycopene level and PC risk. A nested case control study provided no evidence of 
an association between serum lycopene level and overall (OR 1.14; 95% CI, 0.82-
1.58 for highest versus lowest quintile; p-value 0.28) or aggressive PC (OR 0.99; 
95% CI, 0.62-1.57 for highest versus lowest quintile; p-value 0.433) (Peters et 
al., 2007).  
Recent findings from PCPT (Mellon, 2005) also suggested no association between 
serum lycopene level and the risk of overall as well as grade-specific risk (Kristal 
et al., 2011). PCPT had a follow-up of 7 years; the question however still 
remained unanswered that for a disease like PC, where natural history is very 
long and histological lesion starts decades before the presentation, whether 
these factors being studied before the manifestation are truly related to the 
incidence of PC or its progression and clinical presentation.  
In general, systematic review of epidemiological evidence provided insufficient 
evidence that either the tomato products or the lycopene has any significant 
role in prevention of PC or any benefit associated with the presentation of PC 
(Haseen et al., 2009).  
1.4.2.11 Soy intake as a risk factor 
Differential incident rates of cancer between populations have drawn the 
attention of research community to the dietary intake and the risk of chronic 
diseases including cancer. Soy is a plant based dietary ingredient rich in protein, 
and is widely consumed in Asian populations. Laboratory studies have suggested 
that isoflavones within soy derived food have strong antioxidant and anti-
inflammatory actions, both of which are thought to control survival of PC cells 
(Hsu et al., 2010).  
Most of the studies, published from Asian countries, have indicated a preventive 
(or protective) role for soy in the development of PC (Lee et al., 2003). A risk 
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reduction of up to 42% (Lee et al., 2003) in PC has been observed in Chinese 
population among those who had higher intake of soy. A recently published study 
which included 4404 PC patients suggested that the risk reduction of PC was 
attributed to legumes intake and probably not because of the isoflavones in the 
soy products (Park et al., 2008).  
Strong evidence has emerged from studies carried out in the Asian populations. 
However, these findings were not found to be consistent in the Western 
population. In a recent meta-analysis of epidemiological studies, it has been 
suggested that the preventive effect of soy food was only seen for non-
fermented food where the risk reduction of up to 30% was observed whereas in 
fermented food there was no evidence of an association between higher intake 
of soy food and PC risk (Yan and Spitznagel, 2009). This review also highlighted 
that the risk reduction was only observed in studies conducted in Asian 
countries, while there were no evidence of protective effect in Western studies. 
It was therefore suggested that the type of soy food and its compositional 
difference may have some role in protective effect (Yan and Spitznagel, 2009).  
1.4.2.12 Statins  
Many observational studies reported the protective role of statins on PC 
(Boudreau et al., 2008;Murtola et al., 2007). Large population-based studies 
have supported the hypothesis that long term use of statins (series of small 
molecule inhibitors of the 3-hydroxyl-3-methylglutaryl coenzyme reductase, a 
central enzyme in cholesterol synthesis) reduce the risk of advanced PC (Jacobs 
et al., 2007;Murtola et al., 2007;Platz et al., 2006). In addition, the duration of 
statin use has also been linked with reduced risk of high grade PC (Platz et al., 
2006). A major confounding factor is that the statin users tend to have a lower 
level of PSA when compared to those on statin treatment (Mondul et al., 2010). 
This relationship between statins and PSA could be a reason for the lower 
observed incidence of overall and advance grade PC among PC patients. Contrary 
to these, no association between the statin use and the risk of overall as well as 
high grade or stage PC has been reported in more recent studies (Agalliu et al., 
2008;Boudreau et al., 2008).  
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Two pathways implicated in prostate carcinogenesis have been suggested as 
potential targets for statins mediated effects. One pathway is the anti-
inflammatory properties of statins as inflammation has been associated with the 
development of PC (Maitland and Collins, 2008). A study on 236 PC patients 
reported significantly lower intratumoral inflammation among the preoperative 
statins users than nonusers (Banez et al., 2010). In the second pathway, reduced 
levels of cholesterols (the principle effect of statins) might have some impact on 
prostate carcinogenesis. Statins have been widely used to reduce the cholesterol 
level in individuals in order to modulate the risk of cardiac events.  
1.4.2.13 Finasteride and prostate cancer 
Finasteride is a 5-alpha-reductase inhibitor - a group of drugs with anti-
androgenic activity. This is frequently used for the treatment of benign prostatic 
hyperplasia. This drug reduces the level of dihydrotestosterone which is 
synthesised in the peripheral tissues. Evidence suggests that Finasteride is 
protective against PC. A large observational cohort study carried out in Finland 
reported a significant preventive effect of Finasteride on Gleason 2-6 tumours 
while there was no significant reduction in overall PC risk, particularly for higher 
grade disease (Gleason 7-10 tumours)(Murtola et al., 2009).  
The PCPT, a randomised controlled trial established in the US in 1993, was one 
of the largest randomised trials which were conducted to investigate the 
chemopreventive effect of finasteride on PC risk. A total of 18,882 healthy 
individuals were recruited in this trial, who had a normal digital rectal 
examination and PSA level of less than 3ng/ml (Mellon, 2005). The primary end 
point of this trial was to estimate the prevalence of PC in the treatment arm 
(Finasteride group) and in placebo group. After seven years of treatment and 
follow-up, the PCPT reported a significant reduction (24.8%) in the risk of PC 
among the treatment group compared with the placebo arm (Thompson et al., 
2003). However, another striking finding of the study was that men in the 
Finasteride group experienced significantly higher risk of aggressive PC (Banez et 
al., 2010) compared with the placebo group (Thompson et al., 2003). 
Furthermore, some sexual side effects were significantly higher among the 
Finasteride group. These findings were widely debated upon among the 
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urological experts and finasteride was not recommended to be used routinely for 
preventive purposes (Mellon, 2005).  
1.4.2.14 Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory (NSAID) medications are one of the most 
commonly used over-the-counter drugs. Experimental studies suggest that these 
drugs, particularly aspirin may have a chemopreventive effect (Yoo and Lee, 
2007). While the biological mechanism is not clearly understood yet, there is 
some evidence that these drugs enhance the apoptotic activity (programmed cell 
death) in cancerous cells (Yoo and Lee, 2007). In addition, in more recent years, 
inflammation has been widely studied as an aetiological factor in most cancers 
so anti-inflammatory properties of these drugs might have an indirect role in 
suppression of carcinogenic process by inhibiting the inflammatory process. 
Epidemiological evidence on these remains equivocal. A UK-wide cross sectional 
case control study indicated that individuals taking non-aspirin NSAIDs and 
NSAIDs were significantly more likely to have PC with 32% and 25% excess risk 
compared with non-users respectively (Murad et al., 2011). Interestingly, this 
study found no convincing evidence of an association between aspirin use and 
the likelihood of PC (Murad et al., 2011). Precise physiological mechanism has 
not yet established. However using the cross sectional design does not clearly 
explain the risk of disease associated with the use of these drugs. Also, 
individuals using these drugs would be more likely to visit the services compared 
to non-users, it may just be a detection bias which increased the likelihood of 
diagnosis of PC among users of these drugs. 
In contrast to this, a recent finding from Health Professional Follow-up Study, a 
large prospective study, suggests that men taking more than 2 tables of aspirin 
per week had 10% lower risk of developing PC (Dhillon et al., 2011). 
Furthermore, men taking more than 6 tablets per week experienced 28% lower 
risk of high grade and lethal disease compared with non-aspirin users (Dhillon et 
al., 2011). The main indication of aspirin use is cardiovascular diseases, so 
individuals using this drug might have died due to non-cancer causes and 
therefore not remained at risk of being diagnosed with PC. Further stratified 
analyses based on presence and absence of cardiovascular diseases did not 
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materially alter the association between aspirin and PC in this study (Dhillon et 
al., 2011). Analysis was repeated in the same study after excluding the men 
dying from non-cancer causes, but the overall findings remained consistent.  
The overall epidemiological and biological evidence on the use of these drugs 
and PC risk still remains inconclusive and further research is required to confirm 
these findings.  
1.4.2.15 Vitamin D 
Many vitamins and minerals have been studied for their preventive role against 
the risk of PC due to their anti-oxidant and anti-proliferative activities. Among 
these, selected agents are discussed below.  
Experimental studies in animals have suggested that the biologically active form 
of vitamin D reduces the degree of proliferation of prostate cells and serum 
levels of vitamin D may be associated with PC risk. However, clinical data have 
not consistently demonstrated any link between vitamin D level and PC. Most 
recent evidence from a meta-analysis of 25 studies provided little evidence 
about the preventive effects of vitamin D against PC. Significant heterogeneity 
was observed between case control studies, and even in prospective studies the 
role of vitamin D remained inconclusive both for the overall (OR 1.14, 95% CI 
0.99-1.31) as well as aggressive (OR=0.93, 95% CI 0.63-1.39) forms of PC (Gilbert 
et al., 2011).  
1.4.2.16 Vitamin E and Selenium 
Selenium and Vitamin E have been proposed to have anti-tumorigenic activities 
in animal models. Previous evidence suggested a preventive role of selenium in 
PC risk (Clark et al., 1996). Secondary analyses of two randomised controlled 
trials indicated that supplementation of vitamin E and selenium could reduce the 
risk of PC by up to 60 percent (Clark et al., 1998;Hartman et al., 1998). This 
preliminary evidence, reported more than a decade earlier, led to the 
establishment of a randomised control trial, the Selenium and Vitamin E Cancer 
Prevention Trial, in the US. A total of 35,533 healthy middle age men were 
recruited from 427 sites in the US, Canada and Peuto Rico with an intention of a 
maximum of 12 year follow-up (Lippman et al., 2009). However, initial results 
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were reported at a median follow-up of 5.42 years and a maximum of 7 years. 
The findings suggested that the there were no significant differences in risk of 
prostate between four groups of individuals receiving either vitamin E or 
Selenium or Selenium and Vitamin E in combination or a placebo (Lippman et 
al., 2009). Furthermore, there was a statistically non-significant increased risk 
of PC (RR 1.13, 99% CI 0.95-1.35) in men of vitamin E group and an increased risk 
of diabetes mellitus (RR 1.07, 99% 0.94-1.22) among participants of selenium 
group. The trial was stopped after these findings and participants were informed 
to stop the supplements intake as there was no significant preventive effect 
against PC (Lippman et al., 2009).  
More recently, the earlier finding of this report has been confirmed with the 
inclusion of additional 521 PCs diagnosed in interval of first and second report. 
Risk of PC increased up to 17% among those taking vitamin E alone during a 
median follow-up of 7 years (Klein et al., 2011). In summary, as with most drugs 
and dietary factors, the evidence on vitamins and minerals in relation to PC risk 
remains inconclusive. Given that the most prostate lesions remain latent for a 
long time even decades in some cases. Any trials with shorter follow of less than 
10 years are unlikely to reveal the true risk factors of PC as the factors 
investigated in such trials may have been affected by the presence of 
asymptomatic disease. Furthermore, any factors which are related to the 
incidence of PC in such short follow-up studies, they may be associated with 
cancer progression rather than the disease development. Therefore, studies with 
longer follow-up are warranted to understand the aetiology of PC. 
1.4.3 Concluding remarks on risk factors 
Most of the evidence on risk factors of PC has originated from observational 
epidemiological studies. However, some experimental studies also investigated 
the role of different dietary factors to understand the disease process. It is 
essential to understand that factors associated with the development and 
progression of PC may not necessarily be causally responsible to ‘drive’ 
carcinogenesis. The concept of causality is vital to the understanding of cancer 
epidemiology and observational studies.  
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Sir Austin Hills put forward some aspects of associations which should especially 
be considered before deciding that the most likely interpretation of any 
observed relationship is causation (Bradford-Hill, 1965). These aspects then well 
known as Hill’s criteria for causation include strength (current findings are 
robust), consistency (has the similar findings produced from different sources 
and settings), specificity (a cause is only related to that disease), temporality 
(cause appeared before the disease), biological gradient (dose-response 
relationship between risk factor and cancer), plausibility (biological explanations 
of findings), coherence (with previous research), experiment (prevention from 
the disease when factor is removed) and analogy (based on previous findings in 
some other settings or for some other diseases even) (Bradford-Hill, 1965). It is 
not possible that all aspects of this criterion can be fulfilled for every disease 
and its risk factors, particularly for most of the chronic diseases and cancer, 
where interaction of multiple factors is vital or required in disease initiation and 
progression. These criteria have been criticised in more recent years particularly 
due to the multi-factorial aetiology of chronic diseases and cancers. However, 
Hills himself suggested “that we can usefully lay down some hard-and-fast rules 
of evidence that must be obeyed before we can accept cause and effect. None 
of my nine viewpoints can bring indisputable evidence for or against the cause-
and-effect hypothesis and none can be required as a sine qua non” (Bradford-
Hill, 1965).  
This framework provided by Hills more than four decades ago proved to be 
fundamental in the modern epidemiology. Since then, different study designs 
including case-control, cohort and experimental studies such as randomised 
controlled trials are used to investigate the associations of different factors in 
relation to the cancer development and its progression. Epidemiological and 
statistical advancements have brought about many changes in the cancer 
understanding and have improved the health of populations.  
1.5 Determinants of survival of patients with prostate 
cancer 
This section of the chapter will review the literature on major determinants 
associated with survival of PC patients. Given that the aetiology of PC is unclear, 
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and incidence has been increasing in last few decades, it is important to improve 
the survival of those who have been diagnosed with this disease. Generally, 
cancer survival is a term used to describe the proportion of individuals who are 
alive after certain period of time (i.e. usually 1-year, 5-year or 10-years) of their 
cancer diagnosis. Survival of PC patients has improved over time. A substantial 
number of studies have explored the role of different factors in survival of PC 
patients, which could be divided into patient related factors, disease 
characteristics and treatments factors. The role of lifestyle related determinants 
and their impact on PC survival have not been studied extensively. Most of the 
survival studies have been based on data collected by Cancer Registries, which 
do not have the information on lifestyle related factors. This could be a reason 
for lack of literature on lifestyle related factors in association with survival of PC 
patients as the registries do not routinely collect information on lifestyle habits. 
It is imperative to understand that patient survival depends on multifaceted 
interaction of many factors.  
1.5.1 Patient related factors 
1.5.1.1 Age 
Age is one of the major determinants associated with survival of PC patients. 
The independent effect of age on prostate-specific survival has not been well 
established and some evidence also suggests that age is not independently 
associated with cancer specific survival, when co-morbidity and disease related 
factors are taken into account. Some of the survival variations between age 
groups could also be explained by the treatment offered to the patient, as 
individuals older than 75 years are less likely to receive a curative treatment 
(Bechis et al., 2011).  
Disease stage and grade are independent predictors of survival but it is 
important to consider that with increasing age, disease stage and grade also 
advances. Evidence suggests that patients diagnosed after the age of 70 years 
had significantly higher proportion of advance stage (52.1% vs. 33%, p<0.001) 
and high grade (17.2% vs. 9.5%, p<0.001) disease compared with those who were 
less than 60 years (Sun et al., 2009). Indeed, in a large prospective cohort study, 
on competing risk regression, age did not show any significant prognostic value 
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after adjustment for comorbidity, disease characteristics and treatment 
modality (Bechis et al., 2011). This study suggested that the decision of 
treatment should be made based on disease risk rather than the individual’s age. 
Earlier to that, PC patients data from a population-based study in the US 
suggested that survival was poorer among the patients of youngest (40-44 years 
old) and the oldest age group (Merrill and Bird, 2002). Poorer survival among the 
youngest and oldest age group was mainly due to the influence of disease grade 
and stage (Merrill and Bird, 2002).  
These findings from recent, large datasets, suggests that age has an association 
with disease related characteristics and treatment offered to patients. However, 
role of age as an independent predictor of survival of PC patients is not well 
established. 
1.5.1.2 Socio-economic circumstances 
In the UK, survival of PC patients has improved over time but socio-economic 
inequalities in survival have also been reported from regional studies (Hussain et 
al., 2008;Rowan et al., 2008). A deprivation gap in survival (better survival for 
least deprived compared with the most deprived) has been reported previously 
in studies carried out in England, Wales and Scotland (Rowan et al., 2008;Shack 
et al., 2007). Deprivation gap (better survival for least deprived compared with 
the most deprived group) in five years survival of PC in England and Wales 
increased from -1.2% in 1986-1990 to -7.2% in 1996-1999 (Rowan et al., 2008). 
Hybrid analysis based on the follow-up of those diagnosed in 2000 and 2001 
suggested that this gap may not widen further (Rowan et al., 2008). 
Scottish Cancer Registry reported that a significant deprivation gap in relative 
survival of PC patients exists in Scotland. Although the relative survival of PC 
patients improved 11% on average in every five years period during the period of 
1986-2000 (Shack et al., 2007). However the deprivation gap has increased every 
five years during this period and the difference of relative survival between the 
least deprived and the most deprived was 6.9% during the period of 1996-2000 
(Shack et al., 2007). Authors suggested that this difference can be explained by 
the stage of disease at the time of diagnosis and access to health care services 
between the two groups (Shack et al., 2007). However, the study could not 
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assess the impact of these factors on deprivation gap in survival due to the lack 
of information on disease related characteristics. Another important 
consideration, particularly for PC, could be the age and grade at diagnosis. The 
role of factors on widening deprivation gap is unknown yet.  
In the US, the burden of PC is disproportionate between populations of different 
racial backgrounds. Interestingly, race has also been linked with the survival of 
patients with PC. The relationship is unclear and attributed to different factors 
though. Various factors explain the prognostic value of race, including 
differential aggressiveness and disease stage at presentation, socio-economic 
differences and treatment disparities between different racial groups. Blacks are 
known to have a significantly higher PC risk, more advance stage and high grade 
disease and poorer survival outcome compared with Whites in the US (Fowler, 
Jr. et al., 2000).  
A randomized controlled trial on 2,048 patients of localized PC reported that 
Black race was associated with a significantly higher risk of overall and disease 
specific death (p = 0.04, RR = 1.24 and p = 0.016, RR = 1.41, 
respectively)(Roach, III et al., 2003). However, when adjusting for the effects of 
risk group and treatment, this difference was not statistically significant (Roach, 
III et al., 2003).  
Evidence from the Pre-PSA era suggested that the difference of survival between 
the Blacks and Caucasians was largely explained by the socio-economic status 
and survival was mainly dependent on the disease stage and socio-economic 
status (Dayal et al., 1985). In more recent years, these findings have been 
confirmed from National Cancer Database of PC patients. Individuals who did not 
have a medical insurance had double risk of having high PSA and advanced stage 
disease compared with those who had insurance (Fedewa et al., 2010). 
Interestingly, ethnic minorities including Asians, Hispanics and Blacks were 
significantly more likely to be uninsured and had advanced stage disease 
(Fedewa et al., 2010). These differences suggest that access to medical care and 
capacity to pay for health care services could be an important factor in racial 
differences of PC survival. In context of US, Black Americans have worse survival 
compared with Whites. This might be attributed to their less privileged socio-
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economic position and poor access to diagnostic and other health care services 
because access to these is mainly determined by the ability to pay (Roach, III, 
1998).  
In contrast a research, conducted on patients with PC where all men had equal 
access to health care services, showed that the overall cancer specific risk of 
death among Blacks vs. Whites was 1.28 (95% confidence interval CI = 1.14-
1.44); for local stage, 1.23 (95% CI = 1.01-1.51), 1.30 for regional stage (95% CI = 
0.97-1.75), and 1.27 for distant stage (95% CI = 1.07-1.50)(Robbins et al., 1998). 
Similarly, findings of survival disparities have also been reported from the UK 
and New Zealand, where health care services are financed by the Government 
and are equally available for all socio-economic groups. Data from New Zealand 
also reported that the 5-year relative survival of PC patients was significantly 
different - individuals from the most deprived socio-economic groups had a 15% 
lower survival than those from affluent groups (Jeffreys et al., 2009). 
These findings suggest the role of some unknown factors in prognosis other than 
race, socio-economic status and access to services. These factors can be the 
overall health status, diet, lifestyle related characteristics which are difficult to 
quantify in relation to PC prognosis and are largely unexplored up till now.  
1.5.1.3 Inflammation and survival 
Although it is recognised that the development of cancer has a genetic basis, 
there is increasing recognition that the host inflammatory response is associated 
with the progression and survival of patients (Balkwill and Mantovani, 
2001;Colotta et al., 2009;Hanahan and Weinberg, 2011;Vasto et al., 2008).  
Many epidemiological and clinical studies suggested that patients with higher 
local and systemic inflammation experienced poorer survival. Different 
inflammatory markers have been studied in relation to the prognosis of cancer 
patients and reported consistent results that higher inflammation is linked with 
poorer survival. Neutrophil lymphocyte ratio (NLR) showed a significant 
prognostic value as a measure of systemic inflammation in colorectal (Kishi et 
al., 2009), hepatocellular (Gomez et al., 2008), ovarian (Cho et al., 2009) and 
pancreatic cancer (Aliustaoglu et al., 2010) patients. In particular the systemic 
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inflammatory response, as evidenced by an elevated C-reactive protein, has 
been shown to be independently associated with poor prognosis in many common 
solid tumours (Roxburgh and McMillan, 2010). It is therefore of interest that the 
systemic inflammatory response, as measured by the modified Glasgow 
Prognostic Score (mGPS, a combination of C-reactive protein and albumin), has 
been shown to have prognostic value in operable and non-operable cancers 
independent of site (Proctor et al., 2011).  
Although survival in patients with PC has improved in recent years, it is often 
difficult to differentiate patients who require potentially curative treatment 
from those who can be managed conservatively. Considerable effort has gone 
into identifying novel genetic and immunological biomarkers, however, these 
remain time consuming and not validated to be part of routine clinical practice 
(Castelli et al., 2010;Huang et al., 2010). Therefore, in general, current clinical 
decisions are based on readily available tumour related factors, including PSA 
levels, Gleason grade and clinical stage (Verhagen et al., 2002). 
Many biological and laboratory studies have investigated the role of 
inflammation in the development of PC and found a significant relationship 
between inflammation and risk of PC. However, clinical data on the role of 
systemic inflammation on prognosis of PC patients is sparse. Two earlier studies 
investigated the role of C-reactive protein (CRP) as a measure of systemic 
inflammation in relation to survival of PC, and found that men with higher levels 
of C-reactive protein showed poorer survival both in localised (McArdle et al., 
2010) as well as metastatic disease (McArdle et al., 2006). However, smaller 
number of cases and lack of information on socio-economic status in both studies 
preclude any definite conclusion about the role of inflammatory markers in 
prognosis.  
In most of the studies, it remained unclear about the host characteristics, other 
than tumour related factors, and their relationship with increased mGPS or NLR 
in cancer patients which lead to poorer survival. One hypothesis therefore is 
that, a pre-treatment systemic inflammatory response which may be a part of 
any pre-existent co-morbid condition, could lead to an excess risk of death due 
to non-cancer causes (Roxburgh et al., 2011) Another important consideration is 
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that, the socio-economic status of the individuals may influence the systemic 
inflammation among cancer patients and could be responsible for poorer 
survival. 
There has been a considerable amount of interest in systemic inflammation and 
its association with prognosis. Further research is warranted in this area with 
larger cohort studies with bigger samples, complete information on potential 
confounding and longer follow-ups. 
1.5.1.4 Co-morbidity 
Co-morbidity is the presence of one or more diseases in addition to the primary 
disease (i.e. PC in this case). Different tools are used to quantify co-morbidity. 
However, the Charlson Co-morbidity Index (CCI) has been widely used in 
literature (Hall et al., 2005).  
Age and CCI were the most significant predictors of all cause mortality but not in 
cancer specific mortality among PC patients (Sweat et al., 2002). Similar results 
were provided from another study which used CCI as a measure of co-morbidity 
in PC patients and they reported co-morbidity as the most important prognostic 
factor for men less than 70 years (Post et al., 2001). Risk of death was twice in 
patients with one concomitant disease than those with no co-morbidity (95% CI, 
1.0-4.3), whereas the risk was even higher among those who had two or more 
diseases (HR = 7.2, 95% CI 3.1-16.6) (Post et al., 2001).  
As co-morbidity increases the risk of all cause mortality but not cancer specific 
mortality, this may be due to the fact that co-morbidity increases the risk of 
death due to non-cancer causes among PC patients. Interestingly, co-morbidity 
not only influences the survival of patients due to deaths from other causes than 
cancer but also affects the decision making process of treatment. Individuals 
with serious co-morbid conditions at the time of diagnosis are unlikely to receive 
a curative and aggressive management of the cancer therefore, in an indirect 
way co-morbidity influences the cancer specific deaths. Similarly, treatment 
offered to patients is an important predictor of cancer specific mortality (Hall et 
al., 2005). 
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1.5.2 Disease characteristics 
1.5.2.1 Cancer stage and grade 
Cancer stage is perhaps one of the most important determinants of survival. PC 
stage is used to describe the extent of cancer, whether it is localized or 
extended to adjacent or distant structures. Stage of PC has a graded link with 
the survival i.e. highest for the focal incidental cases and worst for the 
metastatic disease. Significant differences in PC specific survival have been 
observed at 10 and 15 years follow-up according to the stage of cancer i.e. for 
incidental cases (100% and 90.6% respectively), for men with localized PC (73.1% 
and 60.8% respectively), for men with locally extended disease (23.4% and 11.4% 
respectively) and for men with metastatic disease (68.1% and 54.5%) (Jonsson et 
al., 2006). These estimates have been taken from historical data, however in 
more recent years, survival seems to be improved for most stages particularly 
for localised disease, however, it remains unclear whether it is due to the better 
application of treatment modalities or lead time and length time biases because 
of PSA-testing.  
Gleason grading of PC is considered as a major determinant of disease biology 
and prognosis. Tumour grading refers to the property of cancer independent of 
tumour location while prognosis is defined as the expected biological aggressive 
potential of a prostatic tumour to spread to other organs (Epstein, 2010). The 
Gleason scoring system is based on microscopic tumor patterns which are 
assessed by pathologist, based upon the degree of loss of the normal glandular 
tissue architecture (i.e. shape, size and differentiation of the glands) (Epstein, 
2010). The Gleason score is a sum of primary and secondary grades representing 
the majority of the tumour and minority of the tumour, respectively. The 
Gleason sum score is represented as number ranging from 2 to 10 – the higher 
the score the more aggressive the tumour is likely to act. The Gleason score has 
been investigated for its impact on survival and reported that disease specific 
mean survival was highest for the Gleason score 4-5 which is well differentiated 
disease (i.e. 20 years), while lowest (i.e. 5 years) for the Gleason score 8-10 
which is a high grade and also known as aggressive disease (Egevad et al., 2002). 
Evidence also highlighted that not only the Gleason sum score strongly impacts 
on survival but individual pattern of grade was also found important with regard 
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to PC specific survival (Egevad et al., 2002). There was a trend towards a shorter 
survival for Gleason 4 + 3=7 (Disease specific mean survival = 9 years) than 
Gleason 3 + 4=7 (Disease specific mean survival 13 years; p = 0.16) (Egevad et 
al., 2002). 
Population-based testing by PSA is carried out with the objective to diagnose the 
cancer at an earlier stage. Role of PSA based screening for cancer detection 
remains controversial. Recently, a study from the “Prostate Testing for Cancer 
and Treatment” trial (ProtecT) reported that due to PSA screening, stage and 
grade migration has taken place in the UK (Moore et al., 2009). It was reported 
that patients who were included in the ProtecT, had a significantly lower stage, 
lower grade and low PSA level compared with the men taken from cancer 
registry (Moore et al., 2009). Population-based PSA screening might also detect 
some low risk patients with PC for whom optimal treatment remains uncertain 
and the health services might end up over treating the patients with PC due to 
population-based PSA screening (Moore et al., 2009).  
1.5.3 Treatment and survival 
Choice of treatment for PC patients is a complex process. Decision about the 
treatment varies from individual to individual and many factors need to be 
considered when selecting an appropriate therapy for an individual. These 
include age, disease stage and grade, overall health status and co-morbidity. 
Treatment modalities range from surgical resection, radiotherapy, 
chemotherapy to non-intervention with watchful waiting.  
Careful interpretation is required when comparing the results (in terms of 
survival) of different treatment modalities because they are not generalisable to 
each other and evidence exists that patients with similar disease characteristics 
under the same health care system are treated differently (Fairley et al., 2009). 
Research carried out on 60,269 low, moderate grade and organ confined PC 
patients compared the three treatment modalities and their impact on overall 
and disease specific mortality (Tward et al., 2006). Prostate specific death at 10 
years was 2.62 deaths/1000 person-years for those treated by surgery, 1.83 
deaths/1000 person-years for brachytherapy and 8.68 deaths/1000 person-years 
for those with no definitive treatment (Tward et al., 2006). Similarly a 
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systematic review comparing different radiotherapeutic modalities with regard 
to the PC survival reported that the risk of death was 1.50 (95% CI 1.29-1.73) for 
external beam radiotherapy relative to brachytherapy, and was 2.33 (95% CI 
2.04-2.66) for external beam radiotherapy combined with a radioactive seed 
implantation relative to brachytherapy (Pieters et al., 2009). As described 
earlier, these treatment modalities are not directly comparable as different 
patient groups tend to be offered different treatment modalities. Patients have 
significant differences in terms of their general health, disease related 
characteristics and existence of co-morbid conditions.  
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1.6 Summary of literature 
 
PC is the most commonly diagnosed cancer after non-melanoma skin cancer, 
among men in the developed world. Variations in incidence between countries of 
developed world are mainly attributed to the varying population structure and 
screening practices between countries. Large variations in incidence have been 
observed even between different socio-economic groups within countries. In the 
UK, socio-economic gap in incidence of PC has been observed in England and 
Wales. Scotland is widely known for poorer health outcomes due to deprivation. 
However, no attempts have been made to investigate the socio-economic 
differences in incidence of PC. The overall increase in incidence of PC in the UK 
is mainly attributed to PSA testing. If PSA testing is responsible for observed 
incidence trends then a grade-shift (relatively more low-grade disease) should 
be observed as PSA tests detected cancer cases are theoretically expected to be 
low grade tumours. Grade-specific and socio-economic trends in incidence may 
be helpful understanding the rising incidence.  
There is no single risk factor responsible for the development and progression of 
PC. There is a wide range of factors capable of interacting in a complex 
temporal manner to influence cancer development and progression. Age, race 
and family history are considered as strong risk factors while the evidence on 
other risk factors is mostly inconsistent. Evidence mainly comes from 
observational studies and a few randomised controlled trials. Many risk factors 
have been studied in case-control studies in earlier decades. PC has a very 
complex aetiology both for incidence and progression and initial lesions typically 
start decades before the clinical presentation of the disease, a fact reported by 
many autopsy studies. Therefore, in such a scenario case-control studies are 
unlikely to capture the true risk factors associated with the disease, as recall 
bias is inherent in this design.  
Evidence emerging from prospective cohort studies and randomised controlled 
trials also remained equivocal for most of the commonly studied lifestyle and 
dietary factors. The majority of prospective cohort studies recruited middle age 
or elderly men and followed them up to 15 to 20 years. Men of these age groups 
might already have a latent lesion in the prostate gland when follow-up began. 
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Such studies were unlikely to unfold the true risk factors as they started follow-
up on an age when men already had a latent disease. Randomised controlled 
trials, mostly had a follow-up of up to 10 years, therefore any factors found 
associated in a short follow-up may have a link with the progression or 
manifestation of the disease but unlikely to be related to the development of 
PC. In such a scenario, studies with large sample sizes with very long follow-up 
periods may help to understand the aetiology of PC.  
Another factor which makes the aetiological studies more complex is the advent 
of PSA. Today, many more patients are diagnosed than ever including a pool of 
biologically indolent tumours. In the pre-PSA era the men who were diagnosed 
with PC displayed a period of progression, or transition from a small volume 
latent disease to a clinically significant PC. The diagnosis in pre-PSA era 
reflected an event while in the PSA era many cancers classified as events are not 
true events - rather they reflect a diagnosis of a previously unknown latent 
cancer. Men diagnosed with PCs in PSA era represent a more heterogeneous 
group of cancers, which ultimately make it more difficult to examine the same 
risk factors for progression which were being studied in the pre-PSA era. In this 
case, it is crucial to understand those factors which are associated with the 
aggressiveness or progression of PC.  
Survival of PC patients has improved in the last two decades. Many factors have 
been investigated for their role in PC survival. Evidence on the role of age and 
race provided inconsistent results, while socio-economic status, tumour related 
characteristics and treatment had a main role in PC survival. Nevertheless, 
management of PC still remains an intricate process as to what treatment to be 
offered to which individual case, to achieve the best possible outcome. 
Prognosis has not been clearly understood despite extensive research. As 
incidence is increasing and no organised population level efforts can be made to 
prevent PC, it is therefore, crucial to understand the prognosis of those who 
have been diagnosed with the disease. In more recent years, systemic 
inflammation has emerged as a prognostic factor for patients with many 
different cancers; however, larger studies are required to understand its role in 
the prognosis patients with PC. Different inflammatory markers are used to 
measure the systemic inflammation including neutrophil lymphocyte ratio, 
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modified Glasgow Prognostic Score and platelet lymphocyte ratio. The evidence 
on these inflammatory markers as a prognostic factor in PC survival is limited to 
two studies with smaller sample size and lack of information on socio-economic 
circumstances. Further work in understanding the prognosis of PC patients is 
warranted as incidence is expected to increase due to ageing population in 
coming years.  
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1.7 Aim and objectives 
The aim of this thesis is to examine the aetiological and epidemiological factors 
associated with incidence and survival of PC in the West of Scotland. These 
factors will be examined with particular attention to the socio-economic 
disparities both in incidence and survival. Prognosis of PC has not been clearly 
understood, therefore, an attempt will be made to investigate some prognostic 
factors associated with the survival of PC patients. 
Each chapter in this thesis is designed to address specific objectives outlined as 
follows:  
1. To undertake a descriptive epidemiological study to understand the 
trends in incidence of overall PC and grade specific disease in last two 
decades with particular focus on socio-economic circumstances.  
2. To conduct a large prospective cohort study to investigate the role of 
cholesterol in development of overall and grade-specific PC.  
3. To conduct a prospective cohort study to investigate the role of dietary 
factors, tea and coffee, on overall and grade-specific PC incidence. 
4. To carry out an epidemiological study to investigate the survival of PC 
patients focusing on socio-economic circumstances of the individuals and 
particularly the impact of age and disease grade at diagnosis. 
5. To conduct a cohort study to investigate the role of systemic 
inflammation on the survival of patients with PC 
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2 Widening deprivation gap in incidence of 
prostate cancer in the West of Scotland: a 
population-based study 
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2.1 Chapter summary 
PC is the commonest cancer among men in Scotland. However, the relationship 
between socio-economic circumstances and histological grade-specific incidence 
as measured by the Gleason score remains unclear. This study describes trends 
in overall and grade specific PC incidence by deprivation group over time in the 
West of Scotland. 
Incident cases of PC (ICD-10 C61) from the West of Scotland were extracted from 
the Scottish Cancer Registry from 1991 to 2007. Socio-economic circumstances 
were measured using the Carstairs scores. Annual population estimates were 
obtained from Information Services Division Scotland. Deprivation-specific 
European age-standardised incidence rates were calculated and disease grade 
(high versus low) was measured using the Gleason score. Joinpoint regression 
analysis was carried out to identify significant changes in trends over time and 
calculate the annual percent change. 
15,519 incident cases of PC were diagnosed in the West of Scotland between 
1991 and 2007. Overall incidence (age adjusted) increased by 70% from 44 per 
100,000 in 1991 to 75 per 100,000 in 2007, an average annual growth of 3.59%. 
This pattern was driven by significant increases in both low and high grade 
cancers. Incidence was inversely associated with deprivation with the highest 
rates among the most affluent group. A widening deprivation gap in incidence 
was evident from 1997 onwards. From 2003-2007, the deprivation gap in 
incidence was 40.3 per 100,000 (P for trend < 0.001), with rates 37% lower 
among the most deprived compared with the affluent. This deprivation gap 
accounts for an estimated 1,764 over-diagnosed men among the most affluent 
group during 2003-2007.  
The relatively large increase in incidence among the most affluent is mainly due 
to an increase in diagnosis of low grade disease. Further work is needed to 
understand whether the detection of low grade disease is associated with 
survival benefits among affluent men. 
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2.2 Introduction 
This chapter will describe the trends of PC incidence in the West of Scotland. 
Earlier evidence suggests that socio-economic differences exists in the incidence 
of PC in England and Wales (Rowan, 2007). In contrast to lung and cervical 
cancers, incidence rates of PC have been higher among least deprived men and 
lowest among the most deprived. Significant differences in age-standardised 
incidence of PC have been reported between different health boards in Scotland 
during 1994-1996. PSA testing may explain the observed variations in the 
incidence between health boards (Brewster et al., 2000). However little is 
known about the recent trends of PC incidence among Scottish men in relation 
to grade of disease and socio-economic circumstances of patients.  
Therefore, the present analysis was conducted to comprehensively describe the 
overall and grade specific trends of PC incidence by socio-economic status in the 
West of Scotland for the most recent period.  
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2.3 Materials and methods  
2.3.1 West of Scotland population characteristics 
The West of Scotland comprises of approximately half of the population of 
Scotland, estimated at 2.4 millions. This includes four NHS health boards, 
Ayrshire and Arran, Forth Valley, Greater Glasgow and Clyde and Lanarkshire. 
The West of Scotland holds some of the most affluent and most deprived 
population of the country. Socio-economic differences have been attributed to 
one of the highest mortality rates and lowest life expectancy of Scottish 
population compared with the rest of the Western Europe (Scottish Public Health 
Observatory (ScotPHO)., 2011). Although health care services are free at the 
point of use for everyone in the UK, significant differences have been observed 
between health outcomes of Scottish population compared with other 
constituent countries of the UK (Hanlon et al., 2005).  
2.3.2 Incidence data 
We extracted incident cases of PC registered in the West of Scotland during 1991 
to 2007 using the International Classification of Diseases (ICD) codes, ICD 9 code 
185 and ICD 10 code C61 for PC. Cancer Registry uses the Scottish Open Cancer 
Registration And Tumour Enumeration System (SOCRATES), which receives the 
electronic notification of cancer from hospital systems - which includes the 
Scottish Morbidity Records (SMR01), records of treatment offered to patients, 
prospective audit dataset and death records from General Registrar office for 
Scotland (GRO(S)) (Information Services Division, 2011). In addition to these, the 
cancer registry also receives some records from private hospitals (Information 
Services Division, 2011). Registry data also includes some demographic details 
including age, post code of residence, date of birth and different measures of 
socio-economic status. Socio-economic deprivation was inferred for each patient 
by using the Carstairs score associated with their postcode.  
Population estimates were required to calculate the age specific incidence rates 
of PC. We used age and deprivation specific population estimates 2001 for the 
West of Scotland, provided by the GRO(S).  
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2.3.3 Statistical analysis 
As the incidence of PC increases sharply with the age and particularly after 50 
years, a significant proportion of increase in the crude incidence rates could be 
due to aging of the population. We used the direct standardisation method to 
calculate the European age-standardised rates (EASR) to control for the 
differences in the age structure of the population between different time 
periods and socio-economic groups. As there were very small number of cases 
among individuals of less than 60 years so we used following age groups for the 
calculation of age-standardised rates, ≤59, 60-64, 65-69, 70-74, 75-79 and ≥80 
years. We also calculated standard errors of EASR’s for each age group and their 
95% confidence intervals.  
Using Carstairs scores, we calculated deprivation specific incidence rates. We 
observed large variations between groups due to small number of cases in each 
category. Therefore we combined the deprivation categories 1 and 2 to make 
most affluent group, categories 3,4 and 5 were combined to create intermediate 
and categories 6 and 7 were combined to form the most deprived group. We 
then calculated the age specific rates for each of these three deprivation 
groups.  
We calculated the incidence rates for every year and also by three time periods 
of 1991-1996, 1997-2002 and 2003-2007. Gleason grade is a pathological score 
which determines the behaviour and morphology of the tumours. Age-
standardised rates were also calculated for low grade (Gleason 2-7) and high 
grade disease (Gleason 8-10). Cancer registry started recording Gleason scores 
from 1st January 1997, so grade-specific rates were calculated from year 1997 
onwards.  
Trend of incidence over time for overall, grade specific and deprivation specific 
PC incidence were also calculated using joinpoint regression analysis. This 
analysis detects the point of time at which significant changes occurred in the 
age-standardised incidence rates. I allowed a maximum of three join points for 
estimations. Annual percentage changes with their corresponding 95% confidence 
intervals and p values were also calculated.  
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I calculated age standardised ratio (ASR) by dividing the EASR of each 
deprivation category with the least deprived category. For calculation of the 
number of excess cases based on deprivation categories, I then divided the 
number of cases in each deprivation category by ASR and subtracting the result 
from incidence cases in that category (Shack et al., 2008) This gives an estimate 
of how many extra or fewer cases there would have been had that deprivation 
category had the same EASR as the least deprived category (Shack et al., 2008). 
Weighted ordinary least square linear regression was used to model EASRs for 
the deprivation categories. The estimate deprivation gap and corresponding 
confidence intervals were then calculated using the models EASR for the most 
deprived minus the modelled EASR for least deprived category (National Cancer 
Intelligence Network, 2008). I calculated the excess cases and deprivation gap 
for overall as well as grade specific PC incidence. 
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2.4 Results 
A total of 15,519 PC patients were identified who were registered in the West of 
Scotland from 1991 to 2007. Mean age at incidence was 72.3 years, standard 
deviation 9.0. Highest incidence rates were observed in the older age groups - 
39.1% of cases (n=6,068) occurring in 65-75 years of age men and 41.6% of cases 
(n=6,455) in men older than 75 years. In the period 1991-2007, 18.8% of patients 
were in the affluent group, 55.9% in intermediate deprivation group and 25.3% in 
deprived group. The whole study period of 17 years (1991-2007) was categorised 
into three categories from 1991-1996, 1997-2002 and 2003 to 2007 (table 2-1). 
Significant differences in demographic and disease characteristics of patients 
were observed between these periods (table 2-1). 
Age at incidence differed significantly over the study periods, from 73.4 years in 
1991-1996 to 71.2 years in 2003-2007 (p value < 0.001). Proportions of patients 
diagnosed both before the age of 65 years and 65-74 years, increased from the 
first to the last period, while the proportion of patients older than 75 years at 
the time of diagnosis reduced during study period (table 2-1).  
There was a significant interaction of socio-economic circumstances overtime in 
relation to incidence of PC. The proportion of patients in the affluent group 
significantly increased during study periods (17.3% in 1991-1996, 20.3% 2003-
2006), while the proportion of men in deprived grouped significantly decreased 
through these same periods (28.3% in 1991-1996, 22.3% in 2003-2006)(table 2-1).  
Both proportions of men with low grade (Gleason ≤ 7) and high grade disease 
(Gleason 8-10) significantly increased during two study periods, as the 
proportion with unknown grade disease significantly reduced from 16.7 in 1997-
2002 to 7.7% in 2003-2007 (table 2-1). 
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Table 2-1: Baseline characteristics of prostate cancer patients registered in the West of Scotland from 1991-2007 
  Period of diagnosis 
 
p-value 
  1991-1996   1997-2002  2003-2007 
    All patients, n %   All patients, n %   All patients, n % 
Total registered cases 4,534 29.2  5,506 35.5  5,479 35.3   
Age at incidence (years)          
 Age < 65 683 15.1  1,027 18.7  1,286 23.5 
<0.001  Age 65-74 1,753 38.7  2,106 38.3  2,209 40.3 
 Age ≥ 75 2,098 46.3  2,373 43.1  1,984 36.2 
Gleason grade          
 Gleason ≤ 7 _ _  3,033 55.1  3,265 59.6 
<0.001  Gleason 8-10 _ _  1,556 28.3  1,793 32.7 
 Unknown Gleason _ _  917 16.7  421 7.7 
Socio-economic circumstances          
 Affluent (Depcat 1,2) 785 17.3  1,028 18.7  1,110 20.3 
<0.001  Intermediate (Depcat 3,4,5) 2,465 54.4  3,052 55.4  3,150 57.5 
 Deprived (Depcat 6,7) 1,284 28.3  1,426 25.9  1,219 22.3 
                 
                
Period of diagnosis was based on incidence date recorded in cancer registry, p-values calculated by chi square test.  
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2.4.1 Trend analysis 
Generally, EASR of PC increased during the study period from 44 per 100,000 
in 1991 to 75 per 100,000 in 2007, an overall increase of 70% with an average 
annual growth of 3.6% (figure 2-1). Overall increasing trend varied between 
different time periods. The highest increase seen in 1991-1996 (average 
annual growth of 8.4%) and in 1999-2004 with a significant average annual 
growth of 7.7% (table 2-2). Both these periods were followed by a non-
significant decline in incidence trends.  
Although there was a general increase in age standardised incidence rates 
during the study period, the increase rates were significantly different 
between age groups. The incidence rates increased 3 times among men of 
less than 65 years of age from 7 per 100,000 in 1991 to 21 per 100,000 in 
2007, while only 75% and 50% increases in EASR were observed for men of age 
65-74 years and ≥75 years respectively during the similar periods (figure 2-2).  
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Figure 2-1: Age-standardised incidence (per 100,000 population) of prostate cancer in 
the West of Scotland from 1991-2007 
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Figure 2-2: Age-standardised incidence (per 100,000 population) of prostate cancer 
between age groups 
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Table 2-2: Trends of prostate cancer incidence by disease grade and socio-economic circumstances from 1991 to 2007: joinpoint analysis 
 No. of incident cases   EASR rate per 106  Annual percentage change 
  (min-max)     (min-max)     (95% CI) 
         
Overall incidence: 1991-2007         
     1991-1996 635-943  43.8-69.2  8.4* (3.5, 13.5) 
     1996-1999 815-943  59.3-63.08  -2.5 (-19.3, 17.8) 
     1999-2004 900-1263  63.08-93.43  7.7* (1.9, 13.9) 
     2004-2007 1016-1263  75.16-93.43  -5.6 (-13.4, 2.9) 
                 
Deprivation specific         
overall incidence: 1991-2007         
         
Affluent (Depcat 1 & 2) 100-250  46.35-120.13  5.28* (3.8, 6.8) 
Intermediate (Depcat 3,4 & 5) 339-736  42.42-96.76  4.05* (3.0, 5.2) 
Deprived (Depcat 6 & 7) 177-277  47.70-75.85  1.33* (0.1, 2.5) 
                 
Grade specific          
overall incidence: 1997-2007         
         
Low grade (Gleason ≤ 7)         
      1997-2004 435-783  31.16-58.25  7.86* (4.3, 11.5) 
      2004-2007 588-783  43.72-47.80  -4.78 (-15.3, 7.1) 
High grade (Gleason 8-10)         
      1997-2000 248-251  17.57-18.37 0.5 (-18.2 23.4) 
      2000-2007 249-433  19.40-31.60 7.6* (2.6 12.8) 
                  
* The average annual percent change is statistically significantly different from 0    
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2.4.2 Deprivation gap 
An increasing trend in incidence of PC was observed in all deprivation groups, 
the largest average annual increase of 5.3% (95% CI 3.8-6.8) was among the 
most affluent group and the smallest increase of 1.3% (95% CI 0.1-2.5) among 
the most deprived group (table 2-2). This gap between deprivation groups 
started appearing after 1997 as trends remained fairly similar in earlier 
periods of this study (figure 2-3). From 1997 to 2002, the age-standardised 
incidence among affluent men was 81.46 per 100,000 compared with 64.26 
per 100,000 in the most deprived, giving a deprivation gap as an absolute 
difference of 17.2 per 100,000 (P = 0.02, trend) (table 2-3). This gap widened 
in the most recent period (2003-2007) as the incidence rate among deprived 
men remained nearly similar compared to previous period, while the 
incidence rate further increased among affluent men (table 2-3). For the 
recent period (2002 to 2007), age-standardised incidence among affluent men 
was 107.01 per 100,000 compared with 66.73 per 100,000 in the most 
deprived, giving a deprivation gap as an absolute difference of 40.28 per 
100,000 (P < 0.001, trend) (table 2-3). 
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Figure 2-3: Age-standardised incidence of prostate cancer between deprivation groups 
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This can be more clearly interpreted from the ratio of EASRs’ (between 
deprived and affluent). The incidence ratio remained 1 till 1997 and 
reduced up to 0.5 in year 2007 (figure 2-4). 
Figure 2-4: Ratio of European age-standardised incidence rate of prostate cancer 
between most deprived and most affluent groups 
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On further analysis of grade specific incidence trends, I observed a 
significant overall increase in both low grade (Gleason ≤ 7) as well as high 
grade disease (Gleason 8-10) (table 2-2). However, significant increasing 
trend of low grade disease was from 1997-2004, while incidence rate of high 
grade disease increased in recent years 2000-2007 (figure 2-5). The ratio of 
low to high grade tumours was about 2 for the first part of the study period 
(figure 2-6). Between 2002 and 2004, there was a slightly higher proportion 
of low grade tumours but between 2005 and 2007 there was a lower 
proportion of them. Thus, there was no convincing evidence of a consistent 
relatively greater increase in incidence of low grade disease over time 
(figure 2-6). 
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Figure 2-5: Incidence of grade-specific prostate cancer in the West of Scotland 
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Figure 2-6: Rate ratio of grade-specific age-standardised incidence rates (low grade: 
high grade) in the West of Scotland: 1997-2007 
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Table 2-3: Prostate cancer incidence by deprivation from 1991 to 2007 in the West of Scotland 
Deprivation 
group 
 Number of 
incident 
cases 
 European age-
standardised rate (EASR) 
per 100 000 
 
95 % Confidence 
Intervals 
   
Estimated 
excess cases 
Annual excess 
cases/100,000 
        EASR ratio 
             
1991-1996             
Affluent  785  61.44  (48.59, 74.30)  1 0 0 
Intermediate 2465  51.92  (39.90, 63.93)  0.84 -452 -75 
Deprived  1284  57.91  (39.24, 76.58)  0.94 -78 -13 
Overall  4534  57.09  (38.46, 75.72)    -531 -88 
P-value for trend  0.76         
             
1997-2002             
Affluent  1028  81.46  (66.32, 96.59)  1 0 0 
Intermediate 3052  64.66  (57.69, 71.62)  0.79 -793 -132 
Deprived  1426  64.26  (44.55, 83.98)  0.79 -381 -64 
Overall  5506  70.13  (49.12, 91.14)    -1174 -196 
P-value for trend  0.02         
             
2003-2007             
Affluent  1110  107.01  (72.63, 141.38)  1 0 0 
Intermediate 3150  80.68  (65.28, 96.08)  0.75 -1028 -206 
Deprived  1219  66.73  (46.35, 87.11)  0.62 -736 -147 
Overall  5479  84.80  (61.42, 108.19)    -1764 -353 
P-value for trend  <0.001         
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When I further investigated the disease specific trends in deprivation 
categories, increasing trend of low grade disease was mainly driven by the 
higher incidence in affluent men (figure 2-7), while there were no significant 
differences in high grade disease incidence between deprivation groups 
(figure 2-8). 
From 1997 to 2002, the age-standardised incidence among the most affluent 
men was 41.79 per 100,000 compared with 34.88 per 100,000 in the most 
deprived, creating a deprivation gap as an absolute difference of 6.9 per 
100,000 (P = 0.07, trend) (table 2-4). This gap widened in the most recent 
period (2003-2007), the age-standardised incidence among the most affluent 
men was 56.20 per 100,000 compared with 45.73 per 100,000 in the most 
deprived, giving a deprivation gap as an absolute difference of 10.47 per 
100,000 (P < 0.001, trend) (table 2-4). An estimated 93 more cases of PC per 
year would be diagnosed in the West of Scotland if both intermediate and 
deprived group had the same incidence rate as of affluent group from 2003-
2007. We did not observe any significant deprivation gap between high grade 
diseases for both, earlier or recent periods (table 2-4).  
Figure 2-7: Incidence of low grade prostate cancer between deprivation groups 
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Figure 2-8: Incidence of high grade prostate cancer between deprivation groups 
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Table 2-4: Grade-specific prostate cancer incidence by deprivation from 1991 to 2007 in the West of Scotland 
Deprivation 
group 
 Number of 
incident cases 
 European age-standardised 
rate (EASR) per 100 000 
 95 % Confidence 
Intervals 
 
EASR ratio 
Estimated 
excess cases 
 Annual excess 
cases/100,000           
Low Grade Disease             
1997-2002              
Affluent  623  41.79  (20.57, 63.01)  1 0  0 
Intermediate 1,709  36.63  (26.32, 46.95)  0.88 -241  -40 
Deprived  701  34.88  (20.19, 49.58)  0.83 -139  -23 
Overall  3,033  37.77  (22.36, 53.18)    -379  -63 
P-value for trend   0.07          
              
2003-2007              
Affluent  682  56.20  (31.19, 81.21)  1 0  0 
Intermediate 1,945  48.33  (36.40, 60.27)  0.86 -317  -63 
Deprived  638  45.73  (28.81, 62.65)  0.81 -146  -29 
Overall  3,265  50.09  (32.13, 68.04)    -463  -93 
P-value for trend   0.02          
              
High Grade Disease             
1997-2002              
Affluent  258  19.30  (05.33, 33.26)  1 0  0 
Intermediate 865  19.02  (11.75, 26.28)  0.99 -13  -2 
Deprived  433  18.11  (07.75, 28.46)  0.94 -28  -5 
Overall  1,556  18.81  (08.28, 29.34)    -41  -7 
P-value for trend   0.36          
              
2003-2007              
Affluent  359  28.80  (11.29, 46.31)  1 0  0 
Intermediate 1,027  26.68  (17.97, 35.38)  0.93 -82  -16 
Deprived  407  23.18  (11.35, 35.01)  0.80 -99  -20 
Overall  1,793  26.22  (13.54, 38.90)    -180  -36 
P-value for trend   0.07                   
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2.5 Discussion 
2.5.1 Main findings of this analysis 
I observed a significant rise in incidence of PC in the West of Scotland during 
1991 to 2007. The largest increase in incidence occurred in men under the age of 
65. Such a pattern has been attributed to PSA testing in England (Moore et al., 
2009) but in the absence of any evidence about age-specific use of PSA testing in 
our study population, I cannot propose that this is likely. PC incidence increased 
in all socio-economic groups over time but low grade disease increased more in 
the most affluent group. This produced a socio-economic gradient in incidence 
from 1997 onwards. While this is consistent with greater diagnostic sensitivity in 
more affluent populations, it did not produce an overall increase in the 
proportion of low grade cases as a significant rise in high grade disease was also 
observed in a most recent period.  
 
2.5.2 Data quality 
In present study, the incident data from the Scottish Cancer Registry has been 
used, and the quality of the available data already discussed. I have a fairly 
large sample size to estimate the differences between the sub groups of 
population. Ecological measures of socio-economic status have been widely used 
in health in general(Carstairs and Morris, 1990) and cancer incidence and 
survival in particular (National Cancer Intelligence Network, 2008;Shack et al., 
2007). Carstairs scores as a measure of deprivation were used in this study. As 
with all the area-based measures of deprivation using the Carstairs score, it is 
assumed that all the individuals living in a given geographical area experience 
the same level of deprivation and associated cancer risk factors. Individual level 
data like level of education, occupation and income can provide the stronger 
evidence of socio-economic circumstances but these data are not routinely 
collected in cancer registries. 
2.5.3 Temporal trends in incidence 
I observed a significant rise in incidence of PC in the West of Scotland during 
1991 to 2007. Age-standardised rates more than doubled from 44 per 100,000 in 
96 
Chapter 2 
 
 
 
1991 to 93 per 100,000 in 2004. Age-standardised incidence on average, 
increased at a rate of 3.6% annually during the study period. These are age-
standardised rates so the rise in incidence observed during the study period is 
unlikely due to the aging of population. Steep increases in incidence of PC have 
also been observed in England and Wales from early 1990’s to 2004 (Evans and 
Moller, 2003;Westlake and Cooper, 2008) and in other European countries as 
well (Bray et al., 2010). Although the testing of older individuals for PSA has 
been mainly attributed to these large observed increases in PC (Bray et al., 
2010), it is still unclear whether the increased incidence since 1991 is 
completely due to increased detection of cases or a real increase in risk of the 
disease. The increase in incidence of PC in the West of Scotland between 1991 
and 2007 was not accompanied by a strong “grade shift” towards lower grade 
disease that might have suggested PSA testing was responsible. A true increase 
in incidence may remain a plausible explanation. 
Interestingly, a significantly higher proportion of patients have been diagnosed 
before the age of 75 years in the recent period (2003-2007) compared with the 
earlier (1991-2002). Age-standardised rate increased 3-fold for those of age less 
than 65 years. Studies from UK and USA data showed the similar pattern of 
increased incidence among younger age groups and that was attributed to the 
PSA testing among these age groups (Collin et al., 2008;Moore et al., 2009). 
2.5.4 Gleason grade-specific temporal trends  
Trend of grade specific incidence also showed similar pattern for both low grade 
(Gleason ≤ 7) and high grade disease (Gleason > 7) of increasing incidence over 
the study period. Low grade disease increased significantly on an annual average 
of 7.9% during 1997-2004 followed by a non-significant decline. High grade 
disease remained fairly stable from 1997 to 2000, while the similar annual 
growth of 7.6% was observed for high grade disease from 2000 to 2007. There is 
evidence that PSA testing has led to stage and grade migration of PC in the UK 
and patients are more likely to be diagnosed at a younger age (<65 years) and 
with low grade disease (Moore et al., 2009). It is very likely that some of the 
observed pattern in our study could be because of the increased use of PSA 
testing in the West of Scotland during that period, which led to an increased 
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incidence of low grade disease. But increased PSA uptake does not explain the 
increased incidence of high grade tumours in a later period. The individuals who 
were diagnosed with high grade disease were significantly older compared with 
those with low grade disease (73.6 vs 70.6, p-value <0.001). This is an important 
finding of this study as little is known about the grade specific trends of PC. 
However, many factors are likely to contribute in the observed trend of 
aggressive PC. First, variations in the use of different treatment modalities could 
have an impact on the PC incidence by tumour grades. For example in the US, 
the surgical removal of prostate gland along with regional lymph nodes was 
modified in early 1980s to preserve the regional innervation and potency (Quinn 
and Babb, 2002). This resulted in an increased utilisation of radical 
prostatectomy through the early 1980s and 1990s, and this could have shifted 
the disease grade towards high grade because more tissue was available for 
pathological examination (Quinn and Babb, 2002). In the Surveillance 
Epidemiology and End Results (SEER) data, it has been observed that patients 
who were treated surgically had higher grade disease than those who were 
treated by other modalities. Thus, it is a possibility that during the higher 
incidence period here in the UK, relatively more tumours were classified as high 
grade than low grade due to the availability of large amount of tissue as a result 
of prostatectomy. Unfortunately current data did not have the complete 
information of treatment provided to the patients so studies from other parts of 
the UK may provide some evidence on this aspect.  
Second, in clinical practice there are more biopsies performed than in the 
earlier period of study, so the observed increase in the high grade disease could 
be due to an increase in the number of biopsies performed. In this data I 
observed a 9% reduction in unknown grade disease in 2003-2007 compared to 
1997-2002. This reduction of unknown grade might have artificially inflated the 
high grades in this period.  
Third, the rate of transurethral resection of prostate (TURP), the treatment of 
benign prostatic hyperplasia, has dramatically declined in recent periods due to 
availability of other treatments (Evans and Moller, 2003). Transurethral 
resections were used to lead to the incidental diagnosis of low grade PCs, which 
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now might not be appearing in earlier age and tumours gained enough time to 
evolve into high grade at a later age in life.  
Finally, if I assume that the increase in high grade disease is not artificially 
driven by the above mentioned factors, then there might be a real increase in 
the incidence of high grade disease. Many epidemiological studies have strongly 
linked obesity with increased risk of high grade PC (Kaaks and Stattin, 2010). 
Recently, high plasma cholesterol level has also been associated with increased 
risk of aggressive PC (Platz et al., 2009). If the observed increase of high grade 
disease in the West of Scotland is genuine, then the increasing obesity and 
dyslipidemia on population level might explain the observed patterns in our 
study (Lawder et al., 2010). 
2.5.5 Socio-economic patterns in incidence 
On further exploration of trend of PCs in the West of Scotland, I observed that 
age-standardised incidence among the most affluent men increased on average 
of 5.3% every year, while this remains only 1.3% among the most deprived group. 
The incidence rate ratio of affluent and deprived remained closer to one in the 
first half of 1990s, and steeply declined from 1997 onwards. Socio-economic 
differences in incidence of PC have also been reported in West Midlands, 
England (Dutta et al., 2005). However, little is known about the factors which 
influence and drive such changes. Evidence on the causes of PC generally 
remained inconclusive except for age, genetic predisposition and race. The 
poorly understood natural history of PC, which in most cases remains a small, 
slow growing tumour and might not even manifest during lifetime of an 
individual, makes it a very unpredictable disease.  
I further analysed the data to investigate the effect of period of diagnosis on 
emerging deprivation gap. Overall the increasing trend of incidence appears to 
be similar in all socio-economic groups till 1997, but a deprivation gap has 
emerged as result of relative increase in incidence among affluent men. PC 
incidence rates among the affluent were 17.2% higher than the deprived in 1997-
2002. This emerging deprivation accounts for an estimated 1,174 under 
diagnosed cases of PC (among the deprived and intermediate group) in the West 
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of Scotland during this period which is approximately 21% of all cases. This gap 
further widened in most recent period from 2003-2007. The absolute difference 
of age-standardised rates was 40.3% among the affluent and deprived, with an 
estimated 1,764 under diagnosed cases among the deprived and intermediate 
compared with the affluent. This is approximately 32% of total cases diagnosed 
in this period.  
On further analysis of grade-specific disease between socio-economic groups, 
affluent men were significantly more likely to have low grade disease compared 
with the most deprived men. This may be explained by differential uptake of 
PSA uptake between socio-economic groups but in the absence of PSA data it 
remains unclear yet. Trends of high grade disease did not show any significant 
difference in incidence between socio-economic groups.  
The observed deprivation gap in this analysis is even larger than recently 
reported gap for the colorectal cancer but in opposite direction (Oliphant et al., 
2011). A similar deprivation gap has been reported for PC in England and Wales 
from 1995-2004, however the size of the gap is even larger in the West of 
Scotland for both earlier and later periods (National Cancer Intelligence 
Network, 2008). The incidence of PC has increased among men in higher socio-
economic groups both in European countries as well as in the US (Liu et al., 
2001;Westlake and Cooper, ;Yin et al., 2010). Even the racial differences in 
incidence of PC have also been attributed to the socio-economic status of the 
individuals within their racial group (Yin et al., 2010).  
Underlying reasons for this widening deprivation gap are unclear yet. Some 
differences in prevalent risk factors and lifestyle habits among different socio-
economic groups might explain the observed association, but since the aetiology 
of PC remains poorly understood, definite conclusion about the increased risk of 
disease among different socio-economic groups could not be established. PSA 
testing has been widely available and utilised in last two decades (Drummond et 
al., 2009) and has led to earlier diagnosis of asymptomatic cases. It is very likely 
that the uptake of PSA testing as a means of diagnosing PC has become relatively 
much more common among the most affluent groups of population and this has 
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influenced the association between socio-economic status and incidence over 
time (National Cancer Intelligence Network, 2008).  
2.5.6 Implications for research  
The present study suggests socio-economic variations in distribution of PC in the 
West of Scotland. One important consideration of socio-economic inequalities in 
the incidence of PC is whether a higher diagnosis among affluent men has any 
health benefits associated with it or is it just a case of over diagnosis and 
treatment among affluent men. Previous research indicated that only 16% of 
asymptomatic men detected by a PSA test would benefit from radical treatments 
and their disease otherwise would not have compromised their life expectancy 
and quality of life (Frankel et al., 2003). As early detection of the individuals 
with PC might not lead to a radical treatment, diagnosis of cancer and living 
with cancer can have serious psychological influences and impact on quality of 
life after diagnosis. The upside is that the early detection by PSA testing has 
provided some evidence that disease grade and stage has been migrated in the 
UK. In this context individuals living in deprived areas are under diagnosed as 
suggested by our study and they might present with a higher grade and more 
advanced stage disease later. Then the question arises whether the early and 
higher detection among affluent men is associated with survival benefits of 
these patients. A deprivation gap of -6.9% (minus sign suggests a higher survival 
among the affluent) in survival of PC patients diagnosed from 1996 to 2000 has 
been reported previously. As I observed a widening gap in the incidence of PC in 
the more recent period, it is important to explore whether this higher incidence 
has influenced the pre-existing deprivation gap in survival of patients during 
most recent periods or not, while taking into account lag-time bias due to the 
PSA based diagnoses. 
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3 Cholesterol and the risk of grade-specific 
prostate cancer incidence: evidence from two 
large prospective cohort studies with up to 37 
years’ follow up. 
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3.1 Chapter summary 
High cholesterol may be a modifiable risk factor for PC but results have been 
inconsistent and subject to potential “reverse causality” where undetected 
disease modifies cholesterol prior to diagnosis. I conducted a prospective cohort 
study of 12,926 men who were enrolled in the Midspan studies between 1970 and 
1976 and followed up to 31st December 2007. I used Cox-Proportional Hazards 
Models to evaluate the association between baseline plasma cholesterol and 
Gleason grade-specific PC incidence. I excluded cancers detected within at least 
5 years of cholesterol assay.  
Six hundred and fifty men developed PC in up to 37 years’ follow-up. Baseline 
plasma cholesterol was positively associated with hazard of high grade (Gleason 
score≥8) PC incidence (n=119). The association was greatest among men in the 
4th highest quintile for cholesterol, 6.1 to <6.69 mmol/l, Hazard Ratio 2.28, 95% 
CI 1.27 to 4.10, compared with the baseline of <5.05 mmol/l. This association 
remained significant after adjustment for body mass index, smoking and height. 
Men with higher cholesterol are at greater risk of developing high-grade PC but 
not overall risk of PC. Interventions to minimise metabolic risk factors may have 
a role in reducing incidence of aggressive PC. 
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3.2 Introduction 
This chapter will investigate the role of cholesterol level in PC risk using the 
data from two large prospective cohort studies - the Midspan studies. In the 
earlier chapter 2 (page 95) it has been shown that the incidence of PC has 
increased over several decades such that it is now frequently diagnosed cancer 
among men in the UK and also in the West of Scotland.  
Three recent reports have suggested that while serum cholesterol has no 
association with overall incidence of PC, patients with low cholesterol are less 
likely to have high grade (Gleason score ≥8) disease (Mondul et al., 2010;Platz et 
al., 2008;Platz et al., 2009). In two of these studies, follow-up was short (3.1 
and 5.5 years) and none excluded early events (Mondul et al., 2010;Platz et al., 
2009) so that “reverse causality” – that is, cholesterol was modified by 
undiagnosed disease and not a causal factor for it – may have partly explained 
their observations. 
Given that age, genetics and ethnicity are not modifiable risk factors, the 
potential role of cholesterol on PC risk may be of clinical importance. In the 
present analysis the association between plasma cholesterol level and both 
overall and grade-specific PC incidence has been evaluated, using two of the 
Midspan prospective cohort studies with up to 37 years’ follow-up. Individuals 
diagnosed with PC within 5 years of baseline cholesterol assay were excluded to 
reduce the potential effects of “reverse causality.” 
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3.3 Materials and methods 
3.3.1 Cohort characteristics 
The Midspan studies began in the 1960s and 1970s in Scotland, UK (Hart et al., 
2005). These studies are called Midspan because they were centred on the 
midspan of life. These studies originated in the post war drive to control 
pulmonary tuberculosis in Scotland using the mass miniature radiography. 
However, later on these studies were extended to detect and investigate the 
risk factors of a wide range of chronic diseases. Midspan was the name given to 
four separate occupational and general population cohort studies based in 
Scotland (Hart et al., 2005). In the present analysis two Midspan studies were 
examined. The first, the Collaborative study, was conducted on employed men 
and women aged from 21 to 75 years from 27 workplaces in Glasgow, Clydebank 
and Grangemouth between 1970 and 1973 (Davey Smith G. et al., 1998). Further 
details of this cohort will be described in chapter 4 (Tea and coffee in relation 
to risk of PC, page 125), as only the Collaborative cohort study’s data has been 
used for that analysis.  
The second Midspan study, the Renfrew/Paisley study, was a general population 
study of residents of the towns of Renfrew and Paisley, conducted between 1972 
and 1976. All residents aged 45–64 years were invited to take part and 80% 
accepted (Hawthorne et al., 1995). Compared to the other population-based 
studies in the UK of that era, Renfrew/Paisley had a particular advantage of 
having a large number of female participants in this study. Compared to the 
other cohorts, men in this study had shorter stature, higher blood pressure, and 
a higher proportion of smokers continuing to smoke and more had chronic 
bronchitis (Hart et al., 2005).  
Because of the geographical proximity of the study populations, a small number 
of individuals participated in both cohorts. For individuals with more than one 
record, only the earliest record was used. Study protocols consisted of a self-
administered questionnaire followed by a screening examination at a specially 
set-up clinic. Questions included demographic details, occupation, lifestyle 
habits, including smoking, and health (Hawthorne et al., 1995). As part of the 
screening examination, measurements were made for height, weight and blood 
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pressure. Body mass index (BMI) was calculated from weight (in kg) divided by 
height (in metres) squared and categorised according to the World Health 
Organisation (WHO) classification in which BMI < 18.50 is underweight, 18.50 to 
24.99 is the normal range, 25.00 to 29.99 is overweight and ≥30.00 is obese. A 
blood sample was obtained at baseline screening for the measurement of total 
circulating plasma cholesterol (Hawthorne et al., 1995). Social class was derived 
from occupation according to the relevant version of the General Register Office 
Classification of Occupation (General Register Office, 1966) and graded into six 
categories: I (professional), II (intermediate), III (skilled non-manual), III (skilled 
manual), IV (partly skilled) and V (unskilled) (Hawthorne et al., 1995).  
Ex-smokers were defined as reporting giving up smoking at least a year before 
screening, otherwise they were defined as current smokers. Cholesterol was 
categorised by quintiles. Only records for male participants were used for this 
study.  
3.3.2 Follow-up 
Follow-up for mortality was carried out by flagging Midspan participants with the 
National Health Service Central Register. Deaths were then notified to the 
Midspan team on a monthly basis. Information on cancer registrations and 
hospital activity was obtained by linkage to the Scottish Morbidity Records (SMR) 
data and was complete from 1972 onwards (Hart et al., 2010). Follow-up began 
on the date of screening to the date of cancer incidence, date of death, date of 
embarkation (leaving the UK) or the censor date of 31st December 2007, 
whichever came first.  
3.3.3 Ethical approval 
An application along with a research proposal was submitted to Midspan Steering 
Committee to access the data of Midspan studies. Following the approval from 
Midspan Steering Committee, a request along with proposal was sent to the 
Privacy Advisory Committee at ISD to use the linked data of Midspan with SMR06 
and SMR01. The Privacy Advisory Committee of the Information Services Division 
of NHS Scotland gave permission for the linked data to be used in this study.  
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3.3.4 Risk factor and outcome definitions 
PC was defined as International Classification of Diseases (ICD) revision 9 code 
185 and ICD-10 code C61. PC incidence was determined if it was included in any 
cancer registration (SMR06), any diagnosis position of an acute hospital record 
(SMR01) or any position on the death record. Where a patient had PC recorded 
on more than one type of record, the earliest date was taken as time of first 
diagnosis. The Gleason grading system is a method used to describe the 
morphology of clinical PC. Data on Gleason score were available from the cancer 
registry (SMR06). The Scottish Cancer Registry began recording Gleason score 
from 1st January 1997 and therefore the analysis of grade-specific associations 
between cholesterol and PC was restricted to the follow-up of the surviving 
cohort as of 1st of January 1997 and these were just records from SMR06.  
3.3.5 Statistical analysis 
Cox proportional hazards models were used to estimate hazard ratios (HRs) for 
PC incidence from screening and for specific histological grades from 1st January 
1997. For inclusion in a multivariate model, all those variables which had a p-
value of less than 0.20 or were previously well known confounders in such 
analysis were included in multivariate analysis in a stepwise approach. For grade 
specific analysis, I excluded men who had died or been diagnosed with PC before 
1st January 1997. Separate models were run for each Gleason category, and men 
with PC and other Gleason scores were censored at their date of diagnosis. Age 
was taken as the timescale with censoring occurring on 31 December 2007. Using 
age as timescale is slightly different than the conventional approach of using 
follow-up time since screening. In age as timescale, the model calculates the 
hazards based on the age at which individual entered in study and age at which 
he exited from the study. This approach is more reliable when studying a disease 
which is strongly associated with age, because for the outcome (incidence of PC 
in this analysis), I would expect the hazard to change more as a function of age 
than as a function of time-on-study. The alternative approach of using time 
since screening as the timescale was also investigated (Korn et al., 1997). There 
were 100 participants in the underweight category (had BMI less than 18.5) and 
only one incident case of PC was identified in this group, so this category was 
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combined with the desirable weight category. Analysis was also carried out after 
excluding underweight individuals as well. 
All analyses were conducted using STATA version 11 (StataCorp, College Station, 
TX, USA). The following covariates were included in all models: smoking status, 
BMI and socio-economic status. Height and smoking status were missing for three 
individuals so they were excluded from multivariate analysis. The lowest 
category was used as referent for cholesterol and all other categorical 
covariates. 
Adherence to the proportional hazards assumption was investigated by plotting 
smoothed Schoenfeld residuals against time; no violations of the assumption 
were identified. All statistical tests were two tailed and statistical significance 
was taken as p < 0.05. The analysis was carried out after excluding individuals 
diagnosed with PC within five years of screening to minimise confounding due to 
the possible effects of early disease affecting cholesterol.  
3.3.6 Alternative categorisation of cholesterol 
Time to event approach was also used, that also did not affect any of the 
conclusions of this study. The present analysis was also repeated by using the 
different cut offs for cholesterol, for instance the clinical cut points for 
cardiovascular diseases (Desirable: <5.17 mmol/l, High: >5.17mmol/l) and 
clinical categories ((Desirable: <5.17 mmol/l, Borderline high: >5.1- <6.21 
mmol/l, High: ≥ 6.21 mmol/l). Also, these analyses were carried out separately 
on each cohort. That did not affect the cholesterol and PC relationship so the 
final analysis was carried by combining the data of two cohorts. In addition to 
that, analysis was also carried out after excluding the men who had a diagnosis 
of diabetes mellitus at the time of screening. Analysis was also stratified based 
on BMI categories (i.e. desirable, overweight, obese), while number of high 
grade cases was small in some categories and no clear pattern emerged so 
analysis was repeated using the median BMI of the sample. Functional form of 
the association of cholesterol, with the relative hazard of Gleason 8 to 10 PCs 
estimated in a Cox proportional hazards model using age as the time axis, this 
was estimated by using a cholesterol level as a continuous variable. The function 
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was fitted using restricted cubic splines with three knots (X). The function was 
standardized such that the HR was 1 at the mean cholesterol level of the lowest 
quintile.  
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3.4 Results 
Data from 13,071 men were available for analysis, 6022 (46.1%) from the 
Collaborative Study and 7049 (53.9%) from Renfrew/Paisley. Five Collaborative 
and nine Renfrew/Paisley participants were lost to follow-up, 42 Collaborative 
and 55 Renfrew/Paisley participants had missing cholesterol data. Twenty six 
individuals who participated in both studies were excluded from the 
Renfrew/Paisley study. This exclusion was on the basis that the longer follow-up 
of these individuals was available when using their data from Collaborative 
cohort study. Eight individuals diagnosed with PC in the first five years of 
screening were also excluded from the analysis. Our final sample therefore 
comprised 12,926 men followed-up for a total of 293,284 person-years. The 
median follow-up period was 24 years, maximum 37 years. Median age was 51 
years at the time of screening (range, 21-75 years).  
Baseline and outcome characteristics of cohort participants are shown in table 3-
1. Increasing weight and BMI were positively associated with cholesterol while 
current smoking and lower social class were inversely associated with 
cholesterol. Mean plasma cholesterol level did not differ (p=0.27) between men 
who were diagnosed with PC (5.85 mmol/l ± 0.99) and those who remained free 
from it (5.87 mmol/l ± 0.99). The mean time between screening (plasma 
cholesterol measurement) and the PC diagnosis was 22.9 (SD 7.84) years.  
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3-1: Baseline characteristics of male Midspan cohorts at screening (1970-76) and prostate 
cancer outcomes.  N=12,926. 
 
  Cholesterol quintiles, level mmol/L   
  
<5.05 5.06 – <5.57 5.58 – <6.09 6.1 – < 6.69 ≥6.7 
          
Sample Size 2,727 
 
2,592 
 
2,821 
 
2,286 
 
2,500 
 
Person-years of follow-up 62,536 
 
59,659 
 
63,340 
 
51,686 
 
56,062 
 
Number of Deaths %(n) 75.4 (2055) 76.2 (1974) 77.0 (2172) 77.7 (1777) 77.3 (1933) 
Number of prostate 
cancers %(n) 
5.1 (138) 4.7 (121) 5.1 (145) 5.5 (125) 4.8 (121) 
Gleason grade ≥8 27.9 (17) 37.3 (19) 46.2 (30) 46.5 (33) 33.9 (20) 
Gleason grade =7 21.3 (13) 13.7 (7) 12.3 (8) 18.3 (13) 27.1 (16) 
Gleason grade <7 24.6 (15) 17.6 (9) 26.2 (17) 16.9 (12) 18.6 (11) 
Unknown 26.2 (16) 31.4 (16) 15.4 (10) 18.3 (13) 20.3 (12) 
           
Mean Age, years (s.d.) 50.8 (7.8) 51.0 (7.2) 51.6 (7.1) 51.4 (6.8) 50.9 (6.8) 
Mean Height, cm(s.d.) 171.2 (7.1) 171.0 (7.0) 171.0 (7.1) 170.9 (7.1) 171.5 (7.2) 
Mean Weight, kg (s.d.) 72.6 (11.5) 74.4 (11.0) 75.0 (11.1) 75.8 (10.7) 76.7 (10.4) 
Height (cm), %(n) 
          
≤165.1 22.7 (618) 22.0 (571) 22.5 (635) 23.2 (531) 21.4 (535) 
165.2-170 19.6 (534) 19.9 (517) 22.2 (626) 22.4 (513) 19.5 (487) 
170.1-172.72 19.6 (535) 20.3 (526) 18.0 (508) 17.7 (405) 18.7 (468) 
172.73-177.8 22.3 (609) 23.6 (611) 21.9 (618) 21.0 (481) 23.6 (591) 
≥177.9 15.8 (431) 14.2 (367) 15.3 (433) 15.5 (355) 16.8 (419) 
Missing 0 (0) 0 (0) 0.0 (1) 0.0 (1) 0 (0) 
Mean BMI (s.d.) 24.7 (3.3) 25.4 (3.3) 25.6 (3.3) 26.0 (3.1) 26.1 (3.0) 
BMI (kg m
-2
), %(n) 
 
18.5 – <25 (Desirable ) 55.0 (1501) 48.0 (1243) 43.6 (1231) 38.8 (886) 36.7 (917) 
25 – <30 (Overweight) 38.8 (1057) 44.0 (1141) 47.4 (1336) 51.6 (1179) 53.4 (1336) 
≥30 (Obese) 6.2 (169) 8.0 (208) 9.0 (253) 9.6 (220) 9.9 (247) 
Missing 0.0 (0) 0.0 (0) 0.0 (1) 0.0 (1) 0.0 (0) 
Smoking, %(n) 
     
Never smoker 16.8 (457) 17.9 (463) 17.6 (496) 18.1 (413) 16.5 (413) 
Smoker 63.2 (1724) 59.5 (1542) 58.1 (1638) 55.2 (1262) 55.2 (1381) 
Ex-smoker 20.0 (546) 22.6 (587) 24.4 (687) 26.7 (610) 28.2 (706) 
Missing 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (1) 0.0 (0) 
Social Class, %(n) 
          
I&II 18.1 (493) 21.4 (555) 25.3 (715) 28.3 (646) 34.8 (871) 
IIIN 13.4 (365) 14.6 (378) 14.5 (408) 15.0 (343) 17.0 (424) 
IIIM 38.4 (1048) 36.7 (952) 34.2 (966) 33.9 (776) 28.5 (713) 
IV&V 29.4 (801) 26.4 (684) 25.3 (713) 22.2 (507) 19.5 (487) 
Missing 0.7 (20) 0.9 (23) 0.7 (19) 0.6 (14) 0.2 (5) 
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Six hundred and fifty men with PC were identified. Among 307 cancers that 
occurred from 1997 onward (when Gleason score was included in cancer registry 
data), 119 (38.8%) were high grade (Gleason score≥8), 57 (18.6%) were 
intermediate grade (Gleason=7), 64 (20.8%) low grade (Gleason≤6) and the 
remaining 67 (21.8%) were of unknown Gleason score. No convincing association 
was observed between cholesterol and overall hazard of PC, nor any consistent 
relationship within low and intermediate grade disease (table 3-2). However, the 
hazard increased consistently from the lowest to the second highest quintile of 
cholesterol among high grade disease (Gleason score ≥ 8) (table 3-2). On further 
exploration, a relationship was observed between cholesterol and high grade 
disease (table 3-3). After adjustment for BMI, smoking and height, a progressive 
increase in risk of high grade prostate remained between the lowest and second 
highest quintiles of cholesterol. This is more clearly shown in figure 3-1, in which 
the smoothed hazard of the most aggressive PCs (Gleason score≥8) increased 
with increasing cholesterol and then declined. We also noted a progressive 
increase in risk of all PCs with increasing height (table 3-3).  
As no significant association was observed between the highest quintile of 
cholesterol and risk of high grade disease, I combined the last two quintiles to 
further investigate the association. I observed significantly higher risk (HR 1.88, 
95 CI 1.08-3.27, p-value 0.03) of developing high grade disease among men in 
the highest cholesterol category (combination of 4th and 5th quintile). 
Furthermore, I also investigated the association between cholesterol and the risk 
of high grade disease using the clinical cut points of desirable, borderline high 
and high cholesterol groups. Men in the high cholesterol group (≥ 6.21 mmols/l) 
had significantly increased risk of developing high grade disease (1.75, 95% CI 
1.03-2.97, p value 0.036) compared with desirable cholesterol group (<5.1 
mmols/l) after adjustment for BMI, smoking and socio-economic status. 
I further stratified the analysis based on BMI. The association between 
cholesterol level and high grade PC differed by BMI, however, no clear 
relationship emerged when using the desirable, overweight and obese 
categories, due to smaller number of aggressive PC cases in two highest 
cholesterol quintiles of obese group (n=7), so analysis was then stratified based 
on the median BMI of the sample. There was no evidence of an association 
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between cholesterol level and risk of high grade disease in men with BMIs lower 
than 25.3. However, among men with high BMI (≥ 25.3, median of the sample), 
those in the second highest cholesterol quintile were significantly more likely to 
develop high grade disease (HR 9.98, 95% CI 2.33–42.78, p value 0.002) after 
adjustments for socio-economic status and smoking status. 
Both in univariate and multivariate models, the relationship between other risk 
factors including social class, BMI and smoking status with overall and grade 
specific PC incidence remained inconclusive. These analysis were also repeated 
using the clinical, cardiovascular cut offs for cholesterol level, however the 
results remain consistent. Additionally, these analyses were also carried out 
after excluding men who had BMI less than 18.5 and those who had diabetes 
mellitus, but no differences in results were observed after these exclusions. 
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Table 3-2: Unadjusted hazard ratios and 95% CI for overall and Gleason-specific prostate cancer by cholesterol quintiles among Midspan subjects who 
survived until 1st January 1997.  N=6486. 
 
                                                      
  All Prostate cancer Gleason < 7 Gleason 7 Gleason ≥8 Unknown 
                                                      
Cholesterol 
(mmol/L) 
quintiles 
  (n) Hazard Ratio (95%CI) % (n) Hazard Ratio (95%CI) % (n) Hazard Ratio (95%CI) % (n) Hazard Ratio (95%CI) [114] (n) Hazard Ratio (95%CI) 
< 5.05  1,384   1  24.6 (15)  1  21.3 (13)  1  15 (17)  1  26.2 (16)  1  
5.06 – <5.57 1,308 (51) 0.87 (0.60, 1.26) 17.6 (9) 0.62 (0.27, 1.41) 13.7 (7) 0.54 (0.22, 1.36) 9 (19) 1.18 (0.61, 2.27) 31.4 (16) 1.04 (0.52, 2.09) 
5.58 – <6.09 1,425 (65) 1.03 (0.72, 1.46) 26.2 (17) 1.10 (0.56, 2.27) 12.3 (8) 0.59 (0.24, 1.42) 17 (30) 1.7 (0.93, 3.07) 15.4 (10) 0.59 (0.27, 1.31) 
6.1 – < 6.69 1,159 (71) 1.36 (0.97, 1.92) 16.9 (12) 0.96 (0.45, 2.05) 18.3 (13) 1.14 (0.53, 2.47) 12 (33) 2.28 (1.27, 4.10) 18.3 (13) 0.95 (0.46, 1.98) 
≥6.7  1,210 (59) 1.09 (0.76, 1.57) 18.6 (11) 0.83 (0.38, 1.81) 27.1 (16) 1.35 (0.65, 2.81) 11 (20) 1.34 (0.70, 2.57) 20.3 (12) 0.85 (0.40, 1.80) 
                                                      
 Hazard ratios and 95% CIs were obtained by using age as time-scale.   
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Table 3-3: Multivariate hazard ratios (HR) for all prostate cancers and those with Gleason grade ≥ 8 
by cholesterol quintiles.   
 
        All Prostate Cancers Prostate cancers Gleason ≥ 8 
        Baseline Sample From 1st January 1997 
        % n Hazard Ratio (95% CI) % n Hazard Ratio (95% CI) 
              Cholesterol (mmol/L) quintiles 
           
< 5.05 
   
5.1 (138) 
 
1 
 
1.2 (17) 
 
1 
 
5.06 – <5.57 
  
4.7 (121) 0.89 (0.70, 1.14) 1.5 (19) 1.18 (0.62, 2.28) 
5.58 – <6.09 
  
5.1 (145) 0.95 (0.75, 1.21) 2.1 (30) 1.72 (0.95, 3.13) 
6.1 – < 6.69 
  
5.5 (125) 1.01 (0.79, 1.29) 2.8 (33) 2.34 (1.30, 4.23) 
≥6.7 
   
4.8 (121) 0.95 (0.74, 1.22) 1.7 (20) 1.40 (0.73, 2.71) 
              
BMI (kg m
-2
) 
            
<25 (Under & Desirable 
weight) 
4.8 (279) 1 2.1 (61) 
 
1 
 
25 – <30 (Overweight) 
 
5.3 (320) 1.02 (0.86, 1.20) 1.5 (47) 0.69 (0.47, 1.02) 
≥30 (Obese) 
  
4.6 (51) 1.03 (0.77, 1.40) 2.3 (11) 1.18 (0.62, 2.27) 
              Smoking 
             
Never smoker 
  
6.6 (149) 1 2.1 (31) 
 
1 
 
Smoker 
   
3.9 (294) 0.90 (0.73, 1.09) 1.6 (52) 0.92 (0.59, 1.45) 
Ex-smoker 
  
6.6 (207) 1.03 (0.77, 1.40) 2.1 (36) 1.06 (0.65, 1.72) 
              Social Class 
            
I&II 
   
5.8 (190) 1 1.9 (38) 1 
IIIN 
   
5.6 (108) 1.10 (0.87, 1.40) 2.2 (22) 1.21 (0.71, 2.05) 
IIIM 
   
4.7 (217) 1.03 (0.85, 1.26) 1.6 (33) 0.95 (0.59, 1.53) 
IV&V 
   
4.2 (135) 0.91 (0.73, 1.14) 1.9 (26) 1.15 (0.69, 1.92) 
              
Height (cm) 
            
≤165.1 
   
4.9 (120) 
 
1 
 
1.8 (17) 
 
1 
 
165.2-170 
  
4.7 (126) 1.05 (0.82, 1.35) 1.8 (23) 1.27 (0.68, 2.37) 
170.1-172.72 
  
4.2 (121) 1.11 (0.86, 1.43) 1.4 (22) 1.54 (0.61, 2.19) 
172.73-177.8 
  
7.5 (165) 1.27 (1.01, 1.61) 3.2 (36) 1.69 (0.94, 3.05) 
≥177.9       4.3 (118) 1.35 (1.04, 1.75) 1.3 (21) 1.32 (0.68, 2.55) 
Multivariate hazard ratios and 95% CIs were obtained by using age as time-scale; all covariates were 
included in the model except height. Estimates for height were obtained by replacing the BMI with height.  
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Figure 3-1: Functional form of the association between cholesterol and high grade prostate cancer 
(Gleason 8-10) 
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Relative hazard estimated in a Cox proportional hazards model using age as the time axis. The function 
was fitted using restricted cubic splines with three knots (X). The function was standardized such that the 
HR was 1 at the mean cholesterol level of the lowest quintile. Dotted lines indicate the 95% confidence 
intervals. 
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3.5 Discussion  
3.5.1 Findings of present analysis and potential explanations 
I found that plasma cholesterol was positively associated with increased risk of 
aggressive PC but not with overall risk of developing the disease in this 
population-based prospective cohort study. Our findings are consistent with 
other reports on US populations ((Mondul et al., 2010;Platz et al., 2008;Platz et 
al., 2009). The underlying mechanism by which cholesterol and prostate 
carcinogenesis may be linked remains unclear. Similarly, data from the Swedish 
Apolipoprotein Mortality Risk (Van et al., 2010) study reported no evidence of a 
relationship between hypercholesterolemia and overall PC risk (Van et al., 
2010). However, a large study of male Finnish smokers reported a positive 
association between increasing total cholesterol level and overall risk of PC 
particularly advanced stage PC (Mondul et al., 2011). The association further 
strengthened when they restricted the analysis to the cases diagnosed after 10 
years from the baseline. However, this study did not find any association 
between aggressive disease, which may be because Gleason score was only 
available for 25% of the PC patients (Mondul et al., 2011). Several underlying 
mechanisms by which cholesterol and prostate carcinogenesis may be linked 
have been proposed. PC cells tend to over accumulate cholesterol in their cell 
membrane, forming large lipid rafts which in the cancer cells may facilitate pro-
carcinogenic cell signalling (Freeman and Solomon, 2004;Hager et al., 
2006;Mondul et al., 2011). Moreover, several other pathways which are 
considered vital in carcinogenesis, such as sonic hedgehog and Akt pathways, are 
also cholesterol sensitive (Oh et al., 2007;Zhuang et al., 2002). Thus, having a 
lower cholesterol level may inhibit these pro-carcinogenic activities in the 
prostate cells. 
Generally, an association has been reported between low cholesterol and 
increased risk of many cancer types and their associated mortality (Hiatt and 
Fireman, 1986;Knekt et al., 1988;Davey Smith et al., 1992) which has been 
ascribed to reverse causality; that is, early undiagnosed cancers lead to 
behavioural and physiological changes that reduce plasma cholesterol. The 
longer period between baseline cholesterol assay and diagnosis in our study 
(about 21 years for grade-specific analyses) compared to others suggests that 
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reverse causality is unlikely to have been responsible for the observed 
association. Moreover, any such effect would have been expected to attenuate 
rather than exaggerate the association.  
In this analysis a significant relationship was observed between height and 
overall risk of PC, while no association with the risk of aggressive disease. 
Although the pattern of result showed increasing risk of developing high grade 
with increasing height, results were not significant, possibly due to smaller 
sample of aggressive PCs in this cohort. Previous evidence suggests that 
increasing height is associated with a modest increase in the risk of overall PC, 
with a stronger effect on aggressive PC incidence (Farwell et al., 2011;Ahn et 
al., 2009;Zuccolo et al., 2008;Sequoia et al., 2006). The findings that height 
may be linked with PC points toward the early childhood experiences and 
environmental factors which could lead to the progression of tumours with a 
worse prognosis. Mechanisms that could underlie the height and its link with PC 
still need to be studied. However, the dietary programming (particularly in early 
childhood) of the Insulin like growth factor-1 (IGF-1) plays an important role in 
the regulation of growth and height in particular (Mucci et al., 2001). There is 
some evidence also suggest that IGF-1 is linked with the PC, so the height 
observation of this analysis might be explained by the variation in the level of 
IGF-1 (Key, 2011). 
The mean age at PC diagnosis is high and a large proportion of men are likely to 
die before diagnosis. The risk estimates I present might therefore have been 
affected by differential competing mortality risks. However, Cancer Registry 
data include Death Certificate Only diagnoses – and may have included, PCs 
detected at post-mortem – that will attenuate such survival biases. The 
proportion of men who develop PC is higher among those who do not smoke, 
have a desirable BMI and are taller. The higher proportion of PC among these 
men results from those factors which confer a survival advantage. They live 
longer and therefore experience a longer risk time. However, the observation 
that height is associated with PC does raise the question whether some of those 
characteristics which promote longevity, are also associated with an increased 
risk of PC or whether such associations spuriously result from the influence of 
competing risk. If competing risks influence our data then selection bias could 
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be large. Cholesterol, height and obesity are related to mortality from 
cardiovascular disease (Lawlor et al., 2006;Neaton et al., 1984;Strandberg, 
1997;Turley et al., 2006) and early death from cardiovascular disease may be an 
important consideration. One possible scenario is that early cardiovascular 
disease mortality exhausts the pool of those men who would otherwise be 
susceptible to PC in later life, consequently systematic selection of more 
resilient individual may take place (men with low risk of PC but with high levels 
of traditional cardiovascular risk factors). This potentially could explain the 
positive association between height and incident PC, but would fail to explain 
the association between cholesterol and aggressive PC which I report.  
The potential clinical implications of our findings are that increasing obesity and 
associated dyslipidemia may have been responsible for the increasing incidence 
of PC and that modifying cholesterol may reduce incidence of more aggressive 
disease. In the present analysis, no association was observed between overall 
incidence and grade specific risk of PC in relation to BMI. Evidence that obesity 
is linked with PC risk is generally divergent. Studies on obesity are significantly 
different from each other, in size, baseline characteristics of cohorts and follow-
up times (Gong et al., 2006;Kaaks and Stattin, 2010;Porter and Stanford, 
2005;Robinson et al., 2005). It has been suggested that body size can influence 
the sex hormone profile in the early life of individuals and that interference in 
sex hormones can play a significant role in development of aggressive PC in later 
age (Robinson et al., 2005). However, studies mainly focusing the obesity failed 
to account for the dietary intake of individuals, which has a strong association 
with body size as well as hormone profiles. 
The evidence that statins may reduce PC incidence remains equivocal. Two 
meta-analyses and a subsequent cohort study did not find any relationship 
between statin use and PC (Boudreau et al., 2008;Browning and Martin, 
2007;Dale et al., 2006). However, Platz and Jacobs found associations between 
statin use and lower risk of advanced PC only and suggested that plausible 
biological mechanisms may existed, for example 3-hydroxy-3-methylglutaryl 
(HMG) coenzyme A reductase inhibition may reduce PC cell survival by 
interfering with membrane-associated signalling. Preliminary evidence suggests 
that prostatic inflammation stimulated by either viral infection, bacterial agent 
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or even because of the chemical damage to the prostatic tissue, is emerging 
primary aetiological agent in the development of prostatic tumours (Maitland 
and Collins, 2008). This hypothesis has been further supported by the evidence 
that the by-products of roasted meat (2-amin-1-methyl-6 phenylimidazo 
pyridine) were present in the prostate of a mouse model of disease and had the 
potential to stimulate the inflammatory and tumorigenic activity within the 
gland (Maitland and Collins, 2008). If inflammation is linked with the 
development of prostatic tumours, then the anti-inflammatory functions of 
statins might have some role in lower observed cancers among statin users. 
Nonetheless, in the absence of more consistent evidence on the effects of 
statins on PC, the most effective means of reducing incidence of the disease 
may therefore be through effective weight management. 
3.5.2 Strength and weaknesses 
This analysis is based on one of the largest population-based prospective studies 
in the UK and used cancer incidence data for the grade-specific analyses, rather 
than death records for cancer outcomes. Mortality data are a product of both 
incidence and case fatality, and do not allow risk factors to be individually 
differentiated. Furthermore, high cholesterol may increase the risk of death 
from other causes in PC patients and not necessarily be a causal factor for PC 
itself. Our study has larger numbers of incident cancers (n=650), longer follow-
up and lower losses to follow-up (0.1%) compared with earlier studies (Mondul et 
al., 2010;Platz et al., 2008). However, our study has some weaknesses. The 
Midspan questionnaire lacked information on family history of PC, PSA testing 
and use of statins. The baseline data of this cohort was obtained at a time when 
all of these factors were not well established in relation to the prostatic cancer. 
I used plasma total cholesterol level because other measures of cholesterol, such 
as lipoprotein fractions (high and low density lipoproteins), were not available. 
PSA and disease stage data were not available which could be used to stratify 
the analyses based on localised and metastatic PC. 
An important consideration is detection bias and whether some population 
subgroups are more likely to report their symptoms or have frequent medical 
examinations. There is some evidence that PC is socio-economically patterned 
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and more common among affluent individual, however in present analysis, social 
class was used as a measure of socio-economic circumstances and no significant 
association was observed between the social class and risk of PC. There can be 
multiple explanations for this. First, this analysis only includes 650 individuals of 
PC, so the number may be too small to detect any significant difference of risk 
across socio-economic groups and PC cases of this cohort might not be a true 
representative of all PCs diagnosed in Scotland. Second, social class was used as 
a measure of socio-economic circumstances, while the earlier analysis showed in 
incidence chapter 2 (page 98), used an area-based measure of deprivation, and 
this difference of measures might have some role in differential findings. Finally, 
there is a possibility that in real life there may be no association of socio-
economic circumstances on overall risk of PC, but the socio-economic status may 
be just associated with the differential detection rates in sub groups of 
population.  
Further consideration in addition to the socio-economic differences in the 
detection rate, is the participants who had higher level of plasma cholesterol 
might be in contact with their GP more frequently to control their 
hypercholesterolemia than others. So their chances of being diagnosed with PC 
might be simply higher due to greater utilisation of services. 
3.5.3 Implications for public health 
This current analysis showed that there is a relationship between cholesterol and 
aggressive PC risk. In chapter 2 (page 96), analyses showed that high-grade PC 
has differentially increased in the West of Scotland during recent periods. Taking 
both these findings together, the observation of increased high grade disease at 
the population level could be because of increases in metabolic risk factors 
associated with hypercholesterolaemia and obesity in Scotland. Given that 
modifiable risk factors are not known for incidence of PC, emerging evidence on 
hypercholesterolaemia and obesity may be important from a population 
perspective. Although further evidence is required on the role of obesity and 
hypercholesterolaemia, in the absence of more consistent evidence effective 
weight management may be the most useful tool to reduce the burden of 
aggressive PC.  
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3.5.4 Implications for future research 
Confirmation of recent findings on cholesterol and PC incidence is required in 
future studies with additional information on PSA and disease stage. In this 
analysis, the number of men with aggressive PC was small (n=119) so the 
subgroup analysis may be an artefact due to small number of cases; further 
investigations on a larger sample may show more clear relationship. An 
important issue which needs to be considered in further research is to separate 
the factors which are associated with the detection of cancer rather than the 
true risk factors of PC. In relation to PC, identification of factors related to 
detection may be important as PSA testing can cause a diagnosis of cancer but it 
is not a true risk factor of PC. In the absence of more conclusive evidence on 
cholesterol and PC, temporal trends of grade and stage-specific incidence from 
other regions of UK and well developed countries may provide some clue about 
the role of increases in obesity on population level in incidence of PC. 
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4 Tea and coffee consumption and the risk of 
overall and grade-specific prostate cancer: a 
large prospective cohort study of Scottish men.  
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4.1 Chapter summary 
Tea and coffee may be potentially modifiable and highly prevalent risk 
factors for the most common cancer in men, PC. However, associations 
between black tea consumption and PC in epidemiological studies have been 
inconsistent. Most evidence is limited to a small number of studies with small 
numbers of cases and short follow-up periods and without grade specific 
information. Similarly, evidence from large prospective studies and a recent 
meta-analysis on role of coffee on PC risk remained inconclusive. Coffee 
intake has been recently linked with reduced risk of aggressive PC incidence. 
Authors concluded that higher coffee consumption can not be recommended 
to prevent PC and further epidemiological evidence on the association is 
required before making any recommendations. I conducted a prospective 
cohort study of 6016 men who were enrolled in the Collaborative cohort study 
between 1970 and 1973 and followed up to 31st December 2007. We used Cox 
Proportional Hazards Models to investigate the association between tea and 
coffee consumption and overall as well as grade-specific risk of PC incidence.  
Three hundred and eighteen men developed PC in up to 37 years’ follow-up. I 
found a positive association between consumption of tea and overall risk of 
PC incidence (p=0.02). The association was greatest among men who drank ≥7 
cups of tea per day (HR 1.50, 95% CI 1.06 to 2.12) compared with the baseline 
of 0-3 cups/day. However, I did not find any significant association between 
tea intake and low (Gleason < 7) or high grade (Gleason 8-10) PC incidence. 
Men with higher intake of tea are at greater risk of developing PC but there is 
no association with more aggressive disease. Higher coffee consumption (3 or 
more cups per day) was inversely associated with risk of high grade (HR 0.46, 
95% CI 0.21 to 0.99) but not with overall risk of PC. This association remained 
significant after adjustment for age, Body Mass Index, smoking, social class, 
cholesterol level, systolic blood pressure tea intake and alcohol consumption.  
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4.2 Introduction 
Tea and coffee are among the most popular beverages worldwide and have 
been investigated for their role in PC development. These beverages are also 
among the few potentially modifiable risk factors for PC but the 
epidemiological evidence is inconclusive and therefore no recommended 
guidelines are available for their consumption.  
Patients may reduce their fluid intake to ameliorate symptoms of PC, such as 
polyuria and nocturia, but I could not identify any study that excluded 
diagnoses made soon after risk factor assessment to minimise apparent 
“reverse causality.” Also the evidence is very limited specifically with regard 
to the role of these beverages on the risk of high grade PC, which 
corresponds to clinically significant disease. A recently published review on 
comparisons between black tea and green tea in relation to PC also 
highlighted the need for further epidemiological evidence (Henning et al., 
2011), while a recently published study has highlighted the importance of 
grade-specific risk associated with coffee intake (Wilson et al., 2011).  
Therefore the purpose of this analysis was to assess the relationship between 
tea and coffee consumption with overall as well as grade-specific risk of 
developing PC among Scottish men in the Collaborative cohort study.  
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4.3 Material and methods 
4.3.1 Cohort characteristics 
The Collaborative cohort study was the second of the Midspan studies that 
began in the 1960s and 1970s in Scotland, UK. Their methods have been 
described in detail elsewhere (Hart et al., 2005). The Collaborative study was 
conducted on employed men and women aged from 21 to 75 years from 27 
workplaces in Glasgow, Clydebank and Grangemouth between 1970 and 1973 
(Davey Smith G. et al., 1998). The response rate was 70% for these 
workplaces for which response rates were available (87% of the sample).  
Study protocols consisted of a self-administered questionnaire followed by a 
screening examination at a specially set-up clinic. Questions included 
demographic details, occupation, lifestyle habits including smoking, and 
health (Davey Smith G. et al., 1998). Daily tea intake reported by the 
participants was categorised into four groups based on roughly equal number 
of participants in each group. Daily coffee intake reported by participants 
was divided into three groups. Weekly reported alcohol consumption was 
categorised by spirits, beer, and wine. This was converted to units of alcohol 
by taking one measure of spirits as 1 unit, 1 pint (0.6 litres) of beer as 2 
units, and one bottle of wine as 6 units (Hart et al., 1999). Four categories of 
alcohol consumption were formed (none, 110, 11-21, > 21 units of alcohol a 
week). As parts of the screening examination, measurements were made for 
height, weight and blood pressure.  
A blood sample was obtained at baseline screening for the measurement of 
total circulating plasma cholesterol. Body mass index (BMI) was calculated 
from weight (in kg) divided by height (in metres) squared and categorised 
according to the World Health Organisation classification in which BMI < 18.50 
is underweight, 18.50 to < 25 is the normal range, 25 to <30 is overweight and 
≥30 is obese. I combined the underweight and normal BMI categories because 
the number of subjects was small in the underweight category and only one 
subject developed PC. Social class was derived from occupation according to 
the relevant version of the General Register Office Classification of 
Occupation (General Register Office, 1966) and graded into six categories:  
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I (professional), II (intermediate), III non-manual (skilled non-manual), III 
manual (skilled manual), IV (partly skilled) and V (unskilled) (General Register 
Office, 1966). Years of full time education was also used as a measure of 
socio-economic status. The Collaborative cohort study has information on age 
at leaving full time education. I subtracted five from the age at leaving full 
time education to calculate years in full time education, assuming that 
everyone started schooling at five years of age. Ex-smokers were defined as 
reporting giving up smoking at least a year before screening, otherwise they 
were defined as current smokers. Only the records for male participants were 
used for this study.  
4.3.2 Follow-up 
Follow-up for mortality was carried out by flagging Collaborative study 
participants with the National Health Service Central Register. Deaths were 
then notified to the study team on a monthly basis. Information on cancer 
registrations and hospital activity was obtained by linkage to the Scottish 
Morbidity Record (SMR) data and was complete from 1972 onwards (Hart et 
al., 2010). Follow-up began on the date of screening to the date of cancer 
incidence, date of death, date of embarkation or the censor date of 31st 
December 2007, whichever came first.  
4.3.3 Ethical approval 
An application was submitted to Midspan Steering Committee to access the 
data of Midspan studies. Following the approval from Midspan Steering 
Committee, a request along with proposed analysis was submitted to Privacy 
Advisory Committee at ISD to use the linked data of Midspan with SMR06 and 
SMR01. The Privacy Advisory Committee of the Information Services Division 
of NHS Scotland gave permission for the linked data to be used in this study.  
4.3.4 Outcome definitions 
PC was defined as International Classification of Diseases (ICD) revision 9 
code 185 and ICD-10 code C61. PC incidence was ascertained if it appeared in 
any of the records from cancer registration (SMR06), acute hospital record 
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(SMR01) or death record. Where a patient had PC recorded on more than one 
type of record, the earliest date was taken as time of first diagnosis. The 
Gleason grading system is a method used to distinguish the morphology of 
clinical PC to provide prognostic information. Data on Gleason score were 
available from the cancer registration data (SMR06). The Scottish Cancer 
Registry began recording Gleason score from 1st January 1997, thus the 
analysis of grade-specific associations between tea intake and PC was 
restricted to follow-up of the surviving cohort as of 1st January 1997.  
4.3.5 Statistical analysis 
Cox proportional hazards models were used to estimate hazard ratios (HRs) 
for PC incidence from screening, and for specific histological grade from 1st 
January 1997. Separate models were run for each Gleason category and men 
with PC and other Gleason scores were censored at their date of diagnosis. 
All analyses were conducted using STATA (stcox in STATA v11 StataCorp, 
College Station, TX, USA). On univariate analysis, variables which had a p-
value less than 0.2 or those which are well known confounders in such risk 
analysis were included in multivariate models. We included smoking status, 
age, BMI, alcohol intake, coffee consumption, cholesterol level, systolic 
blood pressure, years of full time education and social class in the 
multivariate models. Height appeared as a significant factor in previous 
analysis so height was included in multivariate model when BMI was not in the 
model as BMI consists of height and weight.  
There were missing data for some covariates: 11 in social class; 41 in 
cholesterol level; 1 in height and weight; 1 in smoking status; and 9 
individuals’ age at leaving full time education. Total missing data for all 
covariates was less than 0.01% which did not change any of the associations 
when I ran the analysis both including those observations after imputations 
and excluding these individuals. I presented the final results after imputation 
in which missing information on continuous variables was replaced by the 
sample mean while for categorical variables missing data were replaced by 
modal values.  
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The lowest category was used as referent for the tea and coffee intake 
covariates and all other categorical covariates. Adherence to the proportional 
hazards assumption was investigated by plotting smoothed Schoenfeld 
residuals against time; no violations of the assumption were identified. All 
statistical tests were two tailed and statistical significance was taken as p < 
0.05. In total, data for 6022 men were available for analysis, five study 
participants were lost to follow-up and one individual’s tea intake 
information was missing so they were excluded from the analysis.  
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4.4 Results 
Our final sample comprised 6,016 men followed-up for a total of 155,338 
person-years. The median follow-up period was 28 years and maximum 37 
years. The median age was 48 years at the time of screening (range, 21-75 
years). The mean time between screening and PC diagnosis was 25.8 (SD 
10.58) years. 
Baseline and outcome characteristics for the study are shown in table 4-1. 
Three hundred and eighteen men with PC were identified. Individuals who 
consumed seven or more cups of tea per day were older, more likely to be 
smokers, non-alcohol drinkers, non-coffee drinkers and had normal BMIs 
compared with men drinking 0-3 cups per day. However, individuals who 
drank 7 or more cups of tea per day were less likely to drink alcohol (χ2, p 
≤0.001). Individuals of middle social class and who had 7-9 years of education 
were more likely to drink 7 or more cups of tea per day. Individuals who had 
normal BMI, higher social class and smokers were more likely to consume 
three or more cups of coffee per day while those taking high amount of 
alcohol were more likely to be low or non-coffee drinkers (table 4-1).  
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Table 4-1: Baseline characteristics of male participants of Collaborative Cohort study at 
screening and prostate cancer outcome. N= 6,016.  
 
Categories of cups of tea/day   P value* 
  0--3 4--5 6 ≥7   
Sample Size 1,631 1,770 1,188 1,427 
Person-years of follow-up 43,852 45,744 30,170 35,591 
Men with  prostate cancers %(n) 4.6 (75) 5.1 (90) 5.1 (61) 6.4 (92) 0.13 
Mean Age (s.d.) 46.4 (7.6) 47.8 (7.2) 48.2 (7.2) 48.3 (6.8) <0.001 
Mean Height (s.d.) 173.6 (7.1) 172.7 (7.1) 172.7 (7.2) 172.6 (6.8) 0.31 
Mean Weight (s.d.) 76.8 (10.5) 75.1 (10.5) 75.1 (11.1) 73.9 (10.2) 0.02 
Height (cm), %(n) 
≤167.6 24.3 (397) 29.2 (516) 29.0 (344) 29.1 (415) 0.002 
167.7-170.2 12.5 (204) 13.7 (243) 12.5 (148) 12.8 (183) 
170.2-175.3 26.3 (429) 26.0 (461) 27.9 (332) 28.7 (409) 
175.3-180.4 24.3 (397) 20.3 (359) 20.0 (238) 20.5 (292) 
≥180.5 12.5 (204) 10.8 (191) 10.6 (126) 9.0 (128) 
Mean BMI (s.d.) 25.5 (3.1) 25.1 (3.0) 25.2 (3.2) 24.8 (3.0) 0.24 
BMI (kg m-2), %(n) 
<25 (Under & Desirable) 44.8 (730) 50.6 (895) 47.6 (566) 54.4 (776) <0.001 
25 – <30 (Overweight) 48.3 (788) 43.7 (773) 46.3 (550) 40.6 (579) 
≥30 (Obese) 6.9 (113) 5.8 (102) 6.1 (72) 5.0 (72) 
Alcohol intake (units/week), %(n) 
non drinkers 24.2 (394) 29.7 (525) 36.4 (432) 37.9 (541) <0.001 
1--10 30.7 (500) 31.6 (560) 26.4 (313) 25.7 (366) 
11--21 22.0 (358) 19.8 (351) 20.2 (240) 18.5 (264) 
> 21 23.2 (379) 18.9 (334) 17.1 (203) 17.9 (256) 
Cups of coffee/day 
0 16.8 (274) 38.8 (687) 58.9 (700) 67.9 (966) <0.001 
1--2 34.2 (558) 43.3 (767) 31.7 (377) 25.0 (357) 
≥3 49.0 (799) 17.9 (316) 9.3 (111) 7.3 (104) 
Smoking, %(n) 
Never smoker 19.6 (320) 19.2 (340) 17.0 (202) 16.3 (232) <0.001 
Smoker 55.5 (906) 55.3 (978) 60.1 (714) 62.6 (894) 
Ex-smoker 24.8 (405) 25.5 (452) 22.9 (272) 21.1 (301) 
Social Class, %(n) 
I&II 44.5 (725) 32.6 (577) 27.6 (328) 26.4 (377) <0.001 
IIIN 15.9 (259) 18.0 (318) 18.8 (223) 22.0 (314) 
IIIM 23.3 (380) 29.2 (516) 29.9 (355) 29.8 (425) 
IV&V 16.4 (267) 20.3 (359) 23.7 (282) 21.8 (311) 
Years of full time education 
7--9 38.7 (634) 50.3 (890) 54.0 (642) 55.0 (786) <0.001 
10 17.3 (282) 20.2 (357) 19.1 (227) 20.8 (296) 
11--34 44.0 (715) 29.6 (523) 26.9 (379) 24.2 (345)   
* P value for categorical variables calculated by chi-square test and for continuous 
variables by linear regression.  
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I found a convincing association between tea consumption and overall hazard 
of PC (table 4-2). The hazard increased consistently from the lowest category 
of tea intake (0-3 cups/day) to the highest category (≥7 cups/day). 
Individuals taking seven or more cups of tea per day were 65% more likely to 
develop PC (HR = 1.65, 95 % CI 1.22-2.24, p value = 0.001) compared with 
those taking 0-3 cups per day. This association remained but was attenuated 
after adjusting for the effects of age, height, BMI, cholesterol level, systolic 
blood pressure, smoking status, alcohol intake, coffee consumption, years of 
full time education and social class. When I included tea as a continuous 
variable in multivariate analysis the association remained consistent (HR = 
1.05, 95% CI 1.01-1.09, p value=0.02) (table 4-2). I also conducted further 
analyses excluding individuals diagnosed with PC in the first 10 years of 
screening (n=14), and the association between tea consumption of ≥7 
cups/day and increased PC risk remained significant (HR = 1.48, 95% CI 1.08-
2.04) after accounting for the effects of co-variates.  
Among 186 cancers that occurred from 1997 onward (when Gleason score was 
included in the Scottish Cancer Registry data), 70 (37.6%) were high grade 
(Gleason score≥8), 38 (20.4%) were intermediate grade (Gleason=7), 41 
(22.0%) low grade (Gleason≤6) and the remaining 37 (19.9%) were of unknown 
Gleason score. I found no convincing evidence of relationship between tea 
consumption and hazard of grade-specific PC (table 4-3). In univariate 
analysis, individuals taking high amount of tea were significantly more likely 
to have high grade PC but this association was no longer significant (HR = 
1.44, 95% CI 0.66-3.14, p value 0.36) when accounted for the effects of other 
covariates. 
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Table 4-2: Univariate and multivariate hazard ratios (HR) for all prostate cancers by tea 
categories.   
    
  Univariate analysis     Multivariate analysis * 
      Total n 
Hazard Ratio  
(95% CI) 
p value   
Hazard Ratio  
(95% CI) 
p value 
Cups of tea/day 
            
0--3 
  
1,631 (75) 1 
  
1 
 
4--5 
  
1,770 (90) 1.21 (0.89, 1.64) 0.23 
 
1.11 (0.79, 1.48) 0.61 
6 
  
1,188 (61) 1.26 (0.90, 1.76) 0.19 
 
1.10 (0.79, 1.57) 0.55 
≥7 
  
1,427 (92) 1.65 (1.22, 2.24) 0.001 
 
1.50 (1.06, 2.12) 0.02 
Cups of tea (continuous) 6,016 (335) 1.06 (1.02, 1.09) 0.002 
 
1.05 (1.01, 1.09) 0.02 
Cups of coffee/day 
            
0 
  
2,627 (139) 
 
1 
    
1 
  
1--2 
  
2,059 (114) 0.92 (0.71, 1.17) 0.48 
 
0.94 (0.72, 1.23) 0.66 
≥3 
  
1,330 (65) 0.78 (0.58, 1.05) 0.10 
 
0.91 (0.64, 1.29) 0.59 
Cholesterol level 
 
6,016 (318) 1.06 (0.95, 1.18) 0.29 
 
1.01 (0.90, 1.13) 0.87 
Systolic blood pressure 6,016 (318) 1.00 (0.99, 1.01) 0.14 
 
0.99 (0.99, 1.01) 0.54 
Height (cm) 
            
≤167.6 
  
1,672 (75) 1 
  
1 
 
167.7-170.2 
 
778 (31) 0.74 (0.49, 1.12) 0.16 
 
0.79 (0.52, 1.20) 0.27 
170.2-175.3 
 
1,631 (98) 1.11 (0.82, 1.49) 0.51 
 
1.24 (0.91, 1.68) 0.17 
175.3-180.4 
 
1,286 (78) 1.08 (0.79, 1.48) 0.62 
 
1.25 (0.90, 1.74) 0.18 
≥180.5 
  
649 (36) 0.88 (0.59, 1.32) 0.55 
 
1.11 (0.73, 1.68) 0.62 
BMI (kg m
-2
) 
            
  <25 (Under & Desirable) 2,967 (152) 1 
  
1 
 
  25 – <30 (Overweight) 269 (148) 1.12 (0.90, 1.41) 0.31 
 
1.12 (0.89, 1.42) 0.32 
  ≥30 (Obese) 
 
359 (18) 1.35 (0.83, 2.19) 0.23 
 
1.31 (0.79, 2.16) 0.29 
Alcohol intake (units/week) 
           
non drinkers 
 
1,892 (115) 1    
1 
  
1--10 
  
1,739 (102) 0.89 (0.68, 1.16) 0.39 
 
0.98 (0.75, 1.29) 0.89 
11--21 
  
1,213 (52) 0.72 (0.52, 1.00) 0.05 
 
0.88 (0.63, 1.23) 0.45 
> 21 
  
1,172 (49) 0.80 (0.57, 1.12) 0.20 
 
0.99 (0.70, 1.41) 0.97 
Smoking 
             
Never smoker 
 
1,094 (68) 1 
  
1 
 
Smoker 
  
3,492 (136) 0.95 (0.71, 1.27) 0.71 
 
0.94 (0.69, 1.27) 0.69 
Ex-smoker 
 
1,430 (114) 1.68 (1.25, 2.73) 0.001 
 
1.43 (1.05, 1.94) 0.02 
Social Class 
            
I&II 
  
2,007 (122) 1 
  
1 
 
IIIN 
  
1,219 (53) 1.00 (0.72, 1.38) 0.99 
 
1.15 (0.77, 1.72) 0.49 
IIIM 
  
1,114 (68) 1.07 (0.80, 1.44) 0.65 
 
1.23 (0.89, 1.69) 0.21 
IV&V 
  
1,676 (75) 0.96 (0.72, 1.28) 0.80 
 
1.17 (0.82, 1.68) 0.38 
Years of full time 
education            
7--9 
  
2,952 (130) 
 
1 
    
1 
  
10 
  
1,162 (68) 0.95 (0.71, 1.27) 0.73 
 
1.34 (0.97, 1.85) 0.07 
11--34     1,902 (120) 1.01 (0.79, 1.30) 0.91   1.34 (0.98, 1.85) 0.07 
*Multivariate model included age and all co-variates presented in the table. 
Estimates for height were obtained by replacing the BMI with height.
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Table 4-3: Univariate and multivariate analyses for overall and Gleason-specific prostate cancer by tea consumption categories among the Collaborative 
cohort study subjects who survived until 1st January 1997.  N= 3527. 
 
                                                 
  All Prostate cancer Gleason < 7 Gleason 7 Gleason ≥8 Unknown 
                                                  
Cups of 
tea/day 
  n 
Hazard Ratio 
 (95%CI)
a
 
% (n) 
Hazard Ratio  
(95%CI)
 a
 
% (n) 
Hazard Ratio  
(95%CI)
 a
 
% (n) 
Hazard Ratio  
(95%CI)
 a
 
% (n) 
Hazard Ratio  
(95%CI
 a
) 
0--3  1,020 (46) 1 26.1 (12) 1 21.7 (10) 1 28.3 (13) 1 23.9 (11) 1 
4--5  1,051 (60) 1.34 (0.91, 1.97) 20.0 (12) 1.02 (0.46, 2.27) 18.3 (11) 1.13 (0.48, 2.67) 40.0 (24) 1.89 (0.96, 3.73) 21.6 (13) 1.19 (0.40, 3.54) 
6  677 (31) 1.10 (0.69, 1.71) 29.0 (9) 1.20 (0.51, 2.85) 22.6 (7) 1.14 (0.43, 2.99) 38.7 (12) 1.49 (0.68, 3.27) 9.6 (3) 0.26 (0.03, 2.20) 
≥7   779 (49) 1.53 (1.02, 2.28) 16.3 (8) 0.95 (0.39, 2.31) 20.4 (10) 1.46 (0.61, 3.51) 42.9 (21) 2.32 (1.16, 4.64) 20.4 (10) 0.93 (0.26, 3.23) 
  
 
 
Hazard Ratio 
(95%CI)
b
 
  
 
Hazard Ratio 
(95%CI)
b
 
 
 
Hazard Ratio 
(95%CI)
b
   
Hazard Ratio 
(95%CI)
b
   
Hazard Ratio 
(95%CI)
b
 
0--3  1,020 (46) 1 26.1 (12) 1 21.7 (10) 1 28.3 (13) 1 23.9 (11) 1 
4--5  1,051 (60) 1.20 (0.80, 1.79) 20.0 (12) 0.81 (0.35, 1.88) 18.3 (11) 1.28 (0.52, 3.13) 40.0 (24) 1.52 (0.75, 3.09) 21.6 (13) 1.41 (0.44, 4.54) 
6  677 (31) 0.90 (0.55, 1.47) 29.0 (9) 0.90 (0.35, 2.32) 22.6 (7) 1.51 (0.53, 4.30) 38.7 (12) 0.97 (0.42, 2.28) 9.6 (3) 0.39 (0.04, 3.51) 
≥7   779 (49) 1.24 (0.79, 1.96) 16.3 (8) 0.70 (0.26, 1.89) 20.4 (10) 1.97 (0.73, 5.37) 42.9 (21) 1.44 (0.66, 3.14) 20.4 (10) 1.27 (0.29, 5.50) 
a = unadjusted hazard ratio, b = hazard ratio estimates adjusted for age at screening, alcohol intake, coffee consumption, smoking status, BMI, cholesterol level, 
systolic blood pressure, social class and year of full time education 
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Table 4-4: Univariate and multivariate analyses for overall and Gleason-specific prostate cancer by coffee consumption categories among the Collaborative 
cohort study subjects who survived until 1st January 1997.  N= 3527.  
 
                                            
  All Prostate cancer Gleason < 7 Gleason = 7 Gleason 8-10 Unknown Gleason 
                                            
Cups of coffee/day   n 
Hazard Ratio 
 (95%CI)
a
 
% (n) 
Hazard Ratio 
(95%CI)
a
 
(n) 
Hazard Ratio 
(95%CI)
a
 
(n) 
Hazard Ratio 
(95%CI)
a
 
(n) 
Hazard Ratio 
(95%CI)
a
 
0  1,441 (81) 1 41.5 (17) 1 (12) 1 (39) 1 (13) 1 
1--2  1,252 (67) 0.89 (0.65, 1.24) 41.5 (17) 1.09 (0.56, 2.14) (14) 1.25 (0.58, 2.71) (20) 0.55 (0.32, 0.95) (16) 1.53 (0.49, 4.83) 
≥ 3   834 (38) 0.75 (0.51, 1.11) 17.1 (7) 0.67 (0.28, 1.61) (12) 1.59 (0.71, 3.53) (11) 0.45 (0.23, 0.88) (8) 1.96 (0.60, 6.41) 
  
 
 
Hazard Ratio 
(95%CI)
b
 
  
 
Hazard Ratio 
(95%CI)
b
 
 
Hazard Ratio 
(95%CI)
b
 
 
Hazard Ratio 
(95%CI)
b
 
 
Hazard Ratio 
(95%CI)
b
 
0  1,441 (81) 1 41.5 (17) 1 (12) 1 (39) 1 (13) 1 
1--2  1,252 (67) 0.84 (0.60, 1.21) 41.5 (17) 1.04 (0.51, 2.17) (14) 1.23 (0.53, 2.84) (20) 0.53 (0.29, 0.96) (16) 1.17 (0.52, 2.64) 
≥ 3   834 (38) 0.74 (0.47, 1.16) 17.1 (7) 0.54 (0.19, 1.57) (12) 1.79 (0.69, 4.62) (11) 0.46 (0.21, 0.99) (8) 0.88 (0.31, 2.48) 
                                            
a = crude hazard ratio, b = hazard ratio estimates adjusted for age at screening, tea consumption, alcohol intake, smoking status, BMI, cholesterol level, systolic blood 
pressure and social class 
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No convincing association was found between coffee and overall hazard of PC 
(table 4-2). We also conducted further analyses excluding individuals diagnosed 
with PC in the first 10 years of screening (n=14), after multivariate adjustments 
the inverse association between coffee consumption of ≥3 cups/day and reduced 
PC risk slightly changed (HR = 0.80, 95% CI 0.59-1.10, p value 0.18) although 
remained non-significant. 
On further grade-specific analysis, no association was observed between coffee 
intake and low grade as well as intermediate grade PC. However, the hazard 
reduced significantly from the lowest to the highest category of coffee intake 
(HR 0.46, 95% CI 0.22-0.99) among high grade disease (Gleason score ≥ 8) (table 
4-4). These associations did not alter after adjustment for age, height, BMI, 
smoking, social class, tea consumption, alcohol intake, plasma cholesterol and 
systolic blood pressure and a progressive reduction in risk of high grade PC 
remained between the lowest and other two categories of coffee intake (table 
4-4). However, the results were borderline significant which could be due to 
smaller number of cases (n=11) in the highest category of coffee drinkers. We 
further investigated this association by combining the coffee categories as 
coffee drinkers and non-drinkers. Men who consumed any amount of coffee had 
significantly reduced risk of aggressive PC (HR 0.51, 95% CI 0.29-0.87, p = 0.01) 
compared with non-coffee drinkers after adjustments for age, BMI, smoking, 
social class, tea consumption, alcohol intake, plasma cholesterol and systolic 
blood pressure. 
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4.5 Discussion 
4.5.1 Findings and their potential explanations 
In this large prospective study, a strong positive association was observed 
between tea consumption and overall risk of PC, those who drank the most tea, 
7 or more cups per day, had 65% higher risk than those taking none to 3 cups of 
tea per day. But no significant relationship was observed with either low grade 
(Gleason < 7), intermediate grade (Gleason = 7) or high grade disease (Gleason 
8-10). This could be because of the small number of PC cases in these 
categories. Furthermore, coffee intake was associated with reduced risk of high 
grade PC but not with overall risk of developing the disease in this population-
based prospective cohort study. These findings did not alter after adjustments 
for co-variates.  
Many in-vitro and in-vivo studies have demonstrated the role of anti-
carcinogenic activity of tea extracts and polyphenols for many cancers including 
lung, oral cavity oesophagus, small intestine, colon, bladder, liver, pancreas, 
prostate and mammary glands (Peng et al., 2010;Sukhthankar et al., 2008;Yang 
et al., 2011). However, epidemiological evidence on the role of tea remains 
equivocal for all cancers including prostate (Lee et al., 2009;Sun et al., 
2006;Tang et al., 2009). This discrepancy might be due to several factors, 
including lifestyle, correlation between animal models and human and the 
differences in metabolism among individuals.  
The positive association of tea consumption and increased risk of PC that I 
observed was consistent with one recent study (Sharpe and Siemiatycki, 2002) 
and differed from previous studies which showed either no association (Ellison, 
2000;La et al., 1992) or a protective effect against PC (Jain et al., 
1998;Severson et al., 1989). Data on type of tea, socio-economic circumstances 
and lifestyle factors were limited in these studies. Inconsistent results between 
these studies which were conducted in different countries might be due to 
confounding effects of socio-economic and lifestyle factors associated with the 
tea drinkers. Furthermore, either these studies were retrospective in design 
(Ellison, 2000;Jain et al., 1998) or they had short follow-ups and small number 
of cases with PC (Heilbrun et al., 1986;Kinlen et al., 1988).  
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Several biological mechanisms have been proposed which may explain the 
inverse association between high coffee consumption and aggressive PC. Coffee 
consumption can lower the insulin-like growth factor-1 (IGF-1) (Key, 2011) which 
is associated with increased incidence of PC particularly high grade and advance 
stage disease (Mucci et al., 2001;Roddam et al., 2008). Additionally, coffee is 
considered as a major source of antioxidants and many observational studies 
suggested that coffee consumption lower the inflammation (Cardenas et al., 
2011;Kempf et al., 2010). There is growing evidence which suggests that 
inflammation play a vital role in the development of PC through the generation 
of proliferative inflammatory lesions (Maitland and Collins, 2008). Therefore, 
higher consumption of coffee may have a protective role in aggressive PC by 
reducing the inflammatory activity in tumour.  
4.5.1.1 True or artefactual effects 
This positive association of tea with the risk of PC was consistent with increased 
number of cups per day. Heavy tea drinkers were more likely to have a normal 
BMI, be non-drinkers and have desirable cholesterol levels. These associations 
raise the question of whether characteristics that promote longevity are truly 
causally associated with an increased risk of PC or whether they reduce deaths 
from competing risks and thereby increase risk time for the development of PC.  
It might also be hypothesised that reverse causality might explain the protective 
effect of tea or coffee on PC reported elsewhere. That is, men with undiagnosed 
PC may reduce their fluid intake, including tea and coffee, to reduce symptoms 
of polyuria. Thus, PC would be less frequent among men who drank more tea or 
coffee. However, PC often produces no urinary symptoms because most of the 
tumours arise in the peripheral zone of the prostate gland (Simmons et al., 
2011). In addition, I conducted analyses to assess possible reverse causation by 
excluding individuals who were diagnosed in the first 10 years of screening, but 
it did not significantly alter the positive (harmful) association between tea and 
PC risk and inverse association between coffee and PC. 
Another important consideration for epidemiological studies is, in cultures where 
coffee, tea, alcohol intake constitute a major proportion of daily fluid intake the 
mutual confounding effect of total fluid intake and tea/coffee consumption 
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might have significant impact on any observed effect. Further evidence from 
large prospective studies with careful investigation of effect modification and 
confounding might provide piece of evidence which would be of interest for 
biological studies.  
An important consideration is the types of tea and coffee consumed among the 
participants of different studies. For example, green tea has been shown strong 
preventive effect compared to black tea both in animal and epidemiological 
studies (Henning et al., 2011). Participants of the Collaborative cohort study 
probably drank black tea almost exclusively as it has been commonly used in the 
English speaking countries and the UK had the highest tea consumption in that 
era when the participants were screened for this study (Bokuchava and 
Skobeleva, 1980;Stocks, 1970). The brand of tea and coffee may influence its 
carcinogenicity, as the composition of these products is highly dependent on 
their processing, large variations in the flavanol and catechin and contents and 
their antioxidant capacity having been observed in different studies (Graf et al., 
2005;Henning et al., 2003). The inconsistency between epidemiological studies 
might be explained by the differences of chemical contents of different tea and 
coffee brands. 
During the 1970s, coffee was more frequently consumed by middle class 
individuals, whereas tea was consumed more by the working class population, its 
consumption being particularly associated with breaks during the day and with 
evening meals. I observed a strong pattern between tea intake and social class 
(table 4-1), however, I did not observe any association between social class and 
PC risk. I also used years of full time education as a measure of socio-economic 
status; this also did not alter the association of tea intake and PC risk.  
4.5.2 Strengths and weaknesses 
These findings are based on one of the largest prospective cohorts in the UK, 
with long follow-up, lower losses to follow-up, adjustment for other lifestyle 
habits and information on Gleason grades of the diagnosed cases. This study has 
several limitations. First, the Midspan questionnaire did not have information on 
family history of PC and other dietary intake history including lycopene, 
multivitamins, processed meat and calcium which have been linked with the risk 
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of PC in many studies (Key et al., 2007;Park et al., 2007;Rodriguez et al., 2006). 
Second, data on tea and coffee intake was self reported at the time of screening 
which may suffer from information bias. Third, although reverse causation did 
not appear to explain the results, it cannot be ruled out as a possible source of 
bias. Finally, any misclassification in tea and coffee intake due to differences in 
cup size or type of tea and coffee might bias these results. However, such 
misclassification would be expected to bias these results toward the null rather 
than the positive association (tea & PC) which was observed in this analysis.  
4.5.3 Implications of this research 
There has been much interest in the preventive effects of tea on PC risk. I found 
a harmful effect of tea on PC risk and some preventive effect of coffee on high 
grade disease. This questions the preventive effect of tea observed in previous 
studies and further supports current recommendations that tea should not be 
considered a preventive factor for PC. The association between tea and coffee 
intake and PC should be investigated in prospective epidemiological studies in 
relation to different compositions of tea and coffee. 
In conclusion, men who consumed high amounts of tea experienced the highest 
risk of PC, however no association was observed for high or low grade disease. I 
also observed a significant association between coffee and risk of high grade PC 
but not with overall risk. Our findings are important, given the poorly 
understood natural history and lack of known modifiable risk factors of PC.
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5 Widening deprivation gap in survival of prostate 
cancer patients: impact of age and Gleason 
grade at diagnosis 
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5.1 Chapter summary 
In the UK (UK), survival of PC patients has improved in the last two decades, 
however, socio-economic inequalities in survival have also been reported from 
regional studies. This may be attributed to differential detection of localised 
disease between groups, differential existence of comorbidities between groups 
and disparities in treatments between groups. A deprivation gap in survival 
(better survival for least deprived compared with the most deprived) has been 
reported previously in studies carried out in England, Wales and Scotland. The 
present analysis was carried out to describe and compare the trends in relative 
survival between different socio-economic groups of PC patients from 1991-2007 
using the most up to date data available in this region. Furthermore the aim of 
present analysis was to investigate the impact of age at diagnosis and Gleason 
grade on deprivation gap of survival.  
Incident cases of PC (ICD-10 C61) from the West of Scotland were extracted from 
the Scottish Cancer Registry from 1991 to 2007. Socio-economic circumstances 
were measured using the Scottish Index for Multiple Deprivation (2004). Age and 
deprivation specific mortality rates were obtained from General Registrar Office 
for Scotland (GRO(S)). One, three and five year relative survival was estimated 
by using the complete approach. The survival gradient across the five 
deprivation categories based on the SIMD score were estimated with linear 
regression, weighted by the variance of the relative survival estimate, using 
STATA software (StataCorp, version 11) 
The rate of five year-survival increased from 58.2 to 78.6% in men between 1991 
and 2007 (an average deprivation adjusted increase of 10.2% between six years 
periods). Despite substantial improvements in survival of PC patients, there was 
a deprivation gap between the three periods of diagnoses. The deprivation gap 
in five year relative survival widened from -4.76 in 1991-1996 to -10.08 in 2003-
2007. On age and grade specific analyses, a significant deprivation gap in five 
year survival existed between all age groups except among patients’ age ≥ 75 
and both low and high grade disease. On multivariate analyses, deprivation was 
significantly associated with increased excess risk of death independent of age, 
Gleason grade and period of diagnosis.  
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5.2 Introduction 
This chapter will describe the trends in survival of PC patients in the West of 
Scotland from 1991 to 2007. It will discuss the existence of, and widening gap in, 
survival among different socio-economic groups of population and the impact of 
age and Gleason grade at diagnosis on socio-economic inequalities in survival.  
Population-based survival rates are influenced by the quality and effectiveness 
of health care systems. Generally, survival of PC patients has improved in the 
last two decades worldwide, particularly in western countries. However, these 
improvements are not consistent among countries, races and socio-economic 
groups. A deprivation gap of -6.9% was observed among PC patients diagnosed 
during 1996-2000 in Scotland (Shack et al., 2007). These differences in survival 
may have been influenced by differences in health education programs, 
availability and quality of services for early detection and treatment of cancer 
and then post-treatment care and support. In an earlier chapter 2 (page 98), 
analyses showed that a deprivation gap appeared in the incidence of low grade 
disease which might be due to higher uptake of PSA testing among this group. In 
this scenario, it could be expected that the pre-exiting gap in survival will 
further widen in Scotland due to higher detection of low grade disease among 
affluent men.  
Therefore the objective of this analysis was to describe and compare the trends 
in relative survival between different socio-economic groups of PC patients from 
1991-2007. A further aim was to investigate the impact of age and Gleason grade 
at diagnosis on deprivation gap of survival. In addition, a modelling analysis was 
also carried out to examine the major determinants associated with survival of 
PC patients in the West of Scotland.  
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5.3 Material and methods 
5.3.1 Incidence data 
I examined the data of adults (aged 15-100 years) diagnosed with a first, primary 
malignant neoplasm of prostate (excluding non-melanoma skin cancer) during 
1991-2007 in the West of Scotland, using the International Classification of 
Diseases (ICD) codes, ICD 9 code 185 and ICD 10 code C61 for PC. I used the 
incidence data through 31st December 2007 and follow-up data till 31st 
December 2008, as this was the most recent year of complete data available at 
the time of this analysis. The cancer registry receives the notification of cancer 
diagnosis from different sources, described in chapter 1 (page 30). Incidence 
data were linked to death records provided by the General Registrar Office for 
Scotland (GRO(S)). The vital status of all patients was considered to be known up 
to 31st December 2008. Patients identified from death certificate records only 
were excluded (n=225, 0.01% of all registered records) from this analysis. This is 
because they had zero survival due to the same incidence and death dates. 
Thirty patients belonging to areas other than the West of Scotland and one 
patient older than 100 years were also excluded from this analysis.  
Socio-economic status of individuals was assigned by matching their postcode of 
residence at diagnosis using the Scottish Index of Multiple deprivation (SIMD) 
2004 score. In the incidence chapter (page 79) of this thesis, Carstairs score was 
used as a measure of socio-economic circumstances; the particular reason for 
using the SIMD in this analysis was that the age, sex, year and deprivation 
specific population mortality rates were only available based on SIMD groupings. 
So SIMD as was used as measure of socio-economic circumstances for the 
estimation of relative survival as the background mortality is vital in such 
estimations.  
5.3.2 Statistical analysis 
For survival analysis, complete life tables of single year of age (up to 100 years) 
and deprivation category were derived from the number of deaths in each 
deprivation category in Scotland from 1991-2008. These life tables were derived 
from number of deaths for years 1991 to 2008. Corresponding population 
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denominators were drawn from the 1991 and 2001 census population from 
General Registrar office for Scotland. I used the mortality rates of 2007 for the 
year 2008, assuming that there would not be significant differences in rates 
between two years.  
Age at diagnosis was categorised in three groups as ≤65, 65-74 and ≥75 years. To 
explore the time trends in survival, year of diagnosis was categorised into three 
categories as 1991-1996, 1997-2002 and 2003-2007. The rationale behind using 
these categories of year of diagnosis was that Scottish Cancer Registry started 
the recording of Gleason-grade from 1st January 1997. Therefore, by making 
these categories, grade specific analysis was carried out in two later periods. 
Gleason grade was categorised as low (Gleason 2-6), intermediate (Gleason = 7) 
and high grades (Gleason 8-10). 
Cumulative survival following the diagnosis was estimated using the Kaplan-
Meier method and the logrank used to test the independence between groups. 
Cumulative survival was calculated for five years and groupings of variable were 
done by using the above mentioned thresholds. For cancer specific survival, I 
estimated one, three and five year relative survival rates for PC patients 
diagnosed in the West of Scotland by age, deprivation category, Gleason grade 
and calendar period of diagnosis. Relative survival is the ratio of the observed 
(absolute) survival of PC patients and the survival that would have been 
expected if the patient had had the same age and deprivation specific mortality 
in each period (background population mortality); a technique which has been 
used earlier in the estimation of deprivation gap in Scotland (Shack et al., 2007). 
Survival probabilities for cancer patients were estimated at 6 month intervals 
from diagnosis to 5 years. Cumulative relative survival up to 5 years after 
diagnosis was estimated for patients diagnosed in calendar periods 1991-1996, 
1997-2002 and 2003-2007.  
Both cohort and complete approaches were used to estimate the observed 
survival. There is a main difference between two techniques in estimation of 
observed survival. In estimation of five year survival using cohort approach, all 
patients must have a potential follow-up of at least five years. Using complete 
approach, to estimate five year survival some patients must have been 
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diagnosed five years before and the recently diagnosed patients (follow-up less 
than 5 years) can be included in the analysis, even though they cannot be 
followed for five years. Both techniques provided similar results so the results of 
complete approach are presented in this chapter.  
Survival gradients across the five deprivation categories based on SIMD score 
were estimated with linear regression, weighted by the variance of the relative 
survival estimate (Coleman et al., 2004) using STATA software (StataCorp, 
version 11). The difference between the relative survival rates fitted by the 
linear regression model for the least deprived and the most deprived categories 
is presented as “deprivation gap” in survival. The deprivation gap is reported as 
negative (-) if the most deprived group has lower survival than the least 
deprived. Average changes in the deprivation gap between the three periods 
have also been reported, taking into account the shorter duration of the final 
period (1 year shorter than the two earlier periods).  
To investigate the impact of age at incidence and Gleason grade of tumour on 
deprivation gap, the deprivation gap was estimated stratifying by age and 
Gleason grade categories. The deprivation gap was estimated by least-squares 
linear regression, weighted by the variance of each of the relative survival 
estimate stratified by age and Gleason grade. The significance was evaluated 
with a likelihood ratio test at the 5% level.  
To investigate the major determinants associated with mortality, a full 
likelihood approach was used to model the excess mortality (Esteve et al., 
1990). This method estimates the excess risk of mortality associated with PC as 
mortality of PC patients is compared with a matched cohort using the 
background population mortality. Age at diagnosis, Gleason grade, deprivation 
and period of diagnosis were used as independent variables in modelling excess 
risk of death. 
As in all statistical methods, there are certain assumptions associated with 
relative survival analysis and modelling excess risk of death. The key assumption 
associated with this analysis is the “proportional hazards”, i.e. the hazard for 
any two patient subgroups, are proportional over the follow-up time. Scaled 
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Schoenfeld residuals were plotted and proportional hazards were tested for each 
covariate included in the model. The principle is to test whether a regression 
line through residuals differs significantly from y=0 over time (Schoenfeld D, 
1982). In other words, these residuals are used to test the null hypothesis that 
the log hazard-ratio function is constant over time, that is, the ratio of hazard 
between different groups (for example, between patients aged <65 and 65 and 
over) is constant over time. No violation of this assumption was noted. 
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5.4 Results 
A total of 15,519 men were identified who were registered with a diagnosis of PC 
in the West of Scotland from 1991-2007. Men who had zero survival (n=226) and 
were older than 100 years at the date of diagnosis (n=1) were excluded from this 
analysis. A total of 15,292 patients diagnosed in the West of Scotland were 
included in the final analysis. The proportion of men aged 65 and younger at 
diagnosis increased over the study period, from 15.4% between the years 1991-
1996 to 23.6% between the years 2003-2007 (X2, p < 0.001). Mean age at 
incidence decreased during the same periods from 73.2 ± 8.74 to 71.1± 9.08. The 
highest proportion of cases were observed in older age groups, 39.4% of cases 
(n=6,023) occurred in 65-75 years of age and 41.1% of cases (n=6,285) in men 
older than 75 years. Overall, 17.2% of patients were in the least deprived group 
while 27.5% in most deprived group. The study period (1991-2007) was 
categorised into three groups from 1991-1996, 1997-2002 and 2003 to 2007 
(table5-1). Baseline characteristics of study population are described in table 5-
1. 
Regarding disease grade, more than half of the men (57.6%) had either low grade 
(Gleason ≤ 7) or intermediate grade disease (Gleason = 7). Proportions of low 
grade disease significantly increased during the study period while the 
proportion of unknown grade patients significantly reduced from 16.7 in 1997-
2002 to 7.7% in 2003-2007 (X2, p < 0.01). 
 
148 
Chapter 5 
 
 
Table 5-1: Baseline characteristics of prostate cancer patients registered in the 
West of Scotland from 1991-2007 
  Total patients   All deaths  
    n % n % 
Total registered cases 15,549 _ 9,355 60.2 
Patients not residing in the West of Scotland 30 _ 19 63.3 
Zero survival or death certificate only (DCO) 226 _ _ _ 
Age more than 100 years at diagnosis 1 _ 1 100.0 
Patients included in final analysis 15,292  9,109 59.7 
Age at incidence (years)     
 Age < 65 2,984 19.5 1,086 11.9 
 Age 65-74 6,023 39.4 3,232 35.5 
 Age ≥ 75 6,285 41.1 4,791 52.6 
Gleason Grade     
 Gleason < 7 4,065 37.2 1,421 27.1 
 Gleason = 7 2,231 20.4 756 14.4 
 Gleason 8-10 3,311 30.3 2,051 39.0 
 Unknown Gleason 1,316 12.1 1,026 19.5 
SIMD 2004, Quintiles     
 1 (least deprived) 2,623 17.2 1,295 14.2 
 2 2,278 14.9 1,219 13.4 
 3 2,450 16.0 1,444 15.9 
 4 3,737 24.4 2,365 26.0 
 5 (most deprived) 4,202 27.5 2,786 30.6 
Period of Diagnosis     
 1991-1996 4,369 28.6 3,855 42.3 
 1997-2002 5,474 35.8 3,580 39.3 
 2003-2007 5,449 35.6 1,674 18.4 
         
         
Period of diagnosis was based on incidence date recorded in cancer registry.  
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5.4.1 Cumulative survival 
A total of 9,109 (59.6%) patients diagnosed with PC died during the 
study period. Overall, cumulative survival at one year and five year 
after diagnosis were 82.9% and 48.4%, respectively. In general, there 
was a trend towards improved survival in most recent periods, with a 
cumulative five year survival of 38.3% in 1991-1996 and 56.8% in the 
most recent period of 2003-2007. Figure 5-1 shows a significant 
difference in five year survival between three periods of diagnosis 
(logrank p = <0.001).  
Figure 5-1: Cumulative five year survival between different periods of diagnosis 
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Similarly, significant differences in survival were also observed 
between different age groups. Five year survival was significantly 
better (longrank p = <0.001) for younger age group men (<65 years) 
compared with older age group (≥75 years). 
Figure 5-2: Cumulative five year survival between different age groups 
 
Significant disparities in survival were also observed between 
socioeoconomic groups, with better survival for the least deprived and 
poorer for the most deprived group. Cumulative five year survival was 
56.1% and 42.7% for least deprived and msot deprived groups (logrank 
p = <0.001), respectively (figure 5-3). Furthermore, significant 
differences in survival were also seen between Gleason categories 
(figure 5-4). Men in the low Gleason grade category had 41.0% higher 
five year survival compared with the high Gleason grade group (70.8% 
vs 29.8%, logrank p = <0.001) while men with unknown Gleaon had 
even poorer survival compared with the high Gleason grade group 
(figure 5-4).  
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Figure 5-3: Cumulative five year survival of prostate cancer patients between 
different socio-economic groups 
 
Figure 5-4: Grade specific five year cumulative survival of prostate cancer 
patients 
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5.4.2 Relative survival analysis 
Relative survival was calculated stratified by age, disease grade, 
socio-economic circumstances and period of diagnosis using complete 
approach. Five year relative survival was better for men younger than 
65 years (77.4%), having low Gleason grade (92.8%) and those from 
least deprived areas (73.2%). Men in the oldest age group (age ≥ 75) 
had poorer five year survival compared with younger age groups 
(figure 5-5). Grade-specific analysis showed that both low Gleason 
grade (Gleason < 7) and intermediate Gleason grade categories 
(Gleason = 7) had better five year survival than high Gleason grade 
category with an average difference of 40.0% better five year relative 
survival in low grade category (figure 5-6).  
Figure 5-5:  Five year relative survival by age groups (age at diagnosis)  
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Figure 5-6:  Five year relative survival by Gleason grade categories.  
 
Further analysis to explore whether the difference in survival 
between deprivation groups (figure 5-7) could be because of 
differential distribution of high grade disease was carried out. 
Differences in relative survival of deprivation groups (higher survival 
for least deprived and lower for most deprived) for both in low as 
well as high grade disease (figure 5-8) were observed.  
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Figure 5-7:  Five year relative survival by socio-economic groups 
 
 
Figure 5-8:  Five year relative survival of high Gleason grade disease between 
socio-economic groups
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Both short and long term survival of PC patients have improved since 
1991 (table 5-2). Relative survival at 1 year increased significantly 
from 83.2% in 1991-1996 to 92.1% in 2003-2007 (fitted, deprivation 
adjusted increase of 4.5% between periods). Five year survival 
increased from 58.2% to 78.6% in men over the same period, an 
average deprivation adjusted increase of 10.2% between six years 
periods. Five year survival increased in both period, with a larger 
increase in the first periods from 1991-1996 to 1997-2002 (11.8%) 
while relatively smaller increase (7.6%) in survival was seen in later 
period (Table 5-2).  
Figure 5-9: Five year relative survival between different periods of diagnosis in 
the West of Scotland.  
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Table 5-2: Trends in survival (%) of prostate cancer patients by period of diagnosis in the West of Scotland: 1991 to 2007 
  Calendar period of diagnosis   Average change (%)   
Time since 
diagnosis 
 1991-1996  1997-2002  2003-2007  between periods 
a
  
  Survival, % (95% CI)   Survival, % (95% CI)   Survival, % (95% CI)    (95% CI)   
1 year  83.2 (81.7, 84.5)  90.9 (89.9, 91.9)  92.1 (91.2, 93.0)   4.5 (-19.4,28.3)  
3 years  67.4 (65.5, 69.2)  78.1 (76.5, 79.6)  83.1 (81.6, 84.6)  7.8 (-13.1, 28.8)  
5 years  58.2 (56.0, 60.3)  71.0 (69.1, 72.8)  78.6 (76.4, 80.8)  10.2 (-8.9, 29.3)  
                            
a= Mean absolute change in relative survival between periods adjusted for deprivation  
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5.4.3 Deprivation gap in overall relative survival 
Despite substantial improvements in survival of PC patients, there 
was a deprivation gap in each of the three periods of diagnoses 
(figure 5-10). Large improvements in survival were seen in the time 
from earlier to middle periods in all socio-economic groups. The 
deprivation gap was smaller in 1991-1996 and widened during later 
periods, due to large improvements in survival among the least 
deprived group. One year survival for men in the most deprived 
group, diagnosed during 1991-1996 was 4.7% lower than men in the 
least deprived group (deprivation gap -4.68, 95% CI -7.17, 2.19, - sign 
suggests lower survival among most deprived men compared with the 
least deprived). This deprivation gap slightly shrunk during the study 
period (table 5-3). A similar pattern of deprivation gap was observed 
in 3 year survival between the study periods. The deprivation gap 
widened in five year survival from -4.76 in 1991-1996 to -9.08 in 1996-
2002, with a relatively small change in most recent period (table 5-3).  
Figure 5-10: Deprivation gap in 5-year relative survival from 1991-2007 in the 
West of Scotland.  
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Table 5-3: Trends in the deprivation gap in relative survival of prostate cancer patients by time since diagnosis and calendar period in the West of 
Scotland during 1991-2007 
 Calendar period of diagnosis 
a
        Average change (%)   
Time since diagnosis 
1991-1996  1997-2002  2003-2007  between periods 
b
  
Deprivation 
gap (%) (95% CI)   
Deprivation 
gap (%) (95% CI)   
Deprivation 
gap (%) (95% CI)   
Deprivation 
gap (%) (95% CI)   
                 
1 year -4.68 (-7.17, -2.19)  -4.52 (-6.02,-3.02)  -3.96 (-5.7, -2.18)  0.19 (-0.30,0.41)  
3 years -6.72 (-13.21, -0.23)  -8.08 (-12.65, -3.50)  -7.56 (-10.05, -5.07)  -0.42 (-7.31, 6.47)  
5 years -4.76 (-10.55, 1.03)  -9.08 (-12.37, -5.78)  -10.08 (-13.05, -7.11)  -2.65 (-14.83, 23.65)  
                          
 a = Relative Survival estimated by complete approach, b= Mean absolute change in survival in between periods adjusted for deprivation.  
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5.4.4 Impact of age at incidence and Gleason grade on 
deprivation gap 
Further analysis was carried out to investigate the impact of age and 
Gleason grade at diagnosis on the deprivation gap in survival. The 
deprivation gap persisted between age groups in all three periods of 
diagnosis, except for age group ≥75 years. In this age group, there 
was only a significant deprivation gap (-7.4%) in the most recent 
period of 2003-2007 (table 5-4). 
Grade specific analysis showed a significant gap of -7% in five year 
survival between the most deprived and least deprived (higher 
survival among least deprived) existed for low grade disease between 
both study periods, while no significant difference in survival was 
observed for intermediate grade disease (Gleason = 7). A deprivation 
gap of approximately -10% remained stable for high grade disease 
between the two study periods (table 5-4), while the deprivation gap 
of unknown Gleason grade patients, widened from -1.8% for those 
diagnosed during 1997-2002 to -8.8% for those diagnosed during 2003-
2007 (table 5-4).  
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Table 5-4: Deprivation gap in 5-year relative survival of prostate cancer patients by age, Gleason grade and calendar period in the West of 
Scotland during 1991-2007 
 
 Calendar period of diagnosis 
a
 
Characteristics 
1991-1996  1997-2002  2003-2007 
Deprivation gap (%) (95% CI)   Deprivation gap (%) (95% CI)   Deprivation gap (%) (95% CI) 
            
Age < 65 -13.6 (-23.24, -3.95)  -13.32 (-16.23,-10.41)  -7.72 (-24.49, 9.05) 
Age 65-74 -5.36 (-16.28, 5.56)  -11.48 (-13.20, 9.76)  -9.92 (-12.11, -7.73) 
Age ≥ 75 2.00 (-1.65, 5.66)  -1.44 (-12.22, 9.34)  -7.36 (-12.32, -2.40) 
                  
         
Gleason < 7 _ _  -6.64 (-11.82,-1.46)  -6.88 (-12.95, -0.80) 
Gleason = 7 _ _  -0.4 (-7.16, 6.36)  3.92 (-6.47, 14.31) 
Gleason 8-10 _ _  -10.12 (-16.63, -3.61)  -8.76 (-20.37,2.85) 
Unknown Gleason _ _  -1.8 (-14.75,11.14)  -8.76 (-13.72,-3.80) 
                  
 a = Relative Survival estimated by complete approach     
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5.4.5 Determinants of survival 
On both univariate and multivariate analyses, patient demographics 
(including age at incidence and socio-economic circumstances), 
Gleason grade and period of diagnosis were significantly associated 
with excess risk of death due to cancer (table 5-5). Being age 75 years 
or older conferred more than double the risk of death in 5 years (p < 
0.001) adjusting for Gleason grade, period of diagnosis and 
deprivation. The middle age group (age 65-74 years) also showed 
significantly higher risk of death at five year compared with youngest 
age group. Increase in Gleason grade showed a dose-response effect 
on excess risk of death after adjustments for age and socio-economic 
circumstances. Gleason > 7 and unknown Gleason had four and five 
times higher risk of death (p < 0.001) in five years, respectively, after 
adjusting for age, socio-economic circumstances and period of 
diagnosis (table 5-5).  
5.4.6 Period of diagnosis and deprivation 
As survival has improved over time, the period of diagnosis was 
significantly associated with better survival (lower risk of death). 
Individuals diagnosed during 2001-2007 had 14% lower risk of death 
compared to those diagnosed in 1991-2000 after adjusting for age, 
Gleason grade, deprivation and background survival improvements in 
the general population. Socio-economic circumstances were 
independently associated with excess risk of death due to cancer. 
Excess risk of death gradually increased with increasing deprivation. 
Patients from the most deprived group had a 48% higher risk of death 
(RER 1.48, 95% CI 1.31-1.68) compared to those in the least deprived 
group (table 5-5). 
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Table 5-5: Five-year relative survival of prostate cancer patients modelled using the full likelihood approach 
      Univariate analysis   Multivariate analysis 
      Relative Excess Risk (95% CI) p value   Relative Excess Risk (95% CI) p value 
Age at incidence           
 Age ≤ 65  1   1  
 Age 65-74  1.43 (1.26, 1.62) <0.001  1.31 (1.15, 1.48) <0.001 
 Age ≥ 75  2.88 (2.56, 3.24) <0.001  2.31 (2.06, 2.60) <0.001 
Gleason Grade           
 Gleason < 7  1   1  
 Gleason = 7  1.34 (1.12, 1.61) 0.001  1.26 (1.06, 1.49) 0.007 
 Gleason 8-10  5.22 (4.57, 5.95) <0.001  4.33 (3.83, 4.89) <0.001 
 Unknown Gleason  6.68 (5.78, 7.71) <0.001  5.27 (4.61, 6.03) <0.001 
SIMD 2004, Quintiles           
 1 (least deprived)  1   1  
 2  1.05 (0.90, 1.24) 0.35  1.11 (0.96, 1.29) 0.16 
 3  1.33 (1.14, 1.55) <0.001  1.29 (1.13, 1.49) <0.001 
 4  1.47 (1.28, 1.69) <0.001  1.36 (1.19, 1.54) <0.001 
 5 (most deprived)  1.71 (1.50, 1.96) <0.001  1.48 (1.31, 1.68) <0.001 
Period of diagnosis           
 1991-2000  1   1  
 2001-2007  0.69 (0.64, 0.76) <0.001  0.86 (0.79, 0.93) <0.001 
                        
Multivariate model included all co-variates presented in the table.
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5.4.7 Impact of period of diagnosis and deprivation on 
grade specific survival 
Deprivation was associated with increased risk of death, independent 
of age at incidence and period of diagnosis for both low grade and 
high grade disease groups. This was not true for the intermediate 
grade (Gleason = 7). Risk of death reduced for all grades during the 
later period (2003-2007), with 81% reduction in low grade disease 
group, 61% among intermediate group and 22% risk reduction in high 
grade disease group (table 5-6). The risk of death increased among 
those with unknown grade in the later period compared to the earlier 
one.  
As the biggest reduction in risk was observed in low grade disease 
during the study period, the biggest deprivation effect was observed 
in the same disease group. A risk reduction of 81% in excess risk of 
death was seen among low grade category in 2003-2007 compared 
with 1997-2002. This may be because due to change in biological 
spectrum of disease over time. Socio-economic gradient persisted 
even in this disease group and men from the most deprived group 
with low grade disease group had more than doubled the risk of death 
compared with the least deprived group in first five years of diagnosis 
(table 5-6). 
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Table 5-6: Grade specific 5-year relative survival of prostate cancer patients modelled using the full likelihood approach 
     Gleason < 7   Gleason = 7   Gleason 8-10   Unknown Gleason 
      Relative Excess Risk 
(95% CI) 
p value   Relative Excess Risk 
(95% CI) 
p value   Relative Excess Risk 
(95% CI)  
p value   Relative Excess Risk 
(95% CI)  
p value 
                    
SIMD 2004, Quintiles                     
 1 (least deprived)   1     1     1     1   
 2  1.20 (0.41, 3.52) 0.742  0.94 (0.44, 1.99) 0.871  1.05 (0.81, 1.36) 0.702  1.25 (0.90, 1.73) 0.192 
 3  1.69 (0.62, 4.64) 0.309  1.01 (0.48, 2.12) 0.981  1.42 (1.13, 1.79) 0.003  1.02 (0.73, 1.46) 0.875 
 4  1.61 (0.61, 4.26) 0.005  1.36 (0.73, 2.55) 0.331  1.48 (1.19, 1.84) <0.001  1.06 (0.78, 1.43) 0.722 
 5 (most deprived)  2.61 (1.09, 6.26) 0.031  0.84 (0.39, 1.82) 0.657  1.36 (1.10, 1.69) 0.005  1.47 (1.13, 1.92) 0.004 
Period of diagnosis                     
 1997-2002   1     1     1     1   
 2003-2007  0.19 (0.05, 0.74) 0.017  0.39 (0.27, 0.68) <0.001  0.78 (0.68, 0.90) <0.001  1.87 (1.55, 2.40) <0.001 
                                            
      All estimates were adjusted for age at incidence            
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5.5 Discussion 
5.5.1 Main findings 
Present analysis suggests that survival of patients with PC has significantly 
improved in the West of Scotland during the study period. Despite this, socio-
economic inequalities in survival of PC patients existed and widened in most 
recent periods. Furthermore, largest improvements have been observed in low 
grade disease (Gleason < 7) but socio-economic inequalities in survival persisted 
even if men are diagnosed at a relatively younger and with low grade disease. 
Socio-economic circumstances of individuals appeared as a significant 
determinant in the survival of PC patients independent of their age at diagnosis, 
Gleason grade and calendar period of diagnosis. 
5.5.2 Data quality 
Scotland Cancer Registry data for the West of Scotland was used for this analysis 
providing a fairly large sample with long follow-up of patients to carry out this 
analysis. Different techniques were used to estimate the relative survival, i.e. 
cohort and complete approach, both produced identical results. Those who were 
diagnosed with PC from death certificate only or with zero survival time were 
excluded from this analysis - this comprised a small proportion though (n=226, 
0.01%). Exclusion of these cases from the analysis does not explain the existing 
and widening deprivation gap in relative survival for multiple reasons. First, 
there was no significant difference in distribution of these cases between socio-
economic groups. Secondly, the proportion of patients excluded from the 
analysis is very small to have any significant impact on the estimates provided in 
this analysis. 
5.5.3 Temporal trends in survival 
Present analyses suggest that the recent trends in survival of PC patients are 
encouraging. Improvements have been observed in both short term (1-year) and 
long term survival (5-year) in the West of Scotland. One year survival improved 
by approximately 4.5% every six years between 1991-1996 and 2003-2007, while 
five year survival increased by 10% during the same period. Overall, 
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improvement in survival seems consistent with reports from England and Wales 
(Rowan et al., 2008). Survival of patients with PC has improved during 
corresponding periods in many European countries. Denmark for example, 
observed approximately 7% improvement in five year survival between 1985-2004 
(Lund et al., 2007). Another recent report from Denmark also suggested similar 
findings (Borre et al., 2011). In the Netherlands, survival improved by 
approximately 1.8% annually from 1989 to 2006 (Cremers et al., 2010).  
The pattern and trends in PC survival in the West of Scotland are not artefacts - 
there seems a genuine increase of both incidence and survival. There are many 
contributing factors (including patients’ demographics and disease 
characteristics) which can explain these trends. Men in younger age group and 
those from relatively least deprived groups experienced better survival 
compared with older and most deprived groups, respectively. These factors are 
discussed in detail in a following section of this chapter.  
Disease related factors are affected by PSA testing, which can partly explain 
both the increase in incidence and survival. The introduction of PSA testing has 
led to stage and grade migration of PC (Moore et al., 2009). This has resulted in 
a rapid shift in the biological spectrum of the disease and at a population level 
PC is no longer a fatal and incurable disease now as it was in 1980s. Nowadays, a 
higher proportion of individuals are diagnosed with localized, small volume and 
low grade prostate tumours, which are registered and treated aggressively and, 
ultimately, lead to better survival of patients.  
There are some potential problems associated with PSA testing and its impact on 
survival of patients. PSA testing increases the average survival time by 
diagnosing some tumours years before the tumour would have been detectable 
by clinical examination or symptoms. This may result in a lead time bias, 
meaning that men who are identified by PSA testing appear to survive longer 
than men who are identified by other methods. In this case, PSA detected 
individuals show to have longer survival when in reality there would be no real 
difference in time to death between PSA tested or untested men (van Leeuwen 
et al., 2010). The other problem with PSA testing and survival is the length time 
bias. PSA testing is more likely to diagnose slower growing tumours which may 
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remain asymptomatic for longer time prior to their development as symptomatic 
disease compared to fast growing or aggressive tumours. Thus, the men 
diagnosed with PSA testing tend to live longer because they had slow growing 
tumours. These issues associated with PSA testing must be considered while 
interpreting the survival trends (van Leeuwen et al., 2010). Early detection is 
not only associated with PSA testing, evidence suggests that increasing incidence 
trends in Northern Ireland and Republic of Ireland are also due to increasing 
rates of prostatic biopsy and not only because of the PSA (Carsin et al., 2010). 
That study also argued that a reduction in mortality in both countries was not 
fully explained by PSA testing and mortality rates started falling even before the 
expected beneficial effects of widespread PSA testing (Carsin et al., 2010). 
In recent years, greater awareness among public health professionals is another 
factor that might have contributed to better management of patients. For 
instance, greater awareness of PC and its symptoms might have increased 
demands of PSA testing by older men or family members leading to higher 
detection (Drummond et al., 2009). This may ultimately have lead to more 
intensive monitoring of patients after diagnosis and thus could also have played 
a role in better survival and lower mortality. Besides the possible benefits 
associated with PSA testing, there is also a risk of over diagnosis and treatment 
of asymptomatic cases of PC which might have never manifested as clinically 
symptomatic disease during their life time (Moore et al., 2009).  
Treatment may have influence on survival of cancer patients following diagnosis 
but evidence on the effectiveness of treatment modalities and their role in 
improving the survival remains equivocal. Large randomised trial on men with 
early stage PC detected in PSA-era suggests some benefit of radical treatment 
over watchful-waiting (Bill-Axelson et al., 2011b) but subsequent trial in a 
different setting failed to show such benefit (Wilt et al., 2012). In the absence 
of population-based treatment data of PC patients, it is difficult to conclude 
that treatment has contributed in observed survival trends during the studied 
period. Lead time and length time biases, discussed earlier may remain the 
plausible explanations of observed survival trends in the West of Scotland. 
168 
Chapter 5 
 
 
5.5.4 Socio-economic inequalities in survival 
Despite the overall improvement in survival of PC patients, socio-economic 
inequalities in survival of PC patients widened further over the periods 1997-
2002 and 2003-2007. Estimates of one, three and five year deprivation gaps in 
survival have been presented along with the trends of these gaps over time. The 
concurrent increase in survival differences between the least deprived and most 
deprived men, taken with the more rapid increase in incidence of low grade 
disease among least deprived men, may suggests that individuals from higher 
socio-economic groups had greater access to PSA testing during these recent 
periods. The deprivation gap in survival for PC patients has been widening as 
reported earlier from Scottish National dataset (Shack et al., 2007).  
Socio-economic differences in survival have been observed in many countries 
including Australia (Hall et al., 2005), New Zealand (Haynes et al., 2008), 
England and Wales (Rowan et al., 2008) and the US (Dayal et al., 1985). In 
England and Wales, recent improvement in survival of many adult cancers 
including prostate has been more marked for least deprived groups compared 
with most deprived (Coleman et al., 2004). The NHS Cancer Plan was 
implemented in 2000 in England and Wales and one of the major aims of that 
was to tackle the inequalities in cancer survival. However, a recent study 
examined the survival differences among affluent and deprived cancer patients 
before and after the plan and reported that there is very little variation in 
deprivation gap in survival even 10 years after the implementation of the NHS 
Cancer Plan (Rachet et al., 2010).  
Deprivation specific survival cannot be directly compared to other Western 
countries or even with the constituent countries of UK because the measures of 
deprivation used in different studies are not identical and size of effect could 
vary simply because of different measures. However, the relative changes and 
differences can be evaluated. In Scotland, the deprivation gap in survival of 
many adult cancers has been larger for Scottish population as compared to 
England and Wales during a 15 year period between 1986 to 2000 (Shack et al., 
2007). Nonetheless, the overall pattern remained quite consistent, i.e. the 
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deprivation gap in survival of most cancers is widening in both countries (Shack 
et al., 2007).  
Several factors can contribute towards lower survival among more deprived men 
including older age, advanced stage and aggressive disease at presentation, 
higher prevalence of comorbidities and unhealthy lifestyle habits. PSA testing 
seems to play its role in PC; some evidence suggested that deprived population 
might have lower uptake of PSA and thus had a late diagnosis with extended 
disease. This has born out by evidence that presentation of deprived men with 
PC has not changed over the years (Mokete et al., 2006). Whether the lower 
testing rate is due to the lack of availability of the test from the General 
Practitioners or whether the men in more deprived groups do not simply come 
forward for testing is largely unknown.  
Some studies have attributed the socio-economic inequalities in survival to 
higher levels of comorbidity among the more deprived patients (Clarke, 2008). 
Along with comorbidity, there are numerous other factors that can contribute to 
socio-economic inequalities in survival. For example, risk behaviours such as 
heavy smoking or alcohol intake, which are more prevalent among the most 
deprived socio-economic group could explain some of the differences in survival 
from patients from most deprived men (Jeffreys et al., 2009;Lawder et al., 
2010).  
These views are fairly straightforward and inherently plausible as these are 
derived from the clinical experience. However, they can be challenged by some 
of the results of this analysis, keeping in view the design and statistical methods 
used here. As age and deprivation specific background population mortality rates 
were used for the estimation of relative survival in this section, differential co-
morbidity between socio-economic groups can not directly account for the 
excess risk of death associated with cancers. Presence of comorbidity can 
increase the risk of death due to non-cancer causes. The present analyses 
compensated for background population mortality difference between socio-
economic groups. Therefore, these non-cancer deaths will not affect the survival 
estimates presented in this section. Differential co-morbidity can only contribute 
to socio-economic inequalities in relative survival if there is an interaction 
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between the presence of co-morbidity and the actual treatment received for the 
cancer (Rachet et al., 2008). There is some evidence from England that non-
metastatic PC patients from low socio-economic backgrounds are less likely to 
receive aggressive surgical or radiological treatment compared with the least 
deprived population groups (Fairley et al., 2009) possibly due to the presence of 
co-morbidities.  
Generally, survival appears to be improved for both least and most deprived 
groups but it improved more rapidly for the least deprived compared with the 
most deprived or in some cases at a same rate without closing the deprivation 
gap in survival. If differential comorbidity between most deprived and least 
deprived PC patients explains the persistent or widening deprivation gap in 
survival, it would imply that the impact of comorbidity on choice of treatment 
(or outcome) had actually been increasing more among the most deprived than 
the least deprived (Rachet et al., 2008). This seems implausible, rather socio-
economic differences in the diagnosis of PC and/or treatment of this disease 
should be seen as a potential explanation of survival difference between social 
groups. 
5.5.5 Age and grade-specific patterns in survival 
Age and Gleason grade are considered to be strong predictors of prognosis of PC 
patients. Large improvements in survival were observed among those diagnosed 
with low grade disease (Gleason < 7). The risk of death significantly reduced 
among men with low grade disease in the most recent period (2003-2007) 
compared with earlier period (1997-2002). A reduction of 80% in the excess risk 
of death in the most recent period, suggests that the biological spectrum of PC 
has changed over time and in more recent years, we are treating an entirely new 
disease which is perhaps a very low risk cancer. Despite the largest improvement 
in survival in this disease group, more than double the risk of death was 
observed for the most deprived group compared with the least deprived.  
 In this dataset, least deprived were more likely to be diagnosed at a younger 
age and with lower grade. Age and Gleason grade-specific analysis did not show 
any consistent pattern or impact on deprivation gap in this analysis. A 
deprivation gap was seen in all age groups and within both low and high grade 
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disease groups. This suggests that there may be disparities among different 
socio-economic groups other than the difference in age and disease grade at 
presentation. 
Disease stage at diagnosis is also an important factor associated with the survival 
of PC patients (Jeffreys et al., 2009). For example in the US, Black men have 
poorer survival compared to Whites and one of the explanations for that is the 
relatively late presentation by Black men with advanced and metastatic disease 
at diagnosis. Delayed presentation by low socio-economic groups is also 
considered a contributory factor in socio-economic inequalities in cancer survival 
in the UK. However, the hard evidence on this for PC in the UK is still sparse. 
There is some evidence from recent studies investigating the impact of race in 
clinical presentation of PC in UK, but no significant differences were observed 
between White and Black men’s age, disease grade and stage at presentation 
(Evans et al., 2010;Jack et al., 2010). Unfortunately, disease stage information 
was not present in the Scottish Cancer Registry data, so the role of disease stage 
in the existing deprivation gap in survival could not be investigated.  
5.5.6 Implications of this research 
Present analysis highlights a significant socio-economic gap in survival of PC 
patients. Interestingly, clinical commentators mainly attribute this difference in 
survival to the co-morbidities while most epidemiologists emphasise the late 
diagnosis in deprived groups as a key determinant of poorer survival. This 
difference in survival is perhaps combination of different factors rather than the 
co-morbidity or disease stage alone, and highlights the need for further research 
to understand the main determinants of socio-economic inequalities. 
Furthermore, high quality information on staging and comorbidities need to be 
collected to understand the survival differences between socio-economic groups. 
England has already given it a high priority through the Cancer Reform Strategy. 
This is perhaps urgently needed in Scotland as well that clinical team collect the 
staging and co-morbidity information and linking the clinical audit data with 
Cancer Registry may provide further understanding about the reasons of socio-
economic differences.  
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5.5.7 Limitations of this research 
There are some limitations to this analysis which need to be mentioned. The 
SIMD was used as a proxy measure of socio-economic circumstances of PC 
patients in the present analysis. As with all the area-based measures of 
deprivation, using SIMD score assumes that all the individuals living in a given 
geographical area experience the same level of deprivation and other associated 
factors. Individual level data such as level of education, occupation and income 
can provide stronger evidence of socio-economic circumstances; however, these 
data are not routinely collected in cancer registries. Earlier studies carried out 
in different regions of the UK, despite the use of different area-based measures, 
also provided similar results which suggest that the least deprived have better 
survival compared with the most deprived, which suggests that these findings 
are not just due to the measurement index. In addition, race has been widely 
used as a measure of socio-economic circumstances in the US and provided quite 
similar results suggesting that individuals from poorer background experience 
worse survival. Another important limitation is the unavailability of information 
on the stage of the cancer and comorbidity which is well known prognostic 
factors in survival of patients.  
Despite these limitations, the present analyses indicate that overall survival has 
improved in the West of Scotland with the largest risk reduction of death in low 
grade disease in more recent period, which suggests that spectrum of disease 
has changed over time. Improvement in survival among least deprived group was 
at a greater rate than the most deprived, likely to be more important than age 
and grade at diagnosis in maintaining the deprivation gap in survival. Further 
research is needed to better understand the causal factors associated with socio-
economic disparities in survival.
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6 Systemic inflammation and survival of patients 
with prostate cancer: evidence from the 
Glasgow Inflammation Outcome Study. 
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6.1 Chapter summary 
There is some evidence that systemic inflammation may be associated with 
survival in patients with PC. However, it is unclear whether this is independent 
of grade. I therefore investigated the role of inflammation-based prognostic 
scores, the modified Glasgow Prognostic Score and Neutrophil Lymphocyte Ratio 
(NLR), and their associations with Gleason grade in patients with PC. Patients 
from a cohort, the Glasgow Inflammation Outcome Study, who had diagnosis of 
PC, were included in this study. The mGPS was constructed by combining C-
reactive protein and albumin while NLR by calculating the ratio of neutrophils to 
lymphocytes. I estimated five-year relative survival and relative excess risk of 
death by mGPS and NLR categories after adjusting for age, socio-economic 
circumstances and Gleason grade.  
Eight hundred and ninety seven PC patients were identified. Of those 422 (47%) 
died during a maximum follow-up of 6.2 years. Systemic inflammation appeared 
to have significant prognostic value. The mGPS predicted poorer 5-year overall 
and relative survival independent of age, socio-economic circumstances, disease 
grade and NLR. Raised mGPS also had a significant association with excess risk of 
death (mGPS 2: Relative Excess Risk = 2.41, 95% CI 1.37-4.23) among aggressive, 
clinically significant PC (Gleason grades 8-10). The mGPS is a strong measure of 
systemic inflammation, when compared to NLR. PC patients with a raised mGPS 
had significantly higher risk of death for overall as well high grade disease. 
Inflammation-based prognostic scores showed some prognostic value for patients 
with PC, however, further evidence is required to determine their utility in 
routine clinical practice. 
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6.2 Introduction  
The aim of this chapter was to investigate the role systemic inflammation in 
survival of patients with PC. Different markers of systemic inflammation have 
been discovered, however, in this chapter only include neutrophil lymphocyte 
ratio (NLR) and modified Glasgow prognostic scores (mGPS). I have used the 
relative survival and model that to estimate the excess risk of death with PC in 
this chapter.  
The natural history and progression of PC is poorly understood, however some 
evidence suggests an association between the activation of the systemic 
inflammatory response, as evidenced by raised C-reactive protein 
concentrations, and survival in patients with PC (McArdle et al., 2006;McArdle et 
al., 2010). However, these studies were small and it is unclear if these 
relationships remain in a large cohort, independent of Gleason grade, socio-
economic status and time of sampling. Therefore, the aim of the present 
analysis was to investigate the associations between inflammation-based 
prognostic scores (mGPS and NLR) and survival in a large cohort of patients with 
PC. 
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6.3 Materials and methods 
From a cohort previously described, cancer patients in north Glasgow, 
UK,(Proctor et al., 2010) who had a single blood sample taken between 1st 
January 2000 and 31st December 2007 for C-reactive protein, albumin, calcium 
as well as liver function tests, where available, were included in this analysis. 
The limit of detection of C-reactive protein was a concentration of less than 5 
mg l-1 (Proctor et al., 2010). If more than one record was available for a patient 
then only the initial record was used. Patients were excluded if they did not 
have a complete set of identifying details (name, sex, date of birth and hospital 
number) (Proctor et al., 2010). 
PC diagnosis was established by linkage of the above biochemistry data and the 
Scottish Cancer Registry, also known as Scottish Morbidity Record number six 
(SMR06). Linkage was by exact matching of patients’ forename, surname and 
date of birth, followed by Soundex phonetic matching algorithm if initial exact 
matching was unsuccessful. PC was defined as International Classification of 
Diseases (ICD), ICD-10 code C61. Only those patients who had a blood sample 
taken within a period of two years, before or after diagnosis of PC, were 
included in the analysis. 
Socio-economic status of individuals was assigned matching their postcode of 
residence at diagnosis using the Scottish Index of Multiple deprivation (SIMD) 
2004 score. 
The Gleason grading system is known to be associated with prostatic cancer 
prognosis (Sogani et al., 1985) and was used to describe tumour morphology. 
Gleason grade was extracted from the Scottish Cancer Registry where available. 
Date and cause of death was extracted through cancer registration patient 
based-linkage with General Register Office for Scotland (GRO(S)) death records. 
This study was approved by the Research Ethics Committee, North Glasgow NHS 
Trust. 
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The mGPS and NLR were constructed as described in previous studies 
(Aliustaoglu et al., 2010;Gomez et al., 2008;Proctor et al., 2011b) (Table 6-1).   
Table 6-1: Systemic inflammation-based prognostic scores 
Prognostic Scores 
  
Score 
    
      
The modified Glasgow Prognostic Score   
 
C-reactive protein ≤ 10 mg/l  
 
0 
  
 
C-reactive protein > 10 mg/l and albumin ≥ 35 g/l 
 
1 
  
 
C-reactive protein > 10 mg/l and albumin < 35 g/l 
 
2 
  
      
Neutrophil Lymphocyte Ratio    
 
Neutrophil count:lymphocyte count < 5:1 
 
0 
  
 
Neutrophil count:lymphocyte count ≥ 5:1 
 
1 
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Follow-up was from date of incidence of cancer to the date of death or 
censor date (31st December 2008), whichever came first. Relative survival 
was used as a measure of cancer patients’ survival. Relative survival has a 
key advantage over the cause specific survival as it does not rely on the 
accurate classification of cause of death; instead it provides a measure of 
total PC associated excess mortality. 
One and five years relative survival estimates were made by using age, 
gender and deprivation specific life tables provided by General Registrar 
Office (Scotland). These were available through 2007; so for the purposes of 
this study, the 2007 mortality rates were used for comparison as they are 
unlikely to be significantly different from those occurring in 2008. Relative 
survival estimates were made by age, deprivation, Gleason grade and mGPS, 
using the complete and hybrid approach (by STREL and STRS command in 
STATA) (Dickman PW et al., 2008). STRS command in STATA implements the 
Ederer II method by default for the estimation of relative survival; however, I 
repeated the analyses using both the Ederer I and Hakulinen approaches. All 
three methods provided identical results, so the results presented in this 
study are based on the Ederer II Method. Using the full likelihood approach 
adjusted for age, deprivation and Gleason grade, the relative excess risk 
(RER) of death from PC was estimated (Esteve et al., 1990). This approach 
provides the estimate of excess risk of death due to cancer after adjusting 
for the background population mortality.  
Patients who had missing NLR (n=188, 21%) were excluded from the excess 
risk estimation analyses. The lowest category was used as referent for the 
mGPS and all other categorical covariates. All analyses were conducted using 
STATA version 11 (StataCorp, College Station, TX, USA). Adherence to the 
proportional hazards assumption was investigated by plotting smoothed 
Schoenfeld residuals against time; no violations of the assumption were 
identified. I investigated the interactions between different variables in 
every multivariate model, but no significant interaction was found. All 
statistical tests were two tailed and statistical significance was taken as p < 
0.05. 
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6.4 Results 
From the Glasgow Inflammation Outcome Study of 223,303 patients originally 
described, 27,301 patients were identified as having a diagnosis of cancer by 
Scottish Cancer Registry and a blood sample for C-reactive protein, albumin, 
white cells, neutrophil, lymphocyte and platelet counts taken between 
January 2000 and December 2007 (Proctor et al., 2011). From this cohort, 
897 patients who had a diagnosis of PC and had been sampled within two 
years before or after diagnosis were included in this analysis. The majority, 
575 (64%), were aged 75 or over. Nineteen percent of patients lived in 
affluent areas (least deprived quintile of the Scottish population) and 34% in 
deprived areas (most deprived quintile of the Scottish population). The 
median follow-up from the cancer diagnosis was 2.5 years, and maximum 6.2 
years. 
Patients with an elevated mGPS (mGPS = 2) were more likely to be 75 years 
or older (p=0.005) and have high grade disease (Gleason 8-10) (p<0.001), but 
there was no association with socio-economic circumstances based on SIMD 
(p=0.430). Similarly, patients with an elevated NLR (NLR score 1) were more 
likely to be older (p=0.022) and have a raised mGPS (p<0.001) but there was 
no significant association with socio-economic circumstances (p=0.338) or 
Gleason grade (p=0.074). 
The individuals who had missing NLR were significantly older (2.3 years, p 
value <0.002, t = 2.95) than those whose NLR data were available, while no 
significant differences were observed in distribution of Gleason grade (X2, p = 
0.08) and socio-economic circumstances (X2, p = 0.617). Furthermore, mean 
survival time was approximately 6 months higher for those whose NLR was 
missing compared to those whose NLR was available. 
Baseline characteristics of PC patients, before and after sampling, are shown 
in table 6-2. Patients who were sampled in the post-diagnosis group, 
compared with the pre-diagnosis group, were more likely to be older 
(p<0.001), had higher Gleason grade (p<0.001), came from less deprived 
areas (p<0.03) and had higher mGPS (p<0.01) and NLR (p<0.001) values. 
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Patients who died in the post-diagnosis group, compared with the pre-
diagnosis group, were more likely to be younger (p<0.001), had higher 
Gleason grade (p<0.001), and higher mGPS (p=0.03) and NLR (p<0.001) 
values. Because of differences in pre- and post-diagnosis sample 
characteristics, I conducted survival analyses for each separately. 
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Table 6-2: Baseline characteristic of prostate cancer patients in Glasgow Inflammation Outcome Study 
  All patients 
P-value 
All deaths 
P-value   Sampled before 
diagnosis n (%) 
 Sampled after 
diagnosis n (%) 
Sampled before 
diagnosis n (%) 
Sampled after 
diagnosis n (%)       
Age at incidence         
 Age < 65 72 (19.5)  162 (30.7) 
<0.001 
23 (11.9) 48 (21.1) 
<0.001  Age 65-74 118 (32.0)  223 (42.2) 52 (26.8) 88 (38.6) 
 Age ≥ 75 179 (48.5)  143 (27.1) 119 (61.3) 92 (40.4) 
Gleason Grade        
 Gleason < 7 70 (19.0)  136 (25.8) 
<0.001 
17 (8.8) 25 (11.0) 
<0.001 
 Gleason = 7 65 (17.6)  118 (22.4) 10 (5.2) 34 (14.9) 
 Gleason 8-10 131 (35.5)  214 (40.5) 73 (37.6) 122 (53.5) 
 Unknown Gleason 103 (27.9)  60 (11.4) 94 (48.5) 47 (20.6) 
SIMD 2004, Quintiles        
 1 (least deprived) 54 (14.6)  121 (23.0) 
0.034 
24 (12.4) 46 (20.2) 
0.187 
 2 46 (12.5)  64 (12.2) 23 (11.9) 27 (11.8) 
 3 52 (14.1)  75 (14.3) 23 (11.9) 30 (13.2) 
 4 82 (22.2)  97 (18.4) 48 (24.7) 42 (18.4) 
 5 (most deprived) 135 (36.6)  171 (32.4) 76 (39.2) 83 (36.4) 
Inflammation based prognostic scores        
 mGPS        
 0 182 (49.3)  273 (51.7) 
0.004 
80 (41.2) 78 (34.2) 
0.027  1 137 (37.1)  149 (28.2) 80 (41.2) 85 (37.3) 
 2 50 (13.6)  106 (22.1) 34 (17.5) 65 (28.5) 
 NLR        
 0 166 (45.0)  239 (45.3) 
<0.001 
72 (37.1) 71 (31.1) 
<0.001 
 1 99 (26.8)  205 (38.8) 58 (29.9) 110 (48.3) 
 missing 104 (28.2)  84 (15.9) 64 (33.0) 47 (20.6)  
P-value calculated using chi-square test. 
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Increasing age and high or unknown Gleason grade were associated with 
poorer one and 5-year relative survival in those who were sample before 
diagnosis and those following diagnosis (table 6-3). The 5-year relative 
survival of PC patients sampled before diagnosis was modelled using the full 
likelihood approach and is shown in table 6-4. On univariate analysis, 
patients older than 75 years of age (p<0.05), high or unknown Gleason grade 
(p<0.01), raised mGPS (p<0.001) and a raised NLR (p<0.01) were significantly 
more likely to die. On multivariate analysis, high (RER 5.15, 95% CI 1.74-
15.20) and unknown (RER 27.54, 95% CI 9.07-83.64) Gleason grade and mGPS 
of 2 (RER 2.08, 95% CI 1.13-3.81) were the major predictors of relative excess 
risk of death after adjusting for age, Gleason grade, socio-economic 
circumstances and NLR (table 6-4). 
Five year relative survival of PC patients sampled after diagnosis and 
modelled using the full likelihood approach is shown in table 6-5. On 
univariate analysis, patients older than 75 years of age (p<0.05), high or 
unknown Gleason grade (p<0.001), raised mGPS (p<0.001) and raised NLR 
(p<0.001) were significantly more likely to die. On multivariate analysis, 
increasing or unknown Gleason grade, mGPS of 2 (RER = 2.93, 95% CI 1.81-
4.78) and NLR ≥5:1 (RER 2.38, 95% CI 2.38) were significant predictors of 
death after adjusting for other factors (table 6-5). There was no significant 
interaction between the NLR and mGPS while employing these excess risk 
models (table 6-5). 
When this analysis was repeated based on Gleason grade, I observed a 
significant association between raised mGPS and risk of death in the low 
grade group (RER 7.58, 95% CI 1.44-39.76), higher Gleason grade category 
(RER 2.08, 95% CI 1.26-3.45) and those with unknown Gleason grades (RER 
1.97, 95% CI 1.03-3.73) after adjustment for age, socio-economic 
circumstances and NLR (table 6-6). In grade specific analysis, NLR only 
showed a significant association with risk of death for unknown Gleason 
grade after adjustments for age, socio-economic circumstances and mGPS 
(table 6-5). Similarly, age-specific analyses were also carried out and raised 
mGPS showed significantly higher risk of death among those with age <65 and 
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65-74 years at diagnosis. However, a non-significant increased risk of death 
was also observed among those age >75 years.  
Figure 6-1 shows the relative survival of high grade (Gleason 8-10) PC 
patients based on the mGPS. Analysis of this subgroup showed that the mGPS 
was associated with reduced survival with a mGPS of 2 having 29% lower 3-
year relative survival, when compared to those with a mGPS of 0. 
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Table 6-3: 1 year and 5 year relative survival of prostate cancer patients based on blood sampling categories; before and following a diagnosis. 
  
Before cancer diagnosis   After cancer diagnosis 
  
Relative Survival 
 
Relative Survival 
    1-year, % (95% CI)   5-years, % (95% CI) 
 
1-year, % (95% CI)   5-years, % (95% CI) 
     
    
  Age at incidence  
       
 
Age < 65 91.7 (81.9-96.7) 
 
69.2 (54.0-81.2) 
 
90.7 (84.8-94.6) 
 
75.1 (65.4-83.0) 
 
Age 65-74 89.9 (81.9-95.1) 
 
56.1 (41.6-69.8) 
 
93.0 (88.0-96.5) 
 
72.1 (62.8-80.4) 
 
Age ≥ 75 68.2 (59.8-75.8) 
 
49.4 (36.4-63.1) 
 
87.1 (78.7-93.5) 
 
55.9 (42.2-69.9) 
Gleason Grade 
       
 
Gleason < 7 99.1 (89.9-100) 
 
95.2 (74.8-100.1) 
 
100 (97.7-100) 
 
100 (91.5-100) 
 
Gleason = 7 100 (100-100) 
 
100 (82.8-100.2) 
 
98.5 (92.4-100) 
 
88.9 (75.4-99.3) 
 
Gleason 8-10 81.7 (72.8-88.5) 
 
47.2 (33.3-61.3) 
 
83.8 (77.5-88.8) 
 
46.3 (36.7-55.9) 
 
Unknown Gleason 48.3 (37.6-58.6) 
 
9.3 (3.0-20.6) 
 
73.8 (59.3-84.7) 
 
27.8 (14.5-44.3) 
SIMD 2004, Quintiles 
       
 
1 (least deprived) 86.2 (72.3-94.8) 
 
59.0 (35.2-81.0) 
 
86.1 (77.9-91.9) 
 
72.6 (61.3-82.3) 
 
2 79.7 (63.3-90.9) 
 
52.3 (27.8-76.9) 
 
90.9 (79.5-97.2) 
 
60.1 (40.5-77.6) 
 
3 80.5 (65.9-90.2) 
 
67.2 (47.1-84.4) 
 
90.1 (79.6-96.2) 
 
76.5 (60.5-89.7) 
 
4 81.1 (69.5-89.6) 
 
45.3 (27.9-63.5) 
 
91.7 (82.9-97.1) 
 
68.5 (54.1-81.2) 
 
5 (most deprived) 77.2 (68.0-84.7) 
 
55.7 (42.5-68.8) 
 
93.9 (87.8-98.1) 
 
64.9 (52.9-76.2) 
Inflammation based prognostic scores        
       
 
mGPS 
       
 
0 87.8 (81.1-92.9) 
 
65.8 (53.5-77.3) 
 
97.2 (93.4-99.7) 
 
85.5 (76.7-93.0) 
 
1 77.6 (68.7-84.8) 
 
49.5 (37.2-62.0) 
 
88.9 (81.7-94.1) 
 
55.0 (44.0-65.7) 
 
2 59.1 (43.0-72.9) 
 
30.7 (8.1-65.2) 
 
75.5 (66.5-84.4) 
 
45.5 (33.1-58.0) 
 
NLR 
       
 
0 87.6 (80.5-92.9) 
 
64.6 (51.5-76.8) 
 
96.1 (91.8-99.0) 
 
80.7 (70.9-89.0) 
 
1 70.2 (59.0-79.4) 
 
51.7 (34.9-68.7) 
 
83.0 (76.5-88.3) 
 
54.7 (45.1-64.1) 
 
Missing 77.6 (67.2-85.8) 
 
46.8 (33.3-60.6) 
 
94.3 (84.9-99.5) 
 
68.2 (53.1-87.6) 
Relative survival estimates are age, gender, calendar year and deprivation specific. 
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Table 6-4: Relative excess risk of death of prostate cancer patients sampled before diagnosis modelled using the full likelihood approach 
  
 
  Univariate analysis   Multivariate analysis 
      Relative Excess Risk (95% CI) p value   Relative Excess Risk (95% CI) p value 
Age at incidence 
          
 
Age < 65 
  
1 
    
1 
  
 
Age 65-74 
 
1.38 (0.74, 2.58) 0.32 
 
1.55 (0.83, 2.92) 0.173 
 
Age ≥ 75 
 
2.05 (1.14, 3.69) 0.02 
 
1.63 (0.89, 2.98) 0.122 
Gleason Grade 
          
 
Gleason < 7 
 
1 
  
1 
 
 
Gleason = 7 
 
0.81 (0.10, 6.52) 0.84 
 
0.46 (0.05, 4.13) 0.491 
 
Gleason 8-10 
 
7.39 (1.84, 29.73) 0.005 
 
5.15 (1.74, 15.20) 0.003 
 
Unknown Gleason 
 
31.13 (7.78, 124.58) <0.001 
 
27.54 (9.07, 83.64) <0.001 
SIMD 2004, Quintiles 
          
 
1 (least deprived) 
  
1 
    
1 
  
 
2 
 
1.73 (0.69, 4.37) 0.25 
 
1.74 (0.71, 4.27) 0.230 
 
3 
 
1.49 (0.59, 3.79) 0.39 
 
2.41 (0.97, 5.96) 0.061 
 
4 
 
1.82 (0.78, 4.29) 0.17 
 
1.06 (0.45, 2.52) 0.893 
 
5 (most deprived) 
 
1.75 (0.77, 3.97) 0.18 
 
1.39 (0.61, 3.18) 0.442 
modified Glasgow Prognostic Score 
  
      
 
0 
 
 
1 
 
  
 
1 
  
 
1 
 
1.58 (0.97, 2.58) 0.07 
 
0.92 (0.56, 1.49) 0.721 
2 
 
3.05 (1.74, 5.36) <0.001 
 
2.08 (1.13, 3.81) 0.021 
Neutrophil Lymphocyte Ratio 
         
0 
 
 
1 
 
  
 
1 
  1 
 
1.82 (1.19, 2.78) 0.005 
 
1.55 (0.98, 2.48) 0.064 
                      
All estimates were adjusted for age at incidence, socio-economic circumstances, mGPS and NLR.  
Patients with missing NLR were excluded from these analyses 
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Table 6-5: Relative excess risk of death of prostate cancer patients sampled after diagnosis modelled using the full likelihood approach 
  
 
  Univariate analysis   Multivariate analysis 
      Relative Excess Risk (95% CI) p value   Relative Excess Risk (95% CI) p value 
Age at incidence 
          
 
Age < 65 
  
1 
    
1 
  
 
Age 65-74 
 
1.11 (0.71, 1.72) 0.65 
 
1.28 (0.82, 0.91) 0.271 
 
Age ≥ 75 
 
2.07 (1.32, 3.25) 0.002 
 
1.43 (0.91, 2.26) 0.122 
Gleason Grade 
          
 
Gleason < 7 
 
 1  
   
1 
  
 
Gleason = 7 
 
3.12 (0.81, 12.06) 0.09 
 
3.12 (1.05, 9.21) 0.043 
 
Gleason 8-10 
 
13.71 (3.94, 47.69) <0.001 
 
11.09 (4.17, 29.45) <0.001 
 
Unknown Gleason 
 
19.48 (5.42, 70.04) <0.001 
 
20.80 (7.28, 59.44) <0.001 
SIMD 2004, Quintiles 
          
 
1 (least deprived) 
  
1 
    
1 
  
 
2 
 
1.27 (0.68, 2.73) 0.46 
 
1.23 (0.68, 2.63) 0.501 
 
3 
 
0.93 (0.48, 1.78) 0.83 
 
0.70 (0.36, 1.34) 0.282 
 
4 
 
1.13 (0.64, 1.98) 0.68 
 
1.04 (0.59, 1.83) 0.902 
 
5 (most deprived) 
 
1.19 (0.71, 1.98) 0.51 
 
0.75 (0.46, 1.24) 0.261 
modified Glasgow Prognostic Score 
  
      
 
0 
 
 
1 
 
  
 
1 
  
 
1 
 
3.12 (1.89, 5.18) <0.001 
 
1.78 (1.10, 2.89) 0.721 
2 
 
5.36 (3.27, 8.78) <0.001 
 
2.93 (1.81, 4.78) <0.001 
Neutrophil Lymphocyte 
Ratio          
0 
 
 
1 
 
  
 
1 
  1 
 
2.89 (1.95, 4.29) <0.001 
 
2.38 (1.58, 3.59) <0.001 
                      
All estimates were adjusted for age at incidence, socio-economic circumstances, mGPS and NLR.  
Patients with missing NLR were excluded from these analyses 
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Table 6-6: Five year relative survival of prostate cancer patients based on grade specific categories modelled using full likelihood approach 
      Gleason < 7 Gleason = 7   Gleason 8-10 Unknown Gleason 
                                      
Prognostic 
Scores 
Total                   
patients 
Number                       
of deaths 
Relative Excess Risk 
(95%CI) 
Number                       
of deaths 
Relative Excess Risk 
(95%CI) 
Number                       
of deaths 
Relative Excess Risk 
(95%CI) 
Number                       
of deaths 
Relative Excess Risk 
(95%CI) 
mGPS                   
0  349 (11)  1  (14)  1  (55)  1  (28)  1  
1  219 (10) 0.86 (0.08, 9.11) (14) 3.25 (0.85, 12.34) (43) 1.13 (0.69, 1.84) (50) 1.36 (0.76, 2.44) 
2  141 (9) 7.58 (1.44, 39.76) (7) 3.40 (0.86, 13.49) (47) 2.08 (1.26, 3.45) (23) 1.97 (1.03, 3.73) 
NLR                   
0  405 (11)  1  (18)  1  (65)  1  (49)  1  
1  304 (19) 1.43 (0.27, 7.63) (17) 1.84 (0.58, 5.81) (80) 1.52 (1.00, 2.30) (52) 2.38 (1.41, 4.00) 
                                      
All estimates were adjusted for age at incidence, socio-economic circumstances, mGPS and NLR. Patients with missing NLR were excluded from these analyses.  
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Figure 6-1: Three year relative survival of high grade (Gleason 8-10) prostate cancer patients 
based on modified Glasgow Prognostic Score 
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Relative survival estimates are age, gender, calendar year and deprivation specific. 
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6.5 Discussion 
6.5.1 Findings of present analysis and potential explanations 
The results of the present study show that systemic inflammation based 
prognostic scores - whether they are the mGPS or NLR - predict PC specific 
survival. In particular, the mGPS had prognostic value independent of time of 
sample, age at diagnosis, Gleason grade, socio-economic status and NLR. I 
observed 35-40% lower 5-year relative survival among those with raised modified 
Glasgow Prognostic Score (mGPS = 2) compared to the normal (mGPS = 0) for 
those who were sampled either before or following diagnosis of PC. 
In the present study, patients with high Gleason grade disease had a significantly 
raised mGPS compared with low grade disease. In Gleason grade specific 
analysis, a raised mGPS had significant associations with excess risk of death 
among patients with low, high and unknown Gleason grades, while NLR only 
showed significant association with poorer survival of unknown Gleason grade 
patients. In high grade disease, patients with higher systemic inflammation 
(mGPS = 2) had approximately 200% excess risk of death in the first five years 
after diagnosis compared to those with low level of systemic inflammation 
(mGPS= 0). Although there was no significant association between mGPS and 
survival in the intermediate Gleason grade, this could have been due to the 
small number of deaths in the intermediate grade disease category (n=35). The 
largest effect of mGPS was seen in patients with low grade PC (Gleason <7), a 
group for whom there is currently the greatest clinical uncertainty about their 
prognosis and management. Irrespective, taken together these results highlight 
the importance of systemic inflammation in relation to survival in patients with 
PC. 
In the present study patients with unknown Gleason grade had poorer relative 
survival even when compared to those with high grade disease. These unknown 
Gleason grade patients may have had pre-terminal disease that was deemed 
metastatic and therefore histological staging was not considered appropriate. 
Interestingly, both mGPS and NLR were shown to have prognostic value in this 
group of patients. Indeed, in those patients with unknown Gleason grade, those 
who had raised mGPS were twice as likely to die in the first five years following 
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diagnosis as compared to those with lowest level of mGPS. This association 
remained significant even after adjusting for age, socio-economic circumstances 
and NLR. 
6.5.2 Strengths and limitations 
Systemic inflammation measured by C-reactive protein has been associated with 
many chronic conditions including incidental and prevalent cardiovascular 
diseases (Kaptoge et al., 2010;Wensley et al., 2011). Given that PC is a disease 
of old age, patients in the present study may have co-morbid conditions leading 
the activation of the systemic inflammatory response. If this is the case, then 
differences in survival (estimated by conventional techniques using overall and 
cancer specific survival) between mGPS categories, may be explained by the 
distribution of co-morbidity between groups. However, in the present study, 
relative survival was adjusted for the background population mortality and so is 
based on cancer associated deaths. Moreover, when adjusted for NLR, age, 
socio-economic status and Gleason grade, patients with an elevated mGPS were 
significantly more likely to die at five years. 
To my knowledge this is the first study to compare the prognostic value of mGPS 
and NLR in PC patients, taking into account the background population 
mortality, age, Gleason grade and socio-economic status. The present study has, 
however, a number of limitations. Firstly, patients were selected on the basis of 
availability of C-reactive protein, albumin and calcium levels. This is an 
important point need to be considered before interpreting the results of the 
present analysis. The main question is that why these men were sampled to 
obtain the C-reactive protein? Was there any significant clinical condition 
associated with the raised C-reactive protein other than the cancer? Due to 
these issues directly related to the C-reactive protein make this cohort a group 
of patients with uncertain characteristics, C-reactive protein and other 
measurements were taken incidentally. There is a possibility that these patients 
might have had concurrent morbidity for which they were clinically investigated. 
Therefore this cohort of patients might not be representative of all the PC 
patients diagnosed and treated in the north of Glasgow. However, co-morbidity 
is unlikely to have had a major effect on results of this analysis, as I adjusted for 
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background mortality using age, sex and deprivation specific population 
mortality rates. Third, there was no information on the exact timing of 
treatment following diagnosis and it is possible that early treatment may have 
been responsible for increases in acute phase proteins. However, the 
relationship between inflammation and prognosis was similar in samples taken 
before and after diagnosis, suggesting that early treatment was not a significant 
confounding factor. Finally, the existing data did not have the information on 
PSA or disease stage and patients may have had higher inflammatory status due 
to metastatic disease. However, previous studies have shown systemic 
inflammation to be associated with survival, independent of disease stage, for 
gastroesophageal, colorectal (including those with liver metastases), renal, 
breast and PCs (Pierce et al., 2009;Roxburgh and McMillan, 2010). Similarly, 
earlier small studies on PC patients also showed that systemic inflammation 
measured by C-reactive protein was associated with poorer survival both in 
localised and metastatic PC (McArdle et al., 2006;McArdle et al., 2010).  
6.5.3 Implications for practice and research 
The prognosis of PC patients is not well understood and clinicians treating cancer 
patients make decisions on the basis of individual’s age, fitness, comorbidity, 
PSA, Gleason grade and disease stage. Novel genetic and immunological 
biomarkers have been identified but these, to date, have not been incorporated 
into routine clinical practice (Castelli et al., 2010;Huang et al., 2010). The 
results of the present study indicate that systemic inflammation is of clinical 
importance and may suggest the routine use of the mGPS as a readily available 
tool for risk stratification in patients with PC. 
Given the limitation of the data presented in this chapter, there is an 
uncertainty about the patients for whom CRP was measured. Current data do not 
have any information about the conditions which led to sampling for 
inflammatory markers and some unknown confounders may have influenced the 
findings of present analysis. Therefore, further work is required to investigate 
this relationship in a larger, representative sample of PC patients including 
information on other measures of prognosis (e.g. disease stage and PSA) and 
treatment offered to patients. 
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This chapter will briefly review the principal results of the thesis and then 
discuss epistemological aspects of PC epidemiology, before suggesting how 
public health practice and future scientific enquiry might be directed. 
7.1 Review of principal results 
7.1.1 Incidence and risk factors 
The analysis of Scottish cancer registry data found that the incidence of PC 
increased steeply in the West of Scotland since 1991. Both low and high grade 
disease increased. Incidence rates, particularly of low grade disease, increased 
more in men from more affluent areas, leading to the emergence of a 
deprivation gap. PC incidence increased to a greater extent among men aged 
less than 65 years. 
Two analyses of the MIDSPAN prospective cohort study were performed. The first 
suggested that plasma cholesterol level had a significant positive relationship 
with the development of aggressive PCs. Furthermore, height appeared as a 
significant risk factor for PC. The second analysis suggested that tea had a 
positive (harmful) relationship with overall risk of PC. This finding was not 
consistent with previously published analyses of the relationship between tea 
and PC. This may be because other published research reflects the preventive 
effects of green tea while Scottish data reflect consumption of black tea. In 
contrast, coffee consumption appeared to have a weak inverse relationship with 
overall PC risk but a stronger inverse relationship with aggressive PC. 
It seems most likely that incidence patterns reflect PSA testing – whose use may 
have increased over time and to a greater extent in more affluent men - rather 
than a true increase in risk. The effect sizes of cholesterol, tea and coffee are 
relatively small and unlikely to explain the temporal, socio-economic or age 
patterns in PC incidence. 
7.1.2 Survival and prognosis 
Survival of PC patients has improved since 1991 in the West of Scotland, 
consistent with other constituent countries of the UK and Europe. However, the 
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improvement has been greater among least deprived men, leading to increasing 
socio-economic inequalities in survival. These inequalities developed in earlier 
study period and increased over time. Adjustment for age and grade at diagnosis 
attenuated but did not remove the socio-economic differential in survival. 
Analysis of the Glasgow Inflammation Outcome Study data found that systemic 
inflammation (either measured by the modified Glasgow Prognostic Score or 
Neutrophil Lymphocyte Ratio) was an independent determinant of both short 
term and long term survival of PC patients. However, the mGPS appeared to be 
a better prognostic indicator and may help in the clinical management of 
patients. 
7.2 Epistemology of prostate cancer epidemiology 
The epidemiology of PC is particularly affected by temporal, geographical and 
individual influences on detection of the disease. These affect the interpretation 
of both its incidence and survival. In this section, I consider to what extent 
patterns of incidence and survival may be genuine or the result of artefact. This 
leads to conclusions for two areas; ways in which methodological improvements 
might be made to reduce artefact in future research and public health 
implications of the most reliable findings. 
7.2.1 Incidence, aetiology and prevention 
PC incidence is measured so that future healthcare needs can be predicted and 
to evaluate potential risk factors for the disease. These in turn should lead to 
action to plan appropriate health services and to implement preventive 
strategies, respectively. However, factors that are associated with greater 
likelihood of detection may appear themselves to be risk factors for PC. For 
example, PSA testing has been increasingly used over time to test men for 
possible PC and this may partially or wholly explain the temporal rise in PC 
incidence. Other behavioural or anthropometric factors that have also increased 
over time – for example, obesity – may therefore be artefactually associated 
with PC risk. The differential use of PSA testing in men from more affluent 
circumstances, or at younger ages, may also largely explain increases in 
incidence in both groups.   
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If the associations between tea, coffee and cholesterol and PC are not 
artefactual, what is the strength of evidence that they are causal? The findings 
of the MIDSPAN studies presented in this thesis suggest that coffee consumption 
and plasma cholesterol level have a significant relationship with aggressive PCs 
while tea consumption has a strong relationship with overall risk of PC. 
Considering in turn Bradford Hill’s criterion, the sine qua non is a temporal 
association, that exposure always precedes the outcome. In the analysis of 
coffee consumption and cholesterol, data on all exposures were recorded at 
least two decades before incidence of aggressive PC. For tea and overall PC, 
data were recorded at baseline and cancers that occurred within the first ten 
years of follow-up were removed to minimise any effect of reverse causality. 
Thus, there was a clear temporal relationship between exposures (tea, coffee 
and cholesterol) and outcomes (PC and aggressive PC) in the analysis of MIDSPAN 
data. The criterion for strength of association is more equivocal, as many truly 
causal factors have small relative risks or hazards in population-based analyses 
and arbitrary values of a “strong relationship,” such as relative risks or odds of 3 
or more, may not be found. However, hazard ratios of 2 or more were found for 
several associations from the MIDSPAN data. A dose-response relationship was 
found for tea, coffee and cholesterol. For coffee consumption, the risk of 
disease was reduced with increasing consumption of coffee while an inverse 
relationship was found for cholesterol and tea consumption. The findings of this 
thesis are consistent with results published elsewhere for both coffee and 
cholesterol and aggressive PC. In contrast, the evidence for tea consumption 
reported elsewhere has been that its effects, if any, are protective, while I 
found an increased risk with greater consumption. This may be because the 
majority of research reports the effects of green tea, whereas our findings 
reflect black tea consumption. Thus, there is a biologically plausible explanation 
for the inconsistency. The criterion of coherence is similar to that of 
consistency. There is emerging evidence from biological studies that supports 
the plausibility of coffee and cholesterol in the development of aggressive PC. 
With respect to alternative explanations for the findings, I have considered 
above the role that differential PSA testing might explain temporal, socio-
economic and age specific patterns of PC incidence. It is difficult to hypothesise 
that consumption of tea or coffee may affect the likelihood of PSA testing but it 
is possible that they act as markers for other healthcare-seeking behaviours. It is 
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easier to speculate that patients with higher cholesterol levels would be more 
likely to obtain ongoing medical attention and thereby increase their likelihood 
of incidental PSA testing. I am not aware of experimental evidence to support 
the hypothesis that lowering cholesterol or increasing consumption of coffee will 
prevent aggressive PC. The criterion for specificity is considered to be the 
weakest of Hill’s criteria and most of the chronic diseases, including cancers, 
have multifactorial aetiologies. The role of cholesterol as a risk factor in other 
disease, particularly cardiovascular diseases, is well established (Lewington et 
al., 2007). 
On balance, then, the associations between cholesterol and coffee consumption 
and aggressive PC do fulfil some of the main components of Hill’s criteria of 
causation. There is a temporal but not consistent relationship between tea and 
PC. These findings are relatively recent, and it would be too early to recommend 
that coffee and cholesterol can prevent or cause PC. Further epidemiological 
and biological evidence may explain these associations and provide better 
insight into their role in disease aetiology. 
Several established risk factors of PC are non-modifiable (for example, age, 
family history and race) and thus there is little that can be done with such 
knowledge, except, perhaps, to target information on awareness and prompt 
diagnosis. The substantial body of evidence on dietary and lifestyle factors 
remains equivocal and results are so conflicting that no definitive 
recommendations can be made. Although I found some associations between 
tea, coffee and cholesterol level in relation to overall and aggressive PC, the 
effects were either inconsistent with previous studies or the effect sizes too 
small to recommend public health action compared with, for example, the need 
for more effective health promotion on smoking, obesity and alcohol 
consumption. The question remains that if a cohort of tens of thousands of men 
followed-up for decades does not provide any compelling evidence on PC risk, 
should further primary research be carried out and if so, what would be the most 
efficient methodology? A meta-analysis of existing studies may be appropriate. 
The addition of PSA testing has also significantly influenced efforts to 
understand the natural history of PC by adding indolent and asymptomatic 
tumours into the pool of clinically relevant PCs. Most population-based studies 
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which have attempted to understand the aetiology of PC have not had 
information on PSA levels and could not differentiate between clinically 
manifested cases and screen detected cases.  
Case control studies often estimate exposure status by interviewing participants 
following their diagnosis, when exposure may have been affected by 
asymptomatic disease. For instance, most of the evidence from case control 
studies that circulating hormone levels are related to PC is inconsistent, and 
these studies suffered from a major problem that disease status may well alter 
serum concentrations of androgens even before its manifestation (Hsing, 2001). 
Thus an apparent “reverse causal” relationship may be observed. Case control 
studies suffer from a number of other biases, including survivor bias (where 
information on exposure is gathered from living patients only) and recall bias 
(where patients with PC are more likely to report putative exposures than 
patients without cancer). Prospective cohort studies provide better evidence of 
the temporal relationship between hormonal levels and PC risk. Prospective 
studies reduce the likelihood that changes in hormone levels are due to disease 
presence if blood samples are taken some years prior to diagnosis. However, 
prospective studies may also suffer from reverse causality as most recruit 
participants in middle age when early PC may already be present. For instance, 
the prevalence of asymptomatic invasive carcinoma among middle age men has 
been reported from 40% to 60% (Sakr et al., 1993). Thus, observed risk factors 
may have some association with the progression of the disease from 
asymptomatic to clinically significant disease rather than a true primary causal 
role (Giovannucci, 2011). Studies with a follow-up of 5-10 years may also be 
prone to a similar problem of describing factors related to progression rather 
than true incidence of disease. Prospective studies with longer follow-up may 
add something in understanding the aetiology of this complex cancer.  
One limitation of using prospective cohort studies to study risk factors for PC, 
however, is that PC has a long, although uncertain, natural history and it may be 
several decades after exposure to a risk factor before PC is diagnosed. Thus, 
exposure to baseline risk factors may not have continued during the at-risk 
period. In the present data, with a long follow-up period, I found limited 
evidence that any modifiable risk factor can reduce the risk of PC. While a 
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prospective trial with long follow-up can provide some insights into disease 
aetiology, additional PC-specific information is needed. This might include 
further diagnostic testing to confirm the presence or absence of a prostatic 
tumour or lesions at baseline screening along with information on demographics, 
anthropometric measurements, food intake, lifestyle habits and haematological 
measures. The outcome of such a trial can also be subdivided by “testing for a 
cause” or “not for a cause” as reported elsewhere (Giovannucci, 2011). 
7.2.2 Survival of prostate cancer patients 
The patterns of survival reported in chapter 5 (page 165) over a 17 year period 
suggest a real improvement in survival and reflect a rapid and substantial shift in 
the biological and clinical spectrum of PC. Improvements in the effectiveness of 
therapeutic interventions and increasing likelihood of active treatment may well 
have made contributions to the observed survival benefits over time. However, 
data from cancer registries on treatment modalities is limited, particularly in 
earlier years. The observed survival benefits in recent years may be driven by 
other factors such as lead time bias and a change in case-mix towards less 
aggressive disease, rather than advances in treatment modalities (Clarke, 2008).  
The relationship between socio-economic circumstances and survival is complex. 
When considering the “deprivation gap” in survival between socio-economic 
groups, it is important to adjust for higher incidence rates of less aggressive 
disease among more affluent men, as these would be expected to have better 
survival. However, the deprivation gap persisted even when after adjustment for 
age and disease grade. This suggests two things. The first is that the overall 
deprivation gap would not be removed by efforts to ensure that men from more 
deprived areas were diagnosed at an earlier grade. The second is that further 
work is needed to understand what other prognostic factors explain socio-
economic differences in survival of men with the same grade of PC. It may be 
that higher prevalence of co-morbidities in more deprived individuals explains 
some of their excess mortality, but cancer registry data do not contain such 
information. Furthermore, cancer stage is also a significant determinant of 
survival of patients with PC. The socio-economic differential in survival may be 
due to differential distribution of advanced disease between different socio-
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economic groups, however, this analysis couldn’t control for the effect of 
disease stage on survival due to lack of information on stage in cancer registry 
data for the studied period (1991-2007).  
Socio-economic differences in incidence and survival of PC are of concern for 
two main reasons. First, they suggest unacceptable inequities, either in the 
broad determinants of health or in the quality of healthcare (Marmot and 
Feeney, 1997). Second, governments set the targets for health improvements 
and if the health improvements occur at a slower rate in some socio-economic 
groups, then the remainder of population must show much faster and greater 
improvements to keep up the average for the society as a whole (Marmot and 
Feeney, 1997).  
Geoffrey Rose noted that, “the determinants of individual risks of disease – why 
one individual gets sick and other remains healthy – may be different from the 
determinants of population rates of disease” (Rose, 1992). The fundamental 
questions arising from this are, whether there are individual behavioural factors 
(for example, diet, smoking, alcohol, BMI, or physical activity) or health care 
related factors which influence the survival of different socio-economic groups. 
Deprived men, generally, may have poorer general health due to lifestyle and 
dietary factors compared with affluent men (Mensah and Hobcraft, 2008). Poor 
general health can have negative effects on the survival of patients who are 
diagnosed with PC in a number of ways. Men with poorer overall health are less 
likely to receive aggressive surgical, radiological or hormonal therapy due to 
their increased risks of side-effects. The independent effects of co-morbidities 
may be another explanation for observed differences in survival. Although, some 
effects of socio-economically patterned co-morbidities are minimised through 
relative survival analysis, they cannot be removed completely. Cancer registry 
data do not hold information on patients’ lifestyle-related factors or information 
about access and quality of health services.  
Currently, all diagnosed patients are treated by a multidisciplinary team (MDT) 
of specialists. There are no available data either on individual factors or on 
aspects of access, availability or effectiveness of health care, in the West of 
Scotland MDT database. There is a need to collect information about patients’ 
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lifestyle habits which could be obtained conveniently while other routinely 
collected information is obtained during clinical assessment. In addition, service 
related information such as waiting times and availability of supportive care 
services during treatment could also be obtained to better understand the role 
of differential survival patterns between socio-economic groups. 
It might be asked whether, on balance, the incidence and survival differences of 
PC truly disadvantage deprived men. More deprived men may have been spared 
the physical and psychological effects of over-diagnosis and over-treatment 
which is currently the main concern with early detection of PC by PSA-testing 
(Yao and Lu-Yao, 2002). They may also have been spared from the subsequent 
health risks associated with treatment discussed earlier. In this sense, the 
deprived men may, for once, appear better off than their affluent counterparts. 
However, other men in the deprived group, whose cancer is a high risk, 
aggressive disease and a significant threat to their life would have been 
disadvantaged (Clarke, 2008). 
Another aspect is the growing evidence on systemic inflammation and its 
relationship with survival of cancer patients. Compelling evidence has suggested 
that systemic inflammation has a significant prognostic value in many cancers 
(Gomez et al., 2008;Proctor et al., 2011;Walsh et al., 2005). In this thesis, 
systemic inflammation also appeared to have a significant prognostic value in PC 
patients. This could help in multiple ways. The first is in its role in decision 
making for cancer patients. Systemic inflammation-based prognostic scores can 
help in stratifying high-risk groups who need urgent and aggressive treatment. 
Secondly, some preliminary evidence suggests that anti-inflammatory drugs may 
have some role in regulation or reversal of inflammation in cancer tissue, which 
may ultimately reduce the risk of progression of disease and improved survival 
(Vaish and Sanyal, 2011). Further research is required in this area to understand 
the role of inflammation and survival of PC patients.  
The substantial improvements in survival from PC are encouraging but it remains 
uncertain whether these have been driven by greater diagnoses of low risk PCs 
and or are the effects of lead time bias and not true increases in life 
expectancy. Better survival among more affluent patients is not wholly 
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explained by lower grade disease or younger age at diagnosis and further insights 
are needed into socio-economic differentials in survival. 
7.3 Living with prostate cancer 
The results presented in thesis suggest an increasing incidence and improving 
survival of men with PC, leading to substantial increases in the prevalence of the 
disease. In Scotland, 12,887 men were diagnosed with PC during 2003-2007 and 
this is expected to increase to 15,547 in 2008-2012. Five and ten year relative 
survival of these men was 80% and 70% respectively (Information Services 
Division, 2011). 
In recent years, evidence has emerged that after a diagnosis of PC men 
experience increased risks of developing other serious health conditions 
including anxiety, depression, cardiovascular disease, pathological fractures and 
self-harm. Following PSA-testing, a significant proportion of men who are 
diagnosed with either localised or advanced PC develop anxiety and depression. 
The prevalence of these conditions has been reported to be from 20% to 50% in 
different populations (Bennett and Badger, 2005;Couper et al., 2010;Dirksen et 
al., 2009).  
A population-based study from Sweden found that self-reported psychological 
distress among men with PC was significantly higher compared to the general 
population (Bill-Axelson et al., 2011a). The risk of psychiatric hospitalisation due 
to depression, anxiety and post-traumatic stress disorder were significantly 
increased (RR 1.29, (95% CI 1.14-1.45), RR 1.42 (95% CI 1.12-1.80) and RR 1.61 
(95% CI 1.16-2.24), respectively) (Bill-Axelson et al., 2011a). However, 
hospitalisations due to anxiety were only increased in men with more advanced 
tumours (RR 2.28, 95% CI 1.45-3.57). The use of antidepressants was increased in 
all men with PC (RR 1.65, 95% CI 1.54-1.77). The risk of depression increases up 
to five times independent of cancer risk group and treatment strategy (Bill-
Axelson et al., 2011a). 
These psychological conditions not only affect the general health related quality 
of PC survivors (Sharpley et al., 2010;Zenger et al., 2010;Lev et al., 2009) but 
also increase the risk of suicide among these men (Bill-Axelson et al., 
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2010;Llorente et al., 2005). Compared to the general population, the risk of 
suicide was significantly increased during the first and second years following 
diagnosis and even after two years there was a two-fold increase in risk in 
patients with locally advanced tumour stages T3 and T4 (Bill-Axelson et al., 
2010). For patients with distant metastases (M1), there was a two-fold increase 
in the risk of committing suicide (SMR: 2.1; 95% CI, 1.2–3.6). These findings point 
towards the risk of subsequent psychological conditions among PC survivors. 
Most of the studies investigating these psychological conditions are based on 
small numbers of cases using cross sectional approaches, with limited 
information on treatment related factors, and in some cases with short follow-up 
periods. Determinants associated with these conditions are largely unknown and 
how the incidence of these psychological conditions changes over time after the 
diagnosis remains unclear. The stress of having disease, chronicity of pain, 
treatment related adverse effects, comorbidity and socio-economic status have 
been suggested to have significant roles in the development of these conditions. 
However, most studies did not reach a consensus on the major determinants of 
psychological conditions because of different times since diagnosis when 
subjects were interviewed, different stages of disease, treatments offered and 
differences in populations from which the samples were drawn.  
Recent data suggest that half of men diagnosed with PC receive hormonal 
therapy at some point after the diagnosis and most men take it for at least two 
to three years (Alibhai et al., 2009). Besides the poorer quality of life among PC 
survivors who receive hormonal therapy, a growing body of evidence suggests 
that PC survivors who receive hormonal therapy experience increased risk of 
diabetes (Alibhai et al., 2009;Keating et al., 2010;Kintzel et al., 2008;Leahy, 
2008;Smith, 2008), metabolic syndrome (Faris and Smith, 2010;Kintzel et al., 
2008;Leahy, 2008;Nobes et al., 2009), cardiovascular diseases (Keating et al., 
2010;Kintzel et al., 2008;Ribeiro et al., 2010;Saylor et al., 2011) and 
pathological fractures (Abrahamsen et al., 2007;Alibhai et al., 2010;Lau et al., 
2009;Melton, III et al., 2011).  
The relationship between hormonal therapy and metabolic and cardiovascular 
disease is thought to be due to the adverse effects of suppression of 
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testosterone and development of androgen deprivation syndrome (Abrahamsen 
et al., 2007) - the condition characterized by many metabolic changes, including 
increasing fat mass, dyslipidemia and insulin resistance (Faris and Smith, 2010). 
All these metabolic changes increase the risk of cardiovascular and 
cerebrovascular events in later life. Although the evidence is limited, there is 
some suggestion of significant variations in metabolic syndrome following 
hormonal therapy between men of different racial origins (Beebe-Dimmer et al., 
2009). There may also be variations in the development of these conditions 
between socio-economic groups but research is not available.  
PC survivors who receive hormonal therapy are at an increased risk of bone loss 
and osteoporosis. These delayed effects of hormonal therapy increase the risk of 
fractures (Egerdie and Saad, 2010). Hormonal therapy may also increase the risk 
of some fractures (including skull, rib and foot) which are not typical of 
osteoporotic fractures (Alibhai et al., 2010). In 75% of men who had a fracture 
following hormonal therapy, it occurred in the first five years of treatment 
(Abrahamsen et al., 2007). The excess risk of fractures increased from two to 
nine times depending on the site and age of patients with the highest risk among 
men aged 50-65 years (Abrahamsen et al., 2007).  
I am unaware of any published evidence on any of these prevalent health 
conditions among PC survivors in the UK or Scotland in particular. As the 
prevalence of PC continues to increase steeply, there is an urgent need to 
examine these health risks. A thorough investigation into these psychological, 
cardiovascular and musculoskeletal disorders may be able to identify high risk 
groups of PC survivors, which will ultimately help health professionals to make 
better choices when offering treatment and support to patients.  
7.4 Strengths and limitations of this thesis 
The particular strengths and weaknesses of each component study in this thesis 
have been discussed with each relevant chapter. This section considers some of 
the general strengths and limitations of the thesis.  
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7.4.1 Strengths 
The present thesis has made many contributions to the understanding of PC 
epidemiology, particularly in Scotland. Population-based data were used to 
analyse incidence and survival trends in the West of Scotland. The quality of 
cancer registration data is good with high levels of accuracy and completeness 
(Brewster et al., 1994). These data provide a valid picture of the cancer burden 
in the region and consistent methodology has been used over time. Additionally, 
the potential to link cancer registry data with death records and other available 
databases (biochemistry records) provided valuable information on survival and 
determinants of survival. 
The epidemiological studies carried out to understand the aetiology of PC, used 
data from large population-based cohort studies. Perhaps the most cited 
justification for conducting a population-based study is its external validity – 
that is, the applicability of its results to a defined population. The Midspan 
cohorts comprise large samples, very long follow-up periods and low losses to 
follow-up, making them a valuable source of information in understanding the 
aetiology of PC. In addition, the availability of a large number of variables 
including demographic and physical measures further strengthens their value.  
7.4.2 Limitations 
Study-specific design and analytical limitations have been described in each 
chapter. Some methodological limitations related to observational epidemiology 
that are relevant to this research will be discussed in this section. The discussion 
on these limitations will bring forward some new ideas and suggestions that may 
help improve future research studies and understanding of PC epidemiology. 
Some general limitations of epidemiological approaches – that is the descriptive 
and analytical epidemiology – will also be covered in this section. Limitations of 
confounding, bias and ecological fallacy will also be discussed in the context of 
this thesis.  
7.4.2.1 Descriptive epidemiology 
In this thesis, both the incidence and survival trends of PC have been reported in 
relation to time, place and person, the basic principles of descriptive 
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epidemiology (Esteve et al., 1994). A difficulty of descriptive epidemiological 
studies is that both the exposure and outcome measurements are collected at 
one point – which in case of PC incidence was the date of PC diagnosis. Socio-
economic circumstances had a significant relationship with both the outcomes 
(incidence and survival) reported in chapters 2 and 5.  
As discussed above, exposure assessment should be made prior to the occurrence 
of the outcome, while in cancer registry data socio-economic circumstances are 
derived from area of residence using the post code information at the time of 
diagnosis. Thus, it may be that risk factors or symptoms of PC have negative 
effects on socio-economic circumstances (for example, by restricting 
employment) rather than socio-economic effects increasing risks of PC. 
However, socio-economic circumstances of men may still have some role in the 
detection of PC as affluent men may be more likely to access health services or 
be tested by PSA due to greater awareness and health consciousness. In relation 
to socio-economic circumstances and survival, there is a long time lag between 
the diagnosis and death of the individuals. The temporal relationship is fairly 
clear in survival analysis as socio-economic status is measured years before the 
outcome. A further consideration is that both individual and area-based 
inferences of socio-economic status are less valid in older individuals, where 
current income and employment, for example, do not reflect those throughout 
an individual’s lifecourse.  
Descriptive epidemiological studies generate rather than testing hypotheses. In 
both the incidence and survival chapters (chapter 2 & 5) of this thesis, many 
questions have been raised that might be answered in future studies using 
analytical techniques. Therefore, in relation to this particular thesis, this 
limitation does not invalidate any of the results. Indeed, both incidence and 
survival analyses have provided useful insights on the burden of disease and its 
outcome and differential patterns of incidence and survival between sub-groups 
of the population.  
7.4.2.2 Analytical epidemiology 
An analytical epidemiological approach was used in this research to investigate 
risk factors of PC using the prospective cohorts. Study specific limitations have 
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been discussed in relevant chapters but some broader limitations of analytical 
epidemiology which may have some influence on findings are discussed here.  
There are several separate dimensions to critique current epidemiological 
practices as outlined by George Davey Smith and colleagues (Davey Smith, 
2001;Davey Smith and Ebrahim, 2002). First he highlighted the over-emphasis on 
the use of risk factor epidemiology, which he described as “risk factorology” – 
that is the practice of conducting epidemiological studies that relate potential 
exposures with the risk of disease and identifying those which are positively 
related as “risk factors” and those negatively associated as “preventive factors” 
(Davey Smith, 2001). One of the major limitations of such epidemiological 
studies is that different investigators often report contradictory findings using 
data from different settings (Davey Smith, 2001). The findings of analytical 
studies reported in this thesis, perhaps also fall in the category of “risk 
factorology” however, this thesis does not claim that cholesterol level, tea or 
coffee consumption are causally related with the incidence of PC. The other side 
of the argument is, as Petr Skrabanek pointed out, that this apparent weakness 
of contradictory findings in risk factor epidemiology can be turned to an 
advantage. Since one positive association has been identified, it needs further 
investigation and replication, and if re-confirmed, perhaps a real cause of the 
disease is identified while negative findings may be controversial but are still of 
interest (Skrabanek, 1993). Coffee and cholesterol findings reported in this 
thesis confirm recently reported findings from large cohort studies but still 
require further confirmation before recommendations for public health practice 
or policy can be made.  
Another strand of George Davey Smiths’s critique was the ability of 
epidemiological studies to examine the relationship of a large number of 
exposure variables with multiple outcomes by stratifying analysis on sub-
categories, suggested as “data dredging” (Davey Smith and Ebrahim, 2002). They 
debated that large numbers of exposure and outcome variables can lead to at 
least one in 20 associations examined being “statistically significant” at a 
conventional p-value of <0.05 (Davey Smith and Ebrahim, 2002), when in reality 
it may be a false positive association due to chance alone. Although this is a 
major problem of epidemiological studies it is acknowledged in this thesis that 
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presented findings may have been influenced by small numbers of cases and may 
have been affected by unknown confounders as well. Further details of biases 
and confounding are discussed in the subsequent section.  
7.4.2.3 Bias 
A major limitation of epidemiological studies is the potential for bias, defects in 
the design, implementation or both of the study that affect the internal validity 
of that research (Grimes and Schulz, 2002). The main systematic errors in 
epidemiological studies are selection and information biases.  
Selection bias originates from an absence of comparability between groups being 
studied (Grimes and Schulz, 2002). All epidemiological studies, particularly 
observational studies, have built-in bias. A major question to address in cohort 
studies is whether participants who had an exposure were similar to the non-
exposed group except for their exposure. In relation to the prospective studies 
presented in this thesis, selection bias could be a major problem. However, the 
study population was drawn from a defined population using a population-based 
approach, which minimised some of the risk associated with selecting 
participants based on their exposure status. Nonetheless, there were some 
major differences between exposed and non-exposed groups and these may have 
influenced the results in ways that have been discussed and acknowledged in 
relevant chapters.  
In relation to the chapter on systemic inflammation and survival of PC patients, 
selection bias may be an important consideration. The study population was 
identified based on the availability of C-reactive protein and albumin and then 
linked to the cancer registry to ascertain the outcome, that of a diagnosis of 
cancer and death. The external validity of this study can be challenged as 
participants included in the study may not truly represent the population from 
which they were drawn and may not even truly represent all cases of PC in that 
population. Given that selection biases may have had an important impact on 
the findings of this study, its generalisability may be limited. In future, an 
investigation will be carried out in which biochemistry records will be extracted 
for all those patients who had a diagnosis of PC and relationships between 
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systemic inflammation and survival will be examined using a true cohort 
approach.  
Information bias comprises the incorrect determination of exposure and 
outcome, or both (Grimes and Schulz, 2002). It is also called classification or 
measurement bias. In cohort studies, the main concern is not the measurement 
of exposure but any differential ascertainment of outcome between exposed and 
non-exposed groups. In this thesis, prospective studies were carried out using 
data from a population-based cohort study which was set up three to four 
decades earlier and all men were followed-up by flagging in the NHS. Few 
participants were lost to follow-up (0.1%) in these prospective cohort studies, so 
information biases in outcome measurements are unlikely. A further potential 
information bias, which has been described above, is whether baseline exposures 
are valid over the at-risk period of follow-up. No information was available on 
whether cholesterol, tea or coffee consumption remained valid measures after 
their assessment at baseline. 
7.4.2.4 Confounding 
Confounding is an extraneous factor mixing or blurring the effects of other 
factors and is inherent in epidemiological studies (Davey Smith and Ebrahim, 
2002;Grimes and Schulz, 2002). A confounding variable is associated with the 
exposure and it affects the outcome under study, but it is not in an intermediate 
link in the chain of causation. Confounding factors can be minimised at different 
stages of a study; by restricting and matching at the recruitment stage or by 
stratifying or making multivariate statistical adjustments at the analysis stage. 
This latter approach was the main one used in this thesis. 
In relation to the empirical research in this thesis, particular attention was given 
to the confounding effects of co-variates. In the descriptive epidemiological 
studies (incidence and survival chapters of the thesis), lack of ability to control 
for the effect of potential confounders associated with socio-economic 
circumstances, limited the hypothesis testing around socio-economic 
circumstances and incidence or survival. However, the effects of age and 
Gleason grade on survival of patients were removed both by stratifying the 
analysis as well as by multivariate adjustments. Despite multivariate 
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adjustments, socio-economic circumstances had an independent association with 
survival of patients. These findings may still have some confounding effects of 
unknown factors associated with socio-economic circumstances. However the 
presented analysis generated hypotheses which warrant further investigation.  
In addition to these, in chapter 5 and 6, lack of data on co-morbidity and disease 
stage which are well known determinants of survival of cancer patients, may 
have some confounding effects on apparent associations. The potential 
confounding effects of co-morbidity have been controlled by adjusting for the 
background population mortality in those analyses. However there may still be 
some effects of disease stage which could not be studied due to unavailability of 
cancer stage information and this is recognized as a potential limitation of this 
thesis.  
Finally, in prospective studies, there was an opportunity to tease out the effects 
of demographic, lifestyle and physical factors on associations between 
cholesterol levels, coffee and tea consumption on risk of PC. The associations 
remained and were largely unchanged after multivariate adjustments. For some 
well established confounders, stratified analyses were also carried out, such as 
for alcohol consumption, BMI and cigarette smoking but overall relationships 
remained unchanged. Age has a strong independent relationship with incidence 
of PC and so an alternative analysis was conducted which took into account the 
age at which an individual was enrolled in the study and at what age they 
developed the disease. The overall relationship between cholesterol, coffee and 
tea consumption and PC incidence did not change with this alternative analysis. 
Although confounding is inherent in the research presented in this thesis, its 
potential effects were considered seriously in all analyses and findings were 
presented after applying a variety of methods to minimise its effects.  
7.4.2.5 Ecological fallacy 
The ecological fallacy is a type of confounding effect which occurs when it is 
assumed that the characteristics of the population of an area (the ecology) in 
which a study participant lives are true for a given individual within that 
population (Levin, 2006). Although the ecological fallacy is more common in 
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ecological studies, it may be relevant to this thesis for both incidence and 
survival chapters, where an area-based measure of socio-economic 
circumstances has been used. The inference is not fallacious provided that the 
interpretation of socio-economic circumstances is limited to describing the 
environment in which an individual lives. This may reflect access to health and 
social services, environmental factors, or education and employment 
opportunities, amongst others. However, the inference is usually extended to 
suggest that socio-economic circumstances reflect aspects of an individual’s 
socio-economic status – their income, employment and associated health-related 
behaviours. Because very affluent and deprived populations must be relatively 
homogeneous to rank at the extremes, it is more likely that any individual in a 
very deprived or very affluent population is themselves deprived or affluent. 
Area-based measures become less valid in the heterogeneous middle categories. 
Thus, most information is gained by comparisons of most affluent and most 
deprived populations, such as in the “deprivation gap” analysis presented in this 
thesis. 
Population-based cohort studies presented in this thesis used individuals’ socio-
economic status measured by social class based on occupation did not show any 
significant difference in risk of PC between these groups. This particular finding 
suggests that there may not be any difference in risk among individuals from 
different socio-economic groups or this particular finding may have been 
affected by the small number of cases (n=650). In addition, these cases may not 
have been truly representative of their respective socio-economic groups in the 
population. 
Apparently, these two differential findings look contradictory, where individuals’ 
socio-economic status show no significant role in disease development and area-
based measures show differential incidence and survival. Given that most of the 
lifestyle related evidence on risk of PC remains “limited suggestive” and the role 
of PSA-testing has substantial effects on observed incidence and survival 
patterns, these apparent conflicting findings may be reconciled. Assuming that 
PSA-testing was a major determinant and driver of the increasing incidence and 
improving survival in the West of Scotland, the area-based measure provides 
some clues that uptake of PSA may be higher among the least deprived men 
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compared with the most deprived men. There is substantial evidence to suggest 
that men in higher socio-economic groups are more health conscious and access 
health services at earlier stages of disease compared with lower socio-economic 
groups (Clegg et al., 2009). So the area-based measure may represent the 
access-to-services factors more than the individual’s lifestyle and health risk 
behaviours. On the other hand, an individual’s socio-economic status measured 
by occupation may better represent lifestyle-related factors, and as their causal 
effects appear to be small no significant risk differences were observed between 
socio-economic groups.  
7.4.3 Concluding remarks on strengths and limitations 
This thesis comprises research work that originated from observational 
epidemiological studies. The best available population-based datasets were used 
to understand the epidemiology of PC. These data had relatively large numbers 
of cases, long follow-up periods and the population-based nature of the samples 
may have minimised some of the potential biases and confounding inherent in 
observational epidemiology. However, some associations may have been 
influenced by ecological fallacy or the effect of unknown confounders, so 
caution should be taken before making any definitive conclusions.  
7.5 Outstanding hypothesis and future research 
It may be true of observational epidemiology that it generates more questions 
than it answers. This is what George Davey Smith highlighted as the bottom line 
always being that “more research is needed” – a conclusion which is very 
comforting to epidemiologists working in the field (Davey Smith, 2001). A more 
positive perspective is taken by Petr Skrabanek, who considers that “replication 
is the hallmark of science” and we always need more evidence, both positive 
and negative, to understand the risk factors for diseases (Skrabanek, 1993). Both 
the outstanding hypotheses and directions for further research are outlined 
here.  
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7.5.1 Outstanding hypotheses 
Several hypotheses have emerged from the work of this thesis and merit further 
research. These are briefly outlined in this section. 
The true reason for the differential increase in incidence of PC between socio-
economic groups in the West of Scotland remains uncertain. One suggestion is 
that it is due to differential uptake of PSA-testing. A study of population-based 
data of PSA testing may help to determine whether rates of testing are greater 
among more affluent men and if any differential is of a similar magnitude to that 
seen for incidence rates.  
Prospective studies presented in this thesis highlighted that the factors which 
are associated with longevity – desirable BMI, no smoking habit, low alcohol 
intake – may be linked with greater risk of PC. It seems less likely that these risk 
factors have a direct causal relationship with the development of PC and more 
likely that they reduce competing causes of death and therefore increase the at-
risk period in which PC may be diagnosed. However, further work is needed both 
at a basic sciences level to determine whether causality is biologically plausible, 
as well as in competing-risk models using epidemiological data. 
Similarly, further basic science research is needed to determine what biological 
mechanisms may explain a preventive effect of coffee consumption on high 
grade disease, or that explains whether coffee may slow the progression of PC so 
that it is less likely to be diagnosed.  
The extent to which disease stage and co-morbidity contribute to the socio-
economic gradient in survival of PC patients remains unclear. If disease stage 
and co-morbidity do not completely explain the differences in survival between 
socio-economic groups, as described in this thesis, what are the other 
explanatory factors for the effects of socio-economic status and circumstances 
on survival?  
Systemic inflammation is emerging as an important prognostic factor for many 
cancers. Although, the evidence on systemic inflammation and survival of 
patients with PC is very preliminary its effect size is relatively large. Further 
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research in this area with a well defined cohort of patients for whom complete 
information on disease stage, PSA and comorbidity is available may provide 
useful prognostic evidence for clinicians and patients.  
Given that both the incidence and survival is increasing, a large proportion of 
men diagnosed with PC are living with the disease. It is critical to understand 
the survivorship experience of these men, their quality of life and their risk of 
subsequent health outcomes. This area of research is still developing and in the 
UK, very little is known about the survivorship of PC patients.  
7.5.2 Future research 
7.5.2.1 Local context 
In relation to the future research to address these outstanding hypotheses, a list 
of ideas and potential projects could be outlined. However, some projects which 
may have potential benefits and implications are briefly described here.  
To understand the differences in incidence of PC between socio-economic 
groups, the author as lead investigator has obtained approval to obtain PSA 
uptake data in North and South Glasgow from year 2000 to 2008. This project 
will help understand recent incidence trends. It may also explain whether the 
deprivation gap in incidence of PC in the West of Scotland is likely to be due to 
differential PSA testing as complete testing information – in both cancer and 
non-cancer patients – has been obtained. Full biochemistry data has also been 
obtained and this will allow the role of systemic inflammation in survival of PC 
patients to be described in a well-defined, large cohort with long follow-up.  
There may be merit in conducting a cohort study of PC patients and following 
them up to understand the risk of developing subsequent chronic diseases. The 
aim of this research is to estimate the prevalence of anxiety, depression and risk 
of suicide among PC survivors. The risk of developing diabetes mellitus, 
cardiovascular diseases, cerebrovascular disease and pathological fractures 
among PC survivors who received hormonal therapy will also be investigated. A 
grant proposal for this project has been submitted to the Chief Scientist Office 
to obtain funding to carry out this research project.  
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The urological cancer managed clinical network (MCN) also collects detailed 
clinical audit data on PC patients. PSA and disease stage data are available in 
the MCN audit dataset although it is not complete for all patients, even in more 
recent years. However, attempts are being made to improve the quality and 
completeness of MCN data. In the near future, MCN data could be linked with 
cancer registry records to provide useful insights into the diagnosis, presentation 
and survival of patients from different socio-economic groups. 
7.5.2.2 Broader context 
A major problem associated with PC testing or screening is the low sensitivity 
and specificity of PSA for PC. Although there is some evidence that it helps to 
identify and diagnose patients at an earlier stage, it has been widely criticized 
as it leads to over-diagnosis and over-treatment of many slow growing tumours. 
Keeping in view the principles of primary prevention, we might therefore need 
to have a definite screening marker, which could identify high risk disease at an 
earlier stage. Further research is needed to identify a biomarker with high 
sensitivity, specificity and low cost. Early detection with a more accurate new 
biomarker may help clinicians and patients.  
On the other hand, identification of prognostic factors may also be important as 
many more men are now diagnosed with PC. Identification of high risk cases who 
are likely to progress or relapse after treatment, may improve the treatment 
related decision making process and the survival of patients. The emerging 
interest in “personalised medicine” requires information from, for example, 
tumour specific genes or epigenetic markers and their association with response 
to different treatments, so that optimal treatment can be tailored for each 
patient.  
Prevention of PC is only possible once risk factors are more clearly identified. 
Although much work has been done without identifying useful modifiable risk 
factors, a large clinical trial with more accurate information at baseline about 
the presence or absence of disease along with conventional risk factor 
information might provide some useful insight of this disease. As noted already, 
it is unlikely that a single classic risk factor could be identified such that 
modifying that risk would eliminate the disease. Nonetheless, identification and 
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modification of some risk factors may reduce the burden of disease. Given that 
it is one of the most frequent cancers among men and due to aging population 
incidence will continue to increase in the coming decades, a modest decline due 
to modification of some factors might have a sizeable impact at a population 
level.  
7.6 Recommendations 
This section of the thesis will attempt to provide some recommendations based 
on research findings presented in this thesis.  
The main aim of epidemiology is to understand the determinants of disease and 
ultimately reduce the burden or occurrence of disease by modifying those 
determinants. Although completely preventing a cancer is an attractive goal, 
and may be feasible where a single causal agent, such as Human papillomavirus, 
has been identified, it is unlikely to be a realistic ambition in PC. PCs are likely 
to arise from a combination of many risk factors and its very high prevalence in 
men in middle and later life suggests that the main public health priorities are 
to better understand the natural history of the disease so that the large majority 
of men for whom it is unlikely to cause significant morbidity can be separated 
from those for whom it is life-threatening. The large and widening socio-
economic inequalities in incidence and survival are also of public health 
concern. Recommendations have been made below for public health policy and 
for clinical practice.  
7.6.1 Public health policy 
Although most developed countries with overall public health policies have an 
overarching goal to reduce inequalities in health, the extent and success of such 
efforts is variable. The US has recently published “Healthy People 2020”, which 
is an extension of a previous policy “Healthy People 2010” (US department of 
health and human services, 2011). Cancer incidence and mortality is one of the 
main focuses in this policy. The policy highlights groups where disparities lie; 
however, it does not provide any strategy on how the disparities should be 
tackled (US department of health and human services, 2011). The education and 
insurance status of the US population has been suggested to be a stronger 
216 
Chapter 7 
 
  
determinant of inequalities compared to other components of socio-economic 
status that are strongly related to health in the UK.  
Scotland also has a national policy “Better Cancer Care” and tackling 
inequalities is one of the main goals of that policy. A clear commitment has been 
shown to strengthen cancer prevention including tackling inequalities in both 
access to healthcare and cancer outcomes across Scotland (The Scottish 
Government Edinburgh, 2008b). As the incidence and mortality for most cancers 
is higher among the most deprived groups so the policy focuses mainly on 
reducing the burden of overall cancers as well as paying particular attention to 
the most deprived groups(The Scottish Government Edinburgh, 2008b).  
In contrast to other cancers, PC is less common among deprived groups. 
However, the differential appears to lie more in low grade than in high grade 
disease. It might therefore be argued that there remains a need to increase 
awareness among deprived men to have routine clinical assessments so that 
aggressive and clinically significant cancers might be detected at an earlier 
stage and cured. This may reduce the gap in survival between socio-economic 
groups, although evidence from this thesis indicates that survival remains poorer 
in more deprived populations irrespective of PC grade. Public health strategies 
need to be targeted and resources should be allocated to address the issues of 
low socio-economic groups where most problems of inequalities in PC exist. 
Although, the evidence on benefits of screening is very limited, further research 
may help in relation to decisions of screening for certain groups. However, 
currently high risk individuals, that is, those with a family history of PC or any 
other cancer and men from deprived group, may be suitable for PSA testing to 
reduce late presentation of the disease.  
From a broader policy perspective there is a need to understand and redress the 
wider determinants of socio-economic inequalities in health and cancer. The 
Scottish Government and Convention of Local Authorities published a joint 
Framework to Tackle Poverty in Scotland in 2008 (The Scottish Government 
Edinburgh, 2008a). The framework was intended to deliver improvements in four 
main areas – reducing income inequalities, introducing longer-term measures to 
tackle poverty and the drivers of low income, supporting those experiencing 
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poverty and making the tax and benefit system work for Scotland (The Scottish 
Government Edinburgh, 2008a). Although these recommendations are at an early 
stage, there is a need to strengthen and deliver in these areas to reduce the 
socio-economic gaps and ultimately reduce the health, and specifically cancer, 
inequalities.  
7.6.2 Clinical practice 
Health care services have an important role in reducing inequalities. For PC, 
there is a need to ensure that patients are appropriately and equitably referred 
from primary care for diagnostic services. There is no prima facie evidence that 
treatment of PC patients in the NHS Scotland is inequitable or that if inequalities 
in treatment were identified they should be considered to be unfair without fully 
understanding the clinical basis on which decisions were made. However, future 
clinical audit data should allow treatment patterns by socio-economic 
circumstances to be described so that any inequities might be identified.  
It may be appropriate to give patients from more deprived circumstances 
additional care because of their poorer survival from PC. As noted above, there 
is a lack of evidence of whether co-morbidities might explain the excess 
mortality among more deprived patients and this work is needed before 
recommendations might be more conclusively made. However, a diagnosis of PC 
may also be an opportunity for health services to optimise treatment for other 
chronic illnesses and to support patients to adopt more healthy behaviours, 
particularly by stopping smoking, reducing excessive alcohol consumption and 
losing weight. There is evidence that a significant health event may lead 
patients to adopt more healthy behaviours (McBride et al., 2008). 
Modification of systemic inflammation may have some role in routine clinical 
practice. Further clinical evidence is required and this may help to identify high 
risk groups of patients and inflammation-based prognostic scores might help in 
the treatment related decision making process.  
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7.7 Conclusion 
PC is a frequently diagnosed malignancy in men and its incidence continues to 
increase. Despite attempts in this thesis to identify modifiable risk factors using 
large prospective cohort studies with long follow-up periods, few convincing 
answers have emerged. The continuing increase in reported incidence over time 
is probably a reflection of greater testing rather than a true increase in 
incidence but a true increase cannot be dismissed. The increasing socio-
economic differentials in incidence described in this thesis are probably 
artefacts of greater testing of more affluent men rather than reflections of true 
differences in incidence rates. Instead, the priority will be to differentiate 
better between indolent disease that will not cause significant morbidity or 
mortality and more aggressive disease that requires effective and prompt 
treatment. This thesis has provided evidence that the addition of a simple 
measure of systemic inflammation may greatly increase the prognostic accuracy 
of conventional PC grading but further work is needed on other prognostic 
indices. The socio-economic differentials in survival described in this thesis are 
not completely explained by differences in age and disease grade, it may be 
possible that differential distribution of co-morbidities and metastatic disease 
may have some role in socio-economic differentials in survival. Further work is 
needed to gain a fuller understanding of socio-economic differences in co-
morbidities, disease stage at presentation and responses to treatment so that 
effective ways of reducing inequalities in outcomes might be found. 
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